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GenerAl InTrODuCTIOn
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among 
females worldwide, with an estimated 1.7 million cases and more than 500,000 deaths in 2012 [1]. 
Moreover, the incidence of breast cancer rapidly increases, which can partly be explained by the 
increased life expectancy in the past decades and the ageing of the population. Breast cancer alone 
already accounts for 25% of all cancer cases and 15% of all cancer deaths among females worldwide. 
Europe, Northern America, Australia, New Zealand and Japan account for about one half of all breast 
cancer cases and 38% of deaths worldwide and currently the life time breast cancer risk in these 
countries is increasing to 12% [1]. 
early breast cancer
Most breast cancer patients are diagnosed with early stage breast cancer and treated with a 
curative intent including local therapy (surgery and in many cases adjuvant radiotherapy) and often 
perioperative systemic treatment (chemotherapy, endocrine therapy and/or targeted therapy).  These 
systemic treatments can be given before (neoadjuvant) or after (adjuvant) resection of the tumor. 
Neoadjuvant is the treatment of choice especially in case of locally advanced breast cancer and in 
case of need for downstaging in order to perform breast conserving surgery instead of mastectomy. 
Systemic therapies are effective both in reducing the risk of distant and local recurrence. The decision 
whether or not and if so, which (neo)adjuvant systemic therapy should be used, takes many factors 
into account such as age, life expectancy (defined based on age, comorbidities and WHO performance 
status), expression of estrogen and/or progesterone receptors, overexpression of human epidermal 
growth factor receptor 2 (HER2), histomorphological grade, tumor size and nodal status.  Genomic 
analysis of primary tumor tissue is increasingly used, mainly in hormone receptor positive, HER2-
negative breast cancer to better assess the risk of relapse and thereby to determine whether or not 
chemotherapy should be added to endocrine therapy in these patients [2,3].
Postoperative radiotherapy to the breast/chest wall and/or locoregional lymph nodes reduces the 
risk of local recurrence and improves survival in specific patients as well [4,5]. A large proportion of 
patients treated for early stage breast cancer therefore receives postoperative radiotherapy. 
Besides anticancer treatment aiming to exert direct antitumor effects, also supportive measures 
are important in the treatment of early breast cancer.  Especially in patients with cancer treatment 
induced bone loss, osteoclast inhibitors (bisphosphonates or denosumab) decrease the risk of skeletal 
related complications [6]. 
Despite taking all above mentioned factors into account when deciding whether or not to apply 
adjuvant systemic therapy or radiotherapy, still a large (undefined) proportion of patients are 
overtreated and exposed to therapy-associated toxicity while they have no survival advantage of the 
therapy as they are cured by surgery alone. 
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Metastatic breast cancer
Unfortunately, a number of the patients who are treated with curative intent for early breast cancer 
develop local recurrence, a second primary breast cancer or metastatic disease. In addition to 
patients who experience metastatic disease after being treated for a primary tumor, approximately 
five percent of the patients with breast cancer present with metastatic disease at the initial diagnosis. 
Once patients have developed metastatic disease, cure is in general not possible and treatment is 
aimed at prolongation of survival, and preservation or improving quality of life. Overall survival widely 
varies between patients based on subtype of tumor and on sites and burden of metastases. Also in 
metastatic breast cancer, treatment highly depends on tumor and patient characteristics. 
Besides anticancer treatment aiming to exert direct antitumor effects, also supportive measures are 
important in the treatment of metastatic breast cancer.  Especially in patients with bone metastases 
osteoclast inhibitors (bisphosphonates or monoclonal antibodies against RANKL) decrease the risk of 
skeletal related complications [7].
Especially in the treatment of metastatic breast cancer, where cure is no longer possible, it is of 
utmost importance to take quality of life into account. Unfortunately, most anticancer treatments are 
associated with toxicity, which might impair quality of life. 
AIMs AnD OuTlIne Of The ThesIs
Two of the major challenges in breast cancer research are to increase efficacy of anticancer treatments 
without increasing clinical relevant toxicity and/or to decrease toxicity of anticancer treatment 
without decreasing its efficacy. To achieve this, improved insight into the mechanisms underlying 
treatment-induced toxicity is crucial. This thesis describes studies in which it is aimed to optimize 
therapy for patients with breast cancer in various stages of the disease. This might be reached by 
dealing with toxicity in several ways: (1) decreasing toxicity, while maintaining efficacy, (2) increasing 
efficacy, without increasing clinical relevant toxicity,  (3) increasing efficacy by toxicity-based dose 
escalation and (4) prevention of (complications of ) toxicity of anticancer treatments.  
Impaired DnA repair mechanism related to increased treatment-associated toxicity
Carriers of a germline BRCA1 or BRCA2 (BRCA1/2) mutation face an increased lifetime risk of developing 
breast cancer, estimated to range from 47 to 66% for BRCA1 mutation carriers and from 40 to 57% for 
BRCA2 mutation carriers [8,9]. Mean age at breast cancer diagnosis in this subgroup of patients is 45 
years, which is substantially lower than in the general population [9]. 
BRCA1/2-associated breast cancer is characterized by homologous recombination deficiency, leading 
to inadequate repair of double strand DNA breaks [10-12]. Both ionizing radiation (diagnostic radiation 
and radiotherapy) and chemotherapy induce DNA damage by several mechanisms including 
induction of double strand DNA breaks. Especially platinum derivates are strong inducers of double 
strand DNA breaks. The vulnerability of cells for ionizing radiation and chemotherapy largely depends 
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on the capability of the cells to repair DNA damage. Because BRCA1 and BRCA2 proteins play an 
important role in the repair of DNA damage, the acute and late toxicity of ionizing radiation and 
chemotherapy might be increased in BRCA1/2 mutation carriers compared to sporadic controls.
Ionizing radiation
Occurrence of breast cancer is a well-known long term side effect of ionizing radiation [13]. As a 
consequence, also adjuvant radiotherapy for primary breast cancer might increase the risk of a second 
(ipsilateral or contralateral) breast cancer. In Chapter 2 we describe and discuss the current literature 
on the association between ionizing diagnostic and/or therapeutic radiation and the risk of developing 
a first or second primary breast cancer, with particular attention for patients with a BRCA1/2 mutation. 
Relevant data regarding the association between adjuvant radiotherapy and contralateral breast cancer 
risk in younger patients with a BRCA1/2 mutation are sparse. Knowledge about the possible increased risk 
of contralateral breast cancer by radiotherapy might be of great importance for optimal shared decision 
making regarding mastectomy without radiotherapy versus breast conserving surgery including 
radiotherapy at primary breast cancer diagnosis. Therefore, we studied the impact of radiotherapy on the 
risk of contralateral breast cancer among BRCA1/2-associated breast cancer patients in a retrospective 
cohort study with special attention for patients younger than 40 years at breast cancer onset (Chapter 3).
Over the years, an increasing proportion of BRCA1/2 mutation carriers after developing breast cancer 
seems to opt for bilateral mastectomy instead of unilateral mastectomy or breast conserving surgery 
without radiotherapy. These trends might influence the proportion of patients at risk for radiation-
induced breast cancer. We therefore also explored potential tendencies in locoregional treatments and 
the rates of contralateral risk-reducing mastectomies over the past decades. 
Chemotherapy
Platinum derivates, which are strong inducers of double strand DNA breaks, showed higher efficacy 
in breast cancer patients with a BRCA1/2 mutation compared to sporadic breast cancer patients [14-
18]. Increased sensitivity for chemotherapeutic regimens other than platinum-based has also been 
suggested, which might be explained by the induction of double strand DNA breaks through these 
agents but also by the functions of BRCA1 and BRCA2 proteins in the cell cycle [19-22]. 
Thus far, two small studies investigated the acute toxicity of mainly older (neo)adjuvant chemotherapy 
regimens in BRCA1/2 mutation carriers, compared to sporadic breast cancer patients, with inconsistent 
results [23,24]. We therefore performed a larger single center retrospective cohort study to examine 
potential differences in (neo)adjuvant chemotherapy-associated toxicity between BRCA1/2-associated 
and sporadic breast cancer patients (Chapter 4). 
Could toxicity be used to optimize treatment?
Both anthracyclines and cyclophosphamide are highly effective drugs in the treatment of breast 
cancer, although not all patients benefit from anthracycline- and cyclophosphamide-containing 
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chemotherapy, both in (neo)adjuvant and metastatic setting [25,26]. The cumulative dose of 
anthracyclines administered is important. From randomized controlled trials, it is clear that higher 
‘standard dose’ of anthracyclines for early breast cancer improves patient survival compared to lower 
‘standard dose’ [27]. On the other hand, a reason for differences in efficacy among patients who 
have had a similar dose of anthracyclines administered could be the large inter-individual (between 
patients) as well as the intra-individual (within patients) variability in pharmacokinetic parameters 
[28]. Interestingly, some retrospective studies showed that breast cancer patients given adjuvant 
chemotherapy but not attaining at least moderate hematological toxicity have a worse prognosis 
compared to those with more toxicity [29-32]. The current standard of dosing of chemotherapy is 
guided by body surface area with an a posteriori dose reduction in case of excessive toxicity. Dose 
escalation among patients without toxicity is, however, not standard of care. The administration of an 
inappropriately low dose of chemotherapy is therefore not recognized, leaving patients that might 
benefit from an increased dose unidentified. The percentage of breast cancer patients receiving a 
suboptimal dose is unknown, as well as the amount of underdosing in these individuals. We, therefore, 
addressed the feasibility of a simple tool for neutrophil-guided dose adaptation of anthracycline-
cyclophosphamide-containing chemotherapy in female breast cancer patients (Chapter 5). In this 
study we aimed to reach nadir absolute neutrophil count of ≤1.0 x 10e9/L with recovery to ≥1.5 x 
10e9/L at the time of the planned next treatment cycle, without excessive hematological or non-
hematological toxicity.
Treatment related toxicity, compliance and therapeutic drug monitoring
In Chapter 6, we focused on endocrine therapy. Tamoxifen, a selective estrogen receptor modulator, 
is an important drug in the treatment of hormone receptor positive breast cancer. Since tamoxifen 
often has to be used for a longer period of time, therapy adherence, change in environmental factors 
and possibly resistance mechanisms might influence the systemic exposure over time [33]. Prevalence 
of full adherence ranged from 41 to 72% determined at the end of five years of treatment in a recent 
systematic review [34]. In particular treatment side effects were negatively associated with adherence. 
Inter-individual variation in metabolism of tamoxifen, which is influenced by both genetic and 
environmental factors, contributes to the differences in efficacy and toxicity of tamoxifen. Endoxifen is 
believed to be the principal active metabolite of tamoxifen. The best way forward for individualization 
of tamoxifen therapy seems to be therapeutic drug monitoring (TDM). When a ‘therapeutic window’ 
has been established, TDM can not only be used to increase efficacy (by increasing the dose in 
patients below threshold) but also to decrease toxicity without decreasing efficacy adherence by 
decreasing the dose in patients with side effect who have high endoxifen concentrations. The often 
used method of TDM by serial measurements of plasma concentrations of drugs and/or metabolites 
over time might be difficult to incorporate in clinical practice. A potential method, which gives in 
retrospect information about the course of an anticancer drug and/or its metabolites could be to 
measure these concentrations in scalp hair. Scalp hair grows with an average rate of one centimeter 
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per month and so, segmental analysis of hair allows the determination of the historic pattern of drug 
concentration [35]. Chapter 6 describes the validation of an earlier developed high-performance 
highly sensitive ultra performance liquid chromatography/tandem mass spectrometry method for 
quantification of tamoxifen and its three main metabolites (N-desmethyl-tamoxifen, 4-hydroxy-
tamoxifen and 4-hydroxy-N-desmethyl-tamoxifen) in scalp hair. 
Prevention and treatment of toxicity
Cancer treatment induced bone loss is an important toxicity of breast cancer treatment. Several 
causes of bone loss due to cancer treatment have been identified, among which estrogen deprivation 
(by chemotherapy induced amenorrhea and/or treatment with endocrine therapy) and effects on 
the bone of chemotherapy and supportive drugs, such as steroids. One of the newer supportive 
care drugs to prevent bone loss is denosumab, a fully humanized monoclonal antibody against 
the receptor activator of nuclear factor kappa-B ligand (RANKL) [36]. This drug has proven efficacy 
in the treatment of cancer treatment induced bone loss in patients with early breast cancer [37]. 
Furthermore, denosumab was found to be superior to zoledronic acid in delaying or preventing of 
skeletal related complications in patients with bone metastases [38]. In Chapter 7 we describe the 
current indications for denosumab in both early and metastatic breast cancer treatment, with special 
attention for efficacy and short and long term toxicity. 
Postponing (cyto)toxic therapy an option in metastatic her2-positive breast cancer?
In patients with metastatic breast cancer it is not only important to find new treatment options which 
increase efficacy but also to find new treatment options which decrease treatment-associated toxicity 
in order to maintain or improve quality of life. An important way to improve quality of life might be by 
reducing treatment-induced toxicity, for example by delaying the start of chemotherapy. Likewise, in 
patients with hormone receptor positive metastatic breast cancer it is common practice to start with 
endocrine therapy only, whenever possible. For patients with metastatic breast cancer overexpressing 
HER2, standard first line treatment consisted until recently of the combination of trastuzumab with a 
taxane [39,40]. Bevacizumab is a fully humanized monoclonal antibody against vascular endothelial 
growth factor (VEGF) and seems to increase the efficacy of trastuzumab in preclinical research [41,42]. 
In Chapter 8 we describe an open label randomized, non-comparative, phase 2 study of concomitant 
trastuzumab, bevacizumab and paclitaxel versus trastuzumab and bevacizumab, followed by 
trastuzumab, bevacizumab and paclitaxel at progression as first line treatment for patients with HER2-
positive metastatic breast cancer. Primary endpoint was progression free rate at one year. Secondary 
endpoints included progression free survival, overall survival, response, safety and toxicity.
Finally, the results of this thesis are discussed and suggestions for further research are mentioned in 
Chapter 9. 
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ABsTrACT
Occurrence of breast cancer is a well-known long term side effect of ionizing radiation (both 
diagnostic and therapeutic). The radiation-induced breast cancer risk increases with longer follow-up, 
higher radiation dose and younger age of exposure. The risk for breast cancer following irradiation for 
lymphomas is well known. Although data regarding the carcinogenic risk of adjuvant radiotherapy for 
a primary breast cancer are sparse, an increased risk is suggested with longer follow-up mainly when 
exposed at younger age. Particularly, patients with a BRCA1/2 mutation might be more sensitive for 
the deleterious effects of ionizing radiation due to an impaired capacity of repairing double strand 
DNA breaks. This might have consequences for the use of mammography in breast cancer screening, 
as well as the choice between breast conserving therapy including radiotherapy and mastectomy at 
primary breast cancer diagnosis in young BRCA1/2 mutation carriers. Good data regarding this topic, 
however, are scarce, mainly due to constraints in the design of performed studies. In this review, we 
will discuss the current literature on the association between ionizing radiation and developing breast 
cancer, with particular attention to patients with a BRCA1/2 mutation.
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InTrODuCTIOn
Both normal breast tissue and breast cancer tissue are sensitive to ionizing radiation. Although 
adjuvant radiotherapy for early breast cancer reduces the risk of local recurrence and improves 
breast cancer specific survival [1,2], the commonly used dose also entails potentially carcinogenic 
scattered radiation to the surrounding healthy tissue possibly leading to an increased risk of a second 
malignancy.
The earliest evidence that ionizing radiation is associated with an increased risk of breast cancer 
has been obtained from studies among atomic bombing survivors of Hiroshima and Nagasaki [3-
5]. The relative risk (RR) of developing any form of cancer depends on the dose received, age at 
exposure and gender and is as high as 4.5 for women exposed to a high dose of radiation at young 
age [6]. Further evidence for the association of ionizing radiation and breast cancer risk was shown 
in epidemiological studies conducted among patients with scoliosis or tuberculosis intensively 
monitored by X-rays [7-10], and in studies performed in patients treated with radiotherapy for benign 
breast disease, postpartum mastitis and skin hemangioma, reviewed by Preston et al. [10]. The 
strongest and most reliable evidence, however was generated from studies conducted in patients 
treated with radiotherapy for hematological malignancies, mainly for Hodgkin’s lymphoma [11-15]. 
For example survivors of Hodgkin’s lymphoma treated with mantle field irradiation had a 2.7-fold 
increased risk of developing breast cancer, compared to those not treated with mantle field irradiation 
[15]. Importantly, these radiation-induced breast cancers seem to have a worse prognosis compared 
to sporadic breast cancers [16-18].
In this review we summarize the current literature regarding the role of ionizing radiation, used for 
diagnostic imaging or therapeutic purposes, in the development of a (second) primary breast cancer. 
Since patients with a BRCA1/2 mutation might be more sensitive for the carcinogenic effect of both 
diagnostic radiation and radiotherapy because of impaired DNA repair capacity, special attention is 
paid to women with a BRCA1/2 mutation. Possible implications for clinical practice and future research 
directions are proposed.
IOnIZInG rADIATIOn AnD BreAsT CAnCer rIsK
Ionizing radiation: general information
Ionization is the ejection of electrons from a molecule. The threshold for ionization lies in the ultraviolet 
region of the electromagnetic spectrum, so all X-rays used in diagnostic radiation and radiotherapy 
and gamma-rays (sometimes used in radiotherapy) are ionizing radiation. Ionizing radiation can cause 
cellular damage by indirect DNA damage via the production of free radicals but can also induce DNA 
damage directly. Radiation-induced single base damage and single strand DNA breaks are in general 
repaired rapidly and adequately through base excision repair and DNA ligation respectively, which 
eventually results in complete DNA repair. In contrast, repair of radiation-induced double strand DNA 
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breaks is much more complex and inadequate repair often leads to cell death. Repair of double strand 
DNA breaks is possible by so-called homologous recombination by which the breaks are repaired by 
using a sister chromatid or homologous chromosome as a template. However, cells with impaired 
homologous recombination, such as BRCA1/2 deficient cells, make use of the less adequate non-
homologous end-joining to repair the double strand DNA breaks. Using non-homologous end-
joining, the two double strand DNA ends are linked together without using any information of a 
template and, as this is less accurate, often results in cell death [19,20].
The vulnerability of cells for ionizing radiation largely depends on the rate of cell proliferation, the 
total dose of radiation, the fractionation scheme and the capability of the cells to repair DNA damage. 
As a consequence, tumor cells, which in general have an accelerated cell division and frequently 
an impaired DNA repair capacity, are more prone to ionizing radiation compared to surrounding 
healthy tissue. For therapeutic ionizing radiation, it is therefore of great importance to maximize 
the therapeutic window, i.e. to increase the ratio of probability of antitumor effect over the risk of 
causing detrimental effects by exposing healthy tissue to radiation (Figure 1). The total radiation dose 
combined with the capacity of DNA damage repair in both malignant and healthy tissue will finally 
determine the favorable risk ratio of radiotherapy [21].
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figure 1. The vulnerability of particular malignant tumors for ionizing radiation depends to a large extent on the 
total dose of radiation to which the tumor cells are exposed. On the other hand (scattering) ionizing radiation 
to surrounding healthy tissue can cause unwanted acute and late toxicity. For therapeutic ionizing radiation, it 
is therefore of great importance to maximize the therapeutic window, i.e. increasing the ratio of probability of 
antitumor effect over the risk of causing detrimental effects.
Interestingly, the capacity to repair DNA damage might substantially differ between breast cancer 
patients, in particular when considering patients with or without a BRCA1 or BRCA2 mutation. BRCA1 
and BRCA2 proteins are involved in various processes of DNA damage repair, including the repair of 
double strand DNA breaks by homologous recombination. Breast cancer arising in carriers of either 
a BRCA1 or BRCA2 gene mutation lacks BRCA1 or BRCA2 proteins, leading to inadequate repair of 
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double strand DNA breaks [22,23]. This leads to the hypothesis that radiotherapy administered for 
BRCA1/2-associated breast cancer might be more effective than for sporadic breast cancer, while, on 
the other hand, the surrounding healthy breast tissue might be more sensitive to the deleterious 
effects of radiation, among which the development of a second primary breast cancer. If true, the 
risk-benefit ratio of radiation differs between sporadic breast cancer patients and BRCA1/2 mutation 
carriers and may have important clinical implications.
Dose-effect relation
The estimated total dose of ionizing radiation to the breast depends on the type of exposure and 
is reviewed in Table 1 [4,8,11,24-26]. Interestingly, studies among atomic bombing survivors and 
among patients exposed to diagnostic radiation (both low cumulative dose) have shown a statistically 
significantly increased breast cancer risk associated with increasing total radiation dose. The dose-
effect relations found in these studies were linear [5,9,10] and did not show a threshold, which strongly 
suggests that any exposure to ionizing radiation can be carcinogenic [27]. In Hodgkin’s lymphoma 
survivors, treated with high dose of ionizing radiation, the breast cancer risk also increased with larger 
radiation fields and higher cumulative radiation doses, although less sharp [11-13]. The dose-effect 
relation seems therefore to be best described by a linear-quadratic model (Figure 2), with a linear 
increasing risk for low cumulative doses, a flattening of the curve beginning at a cumulative dose of 
10 Gy, and a less steep or even no further increase of the risk above a dose of 20 Gy [28].
Table 1. Estimated breast dose (Gy) by different types of ionizing radiation [4,8,11,24-26].
ionzing radiation Dose
Chest X-ray 0.0005 Gy
Diagnostic mammography (2007) 0.004 Gy 
Diagnostic mammography (1965) 0.0186 Gy
Computed tomography of the chest 0.02 Gy
Atomic bombing survivors 0.02-5 Gy
Scatter to contralateral breast 0.5-4 Gy
Scatter to contralateral breast (older studies) up to 7 Gy
Mantle field radiotherapy (Hodgkin’s lymphoma) 30-40 Gy
Adjuvant radiotherapy breast cancer 50 Gy (+ 16-20 Gy to the tumor bed region)
Duration of follow-up 
Follow-up duration is another important factor to consider when interpreting studies on radiation-
induced breast cancer risk. Studies among atomic bombing survivors and patients exposed to 
diagnostic radiation suggest a minimal latency period of 10-12 years before an increased breast cancer 
risk becomes apparent [4,9]. In studies of Hodgkin’s lymphoma patients, the median latency period 
has been reported to be around 18 years (range 7-30 years) [13,29]. Thus, excluding a carcinogenic 
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effect of ionizing radiation is only possible when the median follow-up period after radiation exposure 
is long enough, e.g. at least longer than 10-15 years.
0 10 20 30 40 50 60 70
ca
rc
in
o
ge
n
ic
 r
is
k
radiation dose (Gy)
diagnostic radiation                                                                radiotherapy
figure 2. The dose-effect relation for the carcinogenic effects of both diagnostic and therapeutic radiation seems 
to be best described by a linear-quadratic model, with a linear increase of risk for low cumulative dose, flattening 
of the curve beginning at a cumulative dose of 10 Gy and less steep or even no evident further increase with a 
dose above 20 Gy.
Carcinogenic effect of adjuvant radiotherapy for primary breast cancer
Adjuvant radiotherapy after breast conserving surgery or mastectomy might be associated with an 
increased risk of a second primary breast cancer applying to the complete area of healthy breast tissue 
(ipsilateral and/or contralateral) exposed to (scattering of ) ionizing radiation. Quantifying this risk, 
however, is quite challenging for several reasons. 
Firstly, developing a true ipsilateral recurrence after breast cancer treatment is not due to the 
detrimental effects of adjuvant radiotherapy, but rather caused by failure of the adjuvant radiotherapy. 
Differentiating between a true recurrence, originating from residual cancer cells, and a second 
primary breast cancer, arising within residual glandular breast tissue, however, was not easy in 
times that molecular techniques were not yet available. Several characteristics have then been used 
trying to distinguish between these two entities, including time between primary breast cancer 
and ipsilateral relapse (<5 years: mostly true recurrence, and >5 years: most likely a second primary 
breast cancer), location of the first and second tumor (similar or different quadrants), and histological 
and immunohistochemical tumor characteristics (similar or different) [30-32]. However, since these 
clinical and pathological variables often failed to reliably distinguish between true recurrences and 
second primaries, other molecular techniques are to be preferred based on loss of heterozygosity 
patterns [33]. Studies in an unselected population of ipsilateral breast tumor recurrences using the 
latter technique found that the majority (60-76%) of recurrences after adjuvant radiotherapy were true 
recurrences [33-35]. Also, the chance that an ipsilateral breast tumor recurrence turned out to be a 
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second primary breast cancer instead of a true recurrence increased with longer disease free interval 
(18, 52 and 67% for breast cancer recurrence within 0-5 years, 5-10 years and >10 years respectively) 
[33], although the number of cases was small (n = 57).
Secondly, it is important to use within studies the most appropriate optimal control group. 
Investigating the risk of an ipsilateral second breast cancer in patients treated with breast conserving 
therapy including radiotherapy, the comparison should be made with patients undergoing breast 
conserving surgery without adjuvant radiotherapy. This question has been previously investigated by 
several randomized trials comparing breast conserving surgery with or without radiotherapy, and the 
results have been studied in a large individual patient data meta-analysis [2] of these studies (17 trials 
activated between 1976 and 1999; including n = 10,801; of whom 87% of patients had node negative 
breast cancer). After a median follow-up of 9.5 years, radiotherapy added to breast conserving surgery 
significantly reduced the locoregional recurrence rate at 10 years from 25 to 8%. While these figures 
are quite striking, it has to be taken into account that at the time these studies were performed, 
adjuvant systemic therapy was less often used and was less effective together with less optimal 
surgery compared to the present time. Unfortunately, these studies did not distinguish between true 
recurrences and second primary breast cancers [2].
Concerning the risk of contralateral breast cancer (CBC) in relation to adjuvant radiotherapy for primary 
breast cancer, this should be studied in patients treated with breast conserving therapy including 
radiotherapy or mastectomy and radiotherapy compared to patients treated with mastectomy or 
breast conserving surgery without adjuvant radiotherapy. Importantly, an increased CBC risk after 
adjuvant radiotherapy for primary breast cancer becomes apparent only after more than 10 years 
[1,8,26], indicating that studying this item requires a long follow-up time period. Valuable results are 
provided by a meta-analysis performed among patients with ductal carcinoma in situ treated with 
breast conserving surgery with or without radiotherapy (n = 3,665). A significantly increased CBC risk 
was found in the group treated with radiotherapy (RR 1.53; 95% confidence interval (CI) 1.05-2.24) 
suggesting a detrimental effect of ionizing radiation [36]. Other studies investigating the risk of CBC 
are reviewed in Table 2 [1,8,26,37-39]. Most of these studies found no significantly increased risk of 
CBC after adjuvant radiotherapy compared to no radiotherapy. The EBCTCG meta-analysis regarding 
the effects of locoregional treatments (surgery and/or radiotherapy) on local recurrence and survival 
found a RR of 1.18 (p = 0.002) for the development of CBC after adjuvant radiotherapy for primary 
breast cancer, resulting in only a small absolute risk of CBC of 4.4% in 15 years after adjuvant (versus no) 
radiotherapy [1]. Two of the other mentioned studies investigated the risk of CBC using an estimation 
of the radiation dose to the quadrant where the second primary breast cancer developed [26,39]. It 
was observed that the amount of (scattered) radiation dose to the contralateral breast in general is 
lower in case of radiotherapy after mastectomy compared to radiotherapy after lumpectomy [39]. 
Stovall et al. found that patients treated with radiotherapy for primary breast cancer had a significantly 
higher proportion of CBCs located in the inner and central quadrants of the contralateral breast, 
compared to the CBC locations of patients not receiving radiotherapy for primary breast cancer [26]. 
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Hooning et al. reported a 1.5-fold increased risk of CBC for patients treated with radiotherapy after 
lumpectomy versus patients treated with radiotherapy after mastectomy [39]. 
In summary, based on the currently available data there seems to be a carcinogenic effect of scatter 
ionizing radiation of adjuvant radiotherapy for primary breast cancer among sporadic patients, 
mainly occurring with longer follow-up and taking the estimated radiation dose at the location of the 
recurrent breast tumor into account. Importantly, the magnitude of the increased breast cancer risk is 
smaller than expected given that the total amount of scatter radiation is comparable to the amount of 
ionizing radiation received by atomic bombing survivors (Table 1) in whom a clearly increased breast 
cancer risk has been found. Potential explanations for the former findings include the relatively short 
follow-up period in the various studies, the small part of healthy breast tissue being exposed during 
radiotherapy to scatter ionizing radiation, and the risk-reducing effect of administered adjuvant 
systemic therapy (or performed oophorectomy) on CBC. Furthermore in case of atomic bombing the 
radiation dose was delivered over a short time period, while in case of radiotherapy the total dose 
is delivered in fractions, resulting in a lower biologically equivalent dose. Finally, carcinogenic risk of 
ionizing radiation might be more pronounced in particular subgroups, for example in patients being 
younger at radiation exposure and/or BRCA1/2 mutation carriers. We will describe these influencing 
factors in more detail below. 
Age in relation to radiation-induced breast cancer risk 
Most of the studies regarding the risk of developing CBC after radiotherapy for primary sporadic 
breast cancer found significantly elevated risks mainly in younger age groups, defined as age below 
40 or 45 years (Table 2) [8,26,38,39]. Studies among women exposed to an even lower dose of ionizing 
radiation from atomic bombing or diagnostic imaging also showed an increased relative risk of 
developing breast cancer with decreasing age [4,5,10].
A possible explanation for the increased breast cancer risk at younger age could be the fact that a 
high breast cell proliferation (during puberty/adolescence and pregnancy) and thus increased DNA 
synthesis might render breast tissue particularly susceptible to the carcinogenic effects of radiation. 
Nulliparous women have been found to be more sensitive for the deleterious effect of radiation to the 
breast compared to parous women [40,41]. Further, it is possible that the observation of the increased 
risk at younger age reflects the fact that women developing breast cancer at younger age more likely 
to have a genetic susceptibility for developing breast cancer, in particular a BRCA1/2 mutation. Still, the 
role of young age as a modifying factor in itself, independent of hereditary predisposition, is strongly 
supported by the finding that breast cancer risk in women treated with mantle field radiotherapy for 
Hodgkin’s lymphoma is the highest in case of exposure around puberty and decreases with increasing 
age at radiotherapy [12,13,15].
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IOnIZInG rADIATIOn In BRCA1/2 MuTATIOn CArrIers 
Impact of radiation in BRCA1/2 mutation carriers: introduction
The lifetime risk of developing both a primary breast cancer and CBC is increased in female BRCA1/2 mutation 
carriers as compared to the population risk [42-46]. Regarding ipsilateral second primary breast cancer no 
significantly increased risk has been found for BRCA1/2 mutation carriers versus sporadic patients. Many 
studies, however, are limited by short follow-up periods and most studies did nog distinguish between a 
second primary breast cancer and an ipsilateral true recurrence. The subsequent question regarding our topic 
of interest is whether BRCA1/2 mutation carriers are relatively more prone to the carcinogenic effect of ionizing 
radiation than non-carriers. We will first focus on the role of diagnostic radiation, and thereafter of therapeutic 
radiation in relation to the risks of developing a primary or second primary breast cancer, respectively.
risk of breast cancer in BRCA1/2 mutation carriers as a result of diagnostic imaging
The ideal study design to investigate this question would be a prospective cohort study, including healthy 
female BRCA1/2 mutation carriers comparing those with and those without exposure to diagnostic 
ionizing radiation. This design, however, is not ethical as identified BRCA1/2 mutation carriers nowadays are 
offered and enrolled in breast cancer screening programs. An acceptable alternative methodology could 
be a retrospective study among female BRCA1/2 mutation carriers investigating the association between 
breast cancer diagnosis and the total amount of ionizing radiation exposure in the past. This methodology 
has been used in several studies [24,47-52] (Table 3). Importantly, three sorts of bias should be kept in 
mind while interpreting the data of such retrospective studies. Firstly, recall bias, i.e. the reporting of more 
exposure by affected women compared to non-affected women, which might lead to an overestimation 
of the breast cancer risks due to diagnostic radiation. This bias is probably low since several studies showed 
a good concordance between self-reported exposure to diagnostic radiation by questionnaires and 
radiation exposure obtained through data collection from the medical records [50]. Another and probably 
more important form of bias is introduced by the fact that those women with relevant abnormalities on 
screening tests will undergo additional diagnostic imaging tests increasing the total radiation dose further. 
Thirdly, survival bias, i.e. the fact that patients who died cannot be included in retrospective studies using 
patient reported exposures, might lead to an underestimation of radiation-induced breast cancer risk.
The studies of Narod et al. and Goldfrank et al., comprising 213 and 3,200 BRCA1/2 mutation carriers 
respectively, did not find an increased breast cancer risk in subjects exposed to ionizing radiation by 
mammography [47,48]. The study by John et al. comprised 727 BRCA1/2 mutation carriers (age <50 
years) and did not find an increased breast cancer risk in subjects exposed to chest X-rays [49]. Details 
of these studies are mentioned in Table 3. Additional analyses among different subgroups, regarding 
age at exposure and age at diagnosis, did not show an increased risk either. The study by Goldfrank et 
al., however, was relatively small and included only a small proportion (14%) of women being younger 
than 30 years at exposure, precluding to draw firm conclusions [48]. Also in the study of John et al., 
only 7% of women were younger than 20 years at exposure [49]. 
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Although the sample size in the study of Narod et al. was sufficiently large, several comments have to 
be made regarding the results interpretation [47]. Information regarding dose-response effects is not 
available, since exposure to ionizing radiation by mammography was used as a dichotomized variable 
(yes/no). Furthermore, information about time between exposure and breast cancer detection is 
lacking. In our opinion, it cannot be excluded that these factors might have underestimated a possible 
detrimental effect of diagnostic ionizing radiation in BRCA1/2 mutation carriers.
In contrast, other retrospective studies found a positive association between diagnostic ionizing 
radiation and risk of developing breast cancer [24,50,52]. First, the large retrospective cohort study of 
Andrieu et al. including 1,601 BRCA1/2 mutation carriers, showed that any exposure to chest X-rays 
versus no exposure was associated with an increased risk of breast cancer (hazard ratio (HR) 1.54 
(1.1-2.1); p = 0.007) [50]. The study of Lecarpentier et al. including 990 BRCA1/2 mutation carriers 
found a HR of 4.29 (95% CI 2.09-8.81) for the risk of breast cancer, comparing any exposure to no 
exposure to chest X-rays [52]. In accordance to the findings among the general female population, 
both Andrieu et al. and Lecarpentier et al. found evidence of both a dose-effect relation and an effect 
of age at exposure (Table 3). Unfortunately, data on ionizing radiation exposure in both studies were 
gathered from questionnaires and data on mammography (or other diagnostic imaging) exposure 
were not available for analyses. Furthermore it is important to mention that there is overlap in patient 
population between these two studies [50,52]. The most detailed study (n = 1,993) was performed 
by Pijpe et al. taking into account the cumulative ionizing radiation exposure to the breast as a result 
of all types of diagnostic imaging procedures [24]. In this study, a clear dose-effect relation between 
any exposure to diagnostic radiation before the age of 30 years (versus above 30 years) and breast 
cancer risk was observed (HR 1.90; 95% CI 1.20-3.00). Interestingly, within the younger age group, a 
positive association was also found within the group exposed to the lowest dose of ionizing radiation 
(below 0.0066 Gy). Ionizing radiation exposure above the age of 30 years, on the other hand, was not 
associated with an increased risk of breast cancer.
In a case control study, Gronwald et al. compared 138 breast cancer patients with a BRCA1 mutation to 
158 age-matched sporadic breast cancer patients not carrying a BRCA1 mutation [51]. Among BRCA1 
mutation carriers, the mean age of first chest X-ray exposure was lower, and the total number of chest 
X-rays before the age of 20 years was higher compared to sporadic cases. The results of this cross-
sectional study could support the hypothesis that early radiation exposure may be a risk factor for 
breast cancer development in BRCA1 mutation carriers. 
Taking into account the results of the study of Pijpe et al., the Dutch guidelines regarding female 
BRCA1/2 mutation carriers advice to start annual breast MRI screening at age 25, and to add annual 
mammography as of the age of 30 years (http://www.oncoline.nl/mammacarcinoom). The United 
Kingdom National Institute for Health and Care Excellence (NICE) guidelines, meanwhile, advice to start 
annual breast MRI screening at age 30, to offer annual mammography from age 40 years onwards and 
to consider annual mammography from age 30 onwards. (http://www.nice.org.uk/guidance/cg164/
resources/guidance-familial-breast-cancer-pdf ). The United States National Comprehensive Cancer 
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Network (NCCN) guidelines still advice to screen BRCA1/2 mutation carriers with annual mammogram 
and breast MRI starting at age 25 years (http://www.nccn.org/professionals/physician_gls/pdf/breast-
screening.pdf ). In our opinion the Dutch policy is supported by several computer simulation models, 
based on data regarding radiation induced breast cancer risk in the sporadic population, known 
sensitivity and specificity of the different screening methods and known risks of developing breast 
cancer in BRCA1/2 mutation carriers, taking into account both beneficial and detrimental effects 
of various types of breast cancer screening. The simulation models incorporating MRI as screening 
tool, suggest that the best approach is to start screening with MRI at age 25 years, followed by the 
combined use of MRI alternating with mammography starting at age 30 [53-55].
risk of breast cancer in BRCA1/2 mutation carriers as a result of therapeutic radiation
As holds true for sporadic breast cancer patients, investigating the potential carcinogenic damage of 
therapeutic radiation for primary breast cancer among BRCA1/2 mutation carriers, it is important to define 
the optimal control population. Furthermore it is important to realize that there are several confounding 
factors such as adjuvant systemic therapy (and oophorectomy) and prophylactic mastectomy.
Ipsilateral second primary breast cancer
As mentioned before, the study question on a possibly increased ipsilateral second primary breast 
cancer risk by adjuvant radiotherapy is challenging, since most studies did not differentiate between 
true recurrences and second primary tumors, while it has been shown that adjuvant radiotherapy 
decreases the risk of an ipsilateral true recurrence, and on the other hand possibly increases the risk 
of developing a second primary tumor in BRCA1/2 mutation carriers. In our opinion, the only way 
to answer this question within the BRCA1/2 mutation cohort is to compare breast cancer patients 
treated with breast conserving surgery followed by adjuvant radiotherapy to those not treated with 
radiotherapy. The previously mentioned very early studies on this issue did not provide data on the 
BRCA1/2 status, and therefore cannot be used in this matter. Further, as omitting radiotherapy after 
lumpectomy for invasive breast cancer is not standard practice anymore, data heron are very rare. 
Metcalfe et al. published data on the risk of ipsilateral breast cancer in 396 women carrying a BRCA1/2 
mutation who were treated with breast conserving surgery, whereby 46 patients were not treated 
with adjuvant radiotherapy [56]. After a median follow-up of 10.5 years, the ipsilateral breast tumor 
recurrence rate was reduced with 72% in the group treated with adjuvant radiotherapy (RR 0.28; 95% 
CI 0.12-0.63; versus no radiotherapy). Again, this study did not distinguish between true recurrences 
and second primary breast cancers.
All other studies investigating the risk of an ipsilateral breast tumor recurrence (IBTR, either recurrence 
or second primary) after breast conserving therapy including radiotherapy compared patients with a 
BRCA1/2 mutation to sporadic patients [45,57-61]. Interestingly in the study of Haffty et al., the pattern 
of IBTR in BRCA1/2 mutation carriers and in sporadic patients followed a similar course for five years 
and then began to diverge with higher risks in BRCA1/2 mutation carriers [45]. Seynaeve et al. also 
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found a higher rate of IBTR in hereditary cases compared to sporadic cases after five years only. Most 
recurrences in the hereditary cases occurred not in the same quadrant of the breast as the primary 
tumor, suggesting second primaries [57]. These findings together suggest that adjuvant radiotherapy 
in BRCA1/2 mutation carriers has a beneficial effect on early ipsilateral recurrence (probably true 
recurrences) which is at least comparable to the effect in sporadic patients, while there might be 
an increased risk of late recurrence (probably second primary tumors). From the reported studies, 
however, it cannot be concluded that the increased risk of second primary tumor on the long term is 
caused by the administered radiotherapy.
Contralateral breast cancer
The available studies regarding the risk of CBC in BRCA1/2 mutation carriers in relation to radiotherapy 
are reviewed in Table 4 [60,62,63]. These studies did not find an increased risk of CBC in patients 
treated with adjuvant radiotherapy compared to patients not treated with radiotherapy. The studies 
of Pierce et al. and Metcalfe et al. were multicenter, retrospective cohort studies of patients attending 
high-risk clinics, and reported after a median follow-up of eight years and eleven years, respectively.
Bernstein et al. performed a nested case control study within the WECARE study, a population-based 
study of patients with metachronous CBC (n = 603) and matched patients with unilateral breast 
cancer (n = 1,199). All patients were tested for BRCA1/2 mutations and 158 BRCA1/2 mutation carriers 
were identified of whom 96 had a metachronous CBC and 62 had no CBC (= controls). In these 
BRCA1/2 mutation carriers no increased risk of CBC after radiotherapy for primary breast cancer was 
observed, even when adjusting for age at primary breast cancer, age at menarche, number of full term 
pregnancies, age at menopause, family history, adjuvant systemic treatment, histology and stage of 
the first primary [63]. 
In a case only study (n = 247), Broeks et al. found a higher proportion of mutations in DNA damage 
repair genes (BRCA1, BRCA2, CHEK2 or ATM) in CBC patients being treated with adjuvant radiotherapy 
for the primary invasive breast cancer versus no radiotherapy. This suggests that carriers of a mutation 
in one of the DNA damage repair genes may be at increased risk of developing CBC after radiotherapy 
compared to non-carriers (odds ratio 2.18; 95% CI 1.03-4.62). The increased CBC risk was higher in 
younger patients, and after an interval between the primary and contralateral breast cancer of more 
than five years. The absolute number of BRCA1/2 mutation carriers (n = 32) in this study was however 
small [64].
Based on the available data from the limited number of studies and patients, and in view of the 
limitations of the available literature, there are no hard data on a carcinogenic effect of scatter ionizing 
radiation after adjuvant radiotherapy for BRCA1/2-associated breast cancer patients. The situation, 
however, may be different for BRCA1/2 mutation carriers at a young age. Since low dose (diagnostic) 
ionizing radiation seems already carcinogenic among young BRCA1/2 mutation carriers, clinicians 
remain concerned regarding a carcinogenic effect of therapeutic ionizing radiation in young BRCA1/2 
mutation carriers.
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The latter question however, cannot be definitely answered with the data from the available studies. 
In the two described retrospective cohort studies [60,62], only approximately 25% of the patients 
were younger than 35 years, and subgroup analyses regarding age at breast cancer treatment were 
not performed. Also in the WECARE study no specific subgroup analyses in younger patients were 
performed, while mean age at first breast cancer diagnosis was 46 years (range 23-55) [63].
COnClusIOns
Ionizing radiation (both diagnostic and therapeutic) is a well-known risk factor for the development 
of primary breast cancer. There is a clear positive dose-risk relation, which is modified by age, whereby 
young age at exposure is associated with an increased risk.
For sporadic breast cancer patients diagnosed above 45 years of age, adjuvant radiotherapy in the 
context of primary breast cancer treatment is associated with no or, if present, a negligibly increased 
risk of a second primary breast cancer and there is no reason to withhold radiotherapy in adjuvant 
setting. For younger patients no definite conclusion can be drawn based on the current data.
For the subgroup of BRCA1/2 mutation carriers, data regarding a carcinogenic effect of ionizing 
radiation (both diagnostic and therapeutic) are scarce, which can be partly explained by the fact that 
it is difficult to conduct well-designed studies excluding selection bias. Nevertheless for screening 
purposes there seems sufficiently enough evidence to incorporate mammography in breast cancer 
screening programs for BRCA1/2 mutation carriers only after the age of 30 years.
For those BRCA1/2 mutation carriers who developed breast cancer above the age of 30 years 
and opting for breast conserving therapy, there are no hard data regarding a possibly increased 
carcinogenic effect of adjuvant radiotherapy with respect to a second primary breast cancer, either 
ipsilateral or contralateral. However, a carcinogenic effect of adjuvant radiotherapy on the long term in 
this population has certainly not been excluded. Since low dose diagnostic radiation increases the risk 
of primary breast cancer in very young BRCA1/2 mutation carriers (<30 years), caution with regard to 
breast conserving surgery and radiotherapy seems warranted in this patient group.
Further research on the carcinogenic effects of specifically therapeutic ionizing radiation in the BRCA1/2 
population is urgently needed to answer the question whether breast conserving treatment is an 
appropriate option for these women, not only on the short but also on the long term. Research should 
focus mainly on the younger age group as in these patients the highest radiation induced risks can be 
expected. For future studies it is crucial to have an adequate study design, sufficiently long period of 
follow-up, information available on total ionizing radiation dose received (both diagnostic and therapeutic) 
and diagnostic plans regarding the distinction between a true recurrence or a second ipsilateral tumor. 
Furthermore, it is important to take other influencing factors into account, such as tumor characteristics, use 
of adjuvant systemic therapy, oophorectomy and/or prophylactic mastectomy. It might also be important 
to make a distinction between BRCA1 and BRCA2 mutation carriers. This requires the concentration of 
BRCA1/2 mutation carriers, at least the data of them, on a national and even an international level. 
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ABsTrACT 
The purpose of this study was to estimate the influence of adjuvant radiotherapy for primary breast 
cancer on the risk of contralateral breast cancer (CBC) in BRCA1 or BRCA2 (BRCA1/2) mutation carriers, 
with special attention to patients irradiated at age younger than 40 years. Additionally, tendencies in 
locoregional treatments and rates of contralateral risk-reducing mastectomy over time were explored. 
In this retrospective cohort study, 691 BRCA1/2-associated breast cancer patients treated between 
1980 and 2013 were followed from diagnosis until CBC or censoring event including ipsilateral 
breast cancer recurrence, distant metastasis, contralateral risk-reducing mastectomy, other invasive 
cancer diagnosis, death, or loss to follow-up. Hazard ratios (HR) for CBC associated with radiotherapy 
were estimated using Cox regression. Median follow-up time was 8.6 years [range 0.3-34.3 years]. 
No association between radiotherapy for primary breast cancer and risk of CBC was found, neither 
in the total population (HR 0.82; 95% confidence interval (CI) 0.45-1.49) nor in the subgroup of 
patients younger than 40 years at primary diagnosis (HR 1.36; 95% CI 0.60-3.09). During follow-up, 
the number of patients at risk decreased substantially since a large proportion of patients were 
censored after contralateral risk-reducing mastectomy or breast cancer recurrence. Over the years, 
increasing preference for mastectomy without radiotherapy compared to breast conserving surgery 
with radiotherapy was found ranging from less than 30% in 1995 to almost 50% after 2010. The rate 
of contralateral risk-reducing mastectomy increased over the years from less than 40% in 1995 to 
more than 60% after 2010. In this cohort of BRCA1/2-associated breast cancer patients, no association 
between radiotherapy for primary breast cancer and risk of CBC was observed in the total group, nor 
in the patients irradiated before the age of 40 years. The number of patients at risk after 10 and 15 years 
of follow-up, however, was too small to definitively exclude harmful effects of adjuvant radiotherapy.
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InTrODuCTIOn
Both normal breast tissue and breast cancer cells are sensitive to ionizing radiation. Although adjuvant 
radiotherapy for early breast cancer reduces the risk of local recurrence and improves breast cancer 
specific survival [1,2], it also leads to a low dose scatter radiation to the surrounding healthy tissue with 
potentially carcinogenic effects. In sporadic breast cancer patients, adjuvant radiotherapy has been 
associated with an increased risk of contralateral breast cancer (CBC), although only among women 
younger than 45 years at primary breast cancer diagnosis and after a latency period of at least 10-15 
years [3-6].
The vulnerability of cells for ionizing radiation largely depends on the rate of cell proliferation, the total 
dose of radiation, the fractionation scheme, and the capability of the cells to repair DNA damage [7]. 
Younger patients have higher breast cell proliferation (in particular during puberty, adolescence, and 
pregnancy) and thus increased DNA synthesis that might render breast tissue particularly susceptible 
to the carcinogenic effects of radiation [8,9]. The capacity to repair DNA damage might substantially 
differ between breast cancer patients, in particular when considering patients with or without a 
BRCA1 or BRCA2 (BRCA1/2) mutation.
BRCA1/2-associated breast cancer is characterized by homologous recombination deficiency, leading 
to inadequate repair of double strand DNA breaks [10, 11]. Ionizing radiation can cause cell damage 
by induction of double strand DNA breaks. This has led to the hypothesis that adjuvant radiotherapy 
administered for BRCA1/2-associated breast cancer might be more effective than radiotherapy 
administered for sporadic breast cancer. On the contrary, surrounding healthy breast tissue among 
breast cancer patients with a BRCA1/2 mutation might be more vulnerable to the deleterious effects 
of adjuvant radiotherapy, including the development of a CBC, compared to those without a BRCA1/2 
mutation.
In unaffected BRCA1/2 mutation carriers, exposure to low cumulative doses of diagnostic radiation 
(including screening mammography) at young age (<30 years) has been reported to be associated 
with an increased risk of breast cancer, with a clear dose-effect relationship compared to no exposure 
to diagnostic radiation [12]. The possible carcinogenic effect of scatter ionizing radiation after adjuvant 
radiotherapy on the contralateral breast in BRCA1/2-associated breast cancer patients, however, is 
not clear. Although a number of studies addressed this question, all these studies are compromised 
by a short duration of follow-up and the lack of subgroup analyses regarding young breast cancer 
patients [13-15]. Knowledge about the possibly increased risk of CBC by radiotherapy might be of 
great importance for optimal shared decision making regarding mastectomy without radiotherapy 
versus breast conserving surgery including radiotherapy at primary breast cancer diagnosis.
We therefore studied the impact of radiotherapy on the risk of CBC among BRCA1/2-associated 
breast cancer patients in a retrospective cohort study, with special attention to patients younger 
than 40 years at primary breast cancer diagnosis. Since over the years an increasing proportion of 
BRCA1/2 mutation carriers after developing breast cancer seems to opt for bilateral mastectomy 
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instead of unilateral mastectomy or breast conserving treatment with radiotherapy [16], we also 
explored potential tendencies in locoregional treatments and the rates of contralateral risk-reducing 
mastectomy over the past decades.
MeThODs
Patient selection
From the Rotterdam Family Cancer Clinic database, we extracted all female patients with early stage 
breast cancer (n = 2,268). From this population, we selected proven or obligate BRCA1 or BRCA2 
mutation carriers, treated at the Erasmus MC Cancer Institute. Patients diagnosed from January 1, 1980, 
corresponding to the start of linear accelerators use for adjuvant breast radiotherapy at the Erasmus 
MC, to January 1, 2013 were included (n = 790). Time of observation ended at April 1, 2014. Patients 
with less than three months of follow-up were excluded (n = 52; see statistical analysis). Patients who 
were treated with breast/chest wall radiotherapy or systemic anticancer therapy because of another 
invasive malignancy, either prior or synchronous to the primary breast cancer, were excluded (n = 
16). Patients who had synchronous bilateral breast cancer and received bilateral radiation therapy 
or mastectomy (n = 31) were also excluded, leaving a total of 691 patients available for the analyses.
For the eligible patients, data on primary breast cancer and CBC characteristics (type of histology, 
differentiation grade, estrogen receptor status, progesterone receptor status, HER2 status, and stage) 
and primary breast cancer therapy (surgery, radiotherapy, chemotherapy, and/or endocrine therapy) 
were retrieved. We also collected data on type of mutation (i.e., BRCA1 or BRCA2), date of birth, primary 
breast cancer and CBC diagnoses, dates of and findings at contralateral risk-reducing mastectomy 
and salpingo-oophorectomy, and dates of disease recurrence and death or date of last follow-up if 
no event occurred.
statistical analysis
The primary endpoint was the development of CBC defined as the occurrence of carcinoma in situ 
or invasive breast cancer in the contralateral breast at least three months after primary breast cancer 
diagnosis and no signs of metastatic disease. CBC diagnosis within three months was considered as 
synchronous bilateral breast cancer and assumed to be unrelated to the delivery of radiotherapy for 
the first breast cancer [3-5]. For this reason, patients with less than three months of follow-up were 
excluded. 
For comparisons of patient, tumor, and treatment characteristics between subgroups, we used 
Pearson’s χ2 tests. Differences in age at primary breast cancer diagnosis and follow-up time were 
analyzed using the Wilcoxon rank-sum test (Mann-Whitney).
In the Cox analyses, we applied left truncation of analysis time and so considered outcome data from 
prospective follow-up only. Hereby, we aimed to correct for potential selection bias, possibly arising 
due to inclusion of patients undergoing genetic testing after primary breast cancer or CBC diagnosis 
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[17,18]. Censoring events were ipsilateral breast cancer recurrence for which radiotherapy or systemic 
therapy was applied, distant metastasis, contralateral risk-reducing mastectomy, other (non-breast) 
invasive cancer for which radiotherapy or systemic therapy was applied, death, and loss to follow-up.
We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for radiotherapy (after 
lumpectomy vs. after mastectomy vs. none), adjuvant chemotherapy (yes vs. no), adjuvant endocrine 
therapy (yes vs. no), salpingo-oophorectomy (treated as time-dependent variable), age at primary 
breast cancer, and BRCA mutation type (BRCA1 vs. BRCA2) using Cox regression in univariate and 
multivariate analyses. The cumulative 5-, 10-, and 15-year risks of CBC were calculated using Kaplan-
Meier analysis including only patients who underwent DNA testing for BRCA1/2 mutation before the 
diagnosis of CBC, to correct for potential selection bias.
Analyses were performed for the total group and for patients younger than 40 years at primary breast 
cancer, as it has been previously reported that younger patients are more susceptible for radiation-
induced breast cancer [3-6].
The proportion of patients undergoing different locoregional treatments over time, including breast 
conserving treatment and mastectomy with or without radiotherapy, was estimated with a regression 
line of best fit and 95% CI based on the proportion per year. The same was performed for the 
proportion of patients undergoing contralateral risk-reducing mastectomy over time. For statistical 
analysis STATA, version 13.0, was used. For computing the figures, R version 3.2.2 (released on 2015-08-
14) and the package GGplot version 1.0.1. were used.
resulTs
A total of 691 BRCA1/2-associated breast cancer patients, consisting of 517 BRCA1 and 174 BRCA2 
mutation carriers, were eligible for data analysis (Tables 1 and 2). Median time of follow-up of the 
entire cohort was 8.6 years with a range from 0.3 to 34.3 years. A total of 439 patients were treated with 
radiotherapy either after lumpectomy (n = 349) or after mastectomy (n = 85). A total of 325 patients 
were younger than 40 years at primary breast cancer diagnosis (Table 2). Further details on patient, 
tumor, and treatment characteristics are presented in Tables 1 and 2.
Of all patients, 161 (23%) developed CBC, of whom 87 were younger than 40 years at breast cancer 
onset. The cumulative 5-, 10-, and 15-year risks of CBC for the total cohort were 8, 19, and 32%, 
respectively. Among the patients younger than 40 years, the cumulative 5-, 10-, and 15-year CBC risks 
were 11, 32, and 40%, respectively. Cumulative risks for BRCA-specific subgroups suggest a higher 
cumulative risk for BRCA1-associated patients compared to BRCA2-associated patients (Table 3). 
Median time interval between primary breast cancer and CBC was 4.8 years (range 0.5-29.0) for the 
entire cohort and 5.5 years (range 0.5-29.0 years) for patients diagnosed before the age of 40. 
Left truncation was applied to correct for survival bias that may occur in studies with patient 
recruitment at a variable time after diagnosis (see statistical analysis). Consequently, a considerable 
number of patients did not contribute person time to the prospective follow-up, leaving 418 patients 
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Table 1. Characteristics of the patients, radiotherapy vs. no radiotherapy.
Total
(n = 691)a
rT after 
lumpectomy
(n = 349)
no rT after 
mastectomy
(n = 252)
rT after 
mastectomy
(n = 85)
p-value
n (%) n (%) n (%) n (%)
Age at primary breast cancer
<30 years
30-34 years
35-39 years
40-44 years
45-50 years
>50 years
55 (8.0)
115 (16.6)
155 (22.4)
129 (18.7)
100 (14.5)
137 (19.8)
29 (8.3)
59 (16.9)
78 (22.3)
64 (18.3)
48 (13.8
71 (20.3)
19 (7.5)
39 (15.5)
57 (22.6)
49 (19.4)
35 (13.9)
53 (21.0)
7 (8.2)
15 (17.0)
20 (23.5)
16 (18.8)
16 (18.8)
11 (12.9) 0.943
Mutation status
BRCA1
BRCA2
517 (74.8)
174 (25.2)
277 (79.4)
72 (20.6)
186 (73.8)
66 (26.2)
50 (58.8)
35 (41.2) <0.001
Period of primary breast cancer
1980-1989
1990-1999
2000-2013
105 (15.2)
256 (37.1)
330 (47.8)
64 (18.3)
139 (39.8)
146 (41.8)
27 (10.7)
101 (35.3)
164 (54.0)
14 (16.5)
27 (31.8)
44 (51.8) 0.017
Tumor stage
Tis
T1
T2
T3
T4
Unknown
26 (4.0)
364 (56.0)
227 (34.9)
25 (3.9)
8 (1.2)
41
14 (4.1)
209 (61.8)
114 (33.7)
0
1 (0.3)
11
12 (5.2)
130 (56.5)
80 (34.8)
7 (3.0)
1 (0.4)
22
0
25 (30.9)
32 (39.5)
18 (22.2)
6 (7.4)
4 <0.001
Nodal status
N0
N1-3
Unknown
424 (64.3)
235 (35.7)
32
241 (71.9)
94 (28.1)
14
169 (70.1)
72 (29.9)
11
13 (16.0)
68 (84.0)
4 <0.001
Histological grade
Grade 1
Grade 2
Grade 3
unknown
17 (3.3)
106 (20.4)
396 (76.3)
172
8 (3.1)
54 (21.0)
195 (75.9)
92
7 (3.6)
37 (19.2)
149 (77.2)
59
2 (3.0)
14 (20.9)
51 (76.1)
18 0.988
Hormone receptor status
Positive
Negative
Unknown
227 (39.5)
348 (60.5)
116
108 (37.8)
178 (62.2)
63
80 (37.9)
131 (62.1)
41
39 (50.0)
39 (50.0)
7 0.124
HER2 status
Positive
Negative
Unknown
17 (6.7)
236 (93.3)
438
9 (8.1)
101 (91.8)
239
5 (5.2)
95 (94.8)
152
3 (7.5)
37 (92.5)
45 0.646
(Contralateral) risk-reducing 
mastectomy
No
Yes 
Unknown
424 (64.5)
233 (35.5) 
34
243 (73.0)
90 (27.0) 
16
127 (51.8)
118 (46.2) 
7 
54 (68.4)
25 (31.7) 
6 <0.001
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Table 1. Characteristics of the patients, radiotherapy vs. no radiotherapy (Continued).
Total
(n = 691)a
rT after 
lumpectomy
(n = 349)
no rT after 
mastectomy
(n = 252)
rT after 
mastectomy
(n = 85)
p-value
n (%) n (%) n (%) n (%)
Salpino-oophorectomy
No
Yes
Unknown
259 (41.2)
370 (58.8)
62
135 (42.5)
183 (57.5)
31
87 (38.2)
141 (61.8)
24
35 (44.3)
44 (55.7)
6 0.499
(Neo)adjuvant chemotherapy
No
Yes
Unknown
319 (46.6)
365 (53.4)
7
176 (51.0)
169 (49.0)
4
109 (43.6)
141 (56.4)
2
30 (35.7)
54 (64.3)
1 0.022
Adjuvant endocrine therapy
No
Yes
Unknown
555 (81.1)
129 (18.9)
7
300 (87.2)
44 (12.8)
5
203 (81.2)
47 (18.9)
2
48 (56.5)
37 (43.5)
0 <0.001
RT: radiotherapy.
a Data on type of surgery (either lumpectomy or mastectomy) was missing in five patients who were treated with 
radiotherapy.
Table 2. Characteristics of the patients with age at primary breast cancer diagnose <40 years, radiotherapy vs. no 
radiotherapy.
Total
(n = 325)a
rT after 
lumpectomy
(n = 166)
no rT after 
mastectomy
(n = 115)
rT after 
mastectomy
(n = 42)
p-value
n (%) n (%) n (%) n (%)
Age at primary breast cancer
<30 years
30-34 years
35-39 years
55 (16.9)
115 (35.4)
155 (47.7)
29 (17.5)
59 (35.5)
78 (47.0)
19 (16.5)
39 (33.9)
57 (49.6)
7 (16.7)
15 (35.7)
20 (47.6) 0.996
Mutation status
BRCA1
BRCA2
261 (80.3)
64 (19.7)
143 (86.1)
23 (13.9)
89 (77.4)
26 (22.6)
27 (64.3)
15 (35.7) 0.004
Period of primary breast cancer
1980-1989
1990-1999
2000-2013
43 (13.2)
114 (35.1)
168 (51.7)
33 (19.9)
68 (41.0)
65 (39.2)
5 (4.4)
35 (30.4)
75 (65.2)
5 (11.9)
10 (23.8)
27 (64.3) <0.001
Tumor stage
Tis
T1
T2
T3
T4
Unknown
9 (2.9) 
179 (58.5) 
103 (33.7) 
8 (2.6) 
7 (2.3) 
19
4 (2.6)
95 (60.5)
57 (36.3)
0
1 (0.6)
9
5 (4.5)
70 (63.6)
31 (28.2)
3 (2.7)
1 (0.9)
5
0
14 (35.9)
15 (38.5)
5 (12.8)
5 (12.8)
3 <0.001
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Table 2. Characteristics of the patients with age at primary breast cancer diagnose <40 years, radiotherapy vs. no 
radiotherapy (Continued).
Total
(n = 325)a
rT after 
lumpectomy
(n = 166)
no rT after 
mastectomy
(n = 115)
rT after 
mastectomy
(n = 42)
p-value
n (%) n (%) n (%) n (%)
Nodal status
N0
N1-3
Unknown
206 (66.0)
106 (34.0)
13
120 (74.5)
41 (25.5)
5
78 (70.3)
33 (29.7)
4
7 (17.9)
32 (82.1)
3 <0.001
Histological grade
Grade 1
Grade 2
Grade 3
Unknown
6 (2.5) 
45 (18.4) 
193 (79.1) 
81
2 (1.7)
21 (17.7)
96 (80.7)
47
2 (2.1)
17 (18.1)
75 (79.8)
21
2 (6.5)
7 (22.6)
22 (71.0)
11 0.561
Hormone receptor status
Positive
Negative
Unknown
93 (33.1)
188 (66.9)
44
41 (29.5)
98 (70.5)
27
31 (30.7)
70 (69.3)
14
21 (52.5)
19 (47.5)
2 0.020
HER2 status
Positive
Negative
Unknown
10 (7.6)
122 (92.4)
193
4 (7.8)
47 (92.2)
115
3 (5.5)
52 (94.5)
60
3 (12.0)
22 (88.0)
17 0.592
(Neo)adjuvant chemotherapy
No
Yes
Unknown
125 (38.9)
196 (61.1)
4
75 (45.7)
89 (54.3)
2
33 (28.9)
81 (71.1)
1
16 (39.0)
25 (61.0)
1 0.019
Adjuvant endocrine therapy
No
Yes
Unknown
262 (81.4)
60 (18.6)
3
148 (90.2)
16 (9.8)
0
90 (78.9)
24 (21.1)
1
22 (52.4)
20 (47.6)
0 <0.001
Contralateral risk-reducing 
mastectomy
No
Yes
Unknown
174 (55.8)
138 (44.2) 
13
105 (66.0)
54 (34.0)
7
46 (41.1)
66 (58.9)
3
23 (56.1)
18 (43.9)
1 <0.001
Salpingo-oophorectomy
No
Yes
Unknown
128 (42.8)
171 (57.2)
26
66 (43.7)
85 (56.3)
15
43 (40.6)
63 (59.4)
9
18 (45.0)
22 (55.0)
2 0.825
RT: radiotherapy.
a Data on type of surgery (either lumpectomy or mastectomy) was missing in two patients who were treated with 
radiotherapy.
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for the main analyses. In univariate analysis, the risk of CBC was increased in patients younger than 
40 years compared to those older than 40 years at primary breast cancer (HR 2.42; 95% CI 1.34-4.38). 
Furthermore, mutation carriership of BRCA1 was associated with increased risk of CBC as compared 
to BRCA2 mutation carriership (HR 2.32; 95% CI 0.98-5.51). Both chemotherapy and endocrine therapy 
were significantly associated with a decreased risk of CBC (HR 0.45; 95% CI 0.25-0.81 and HR 0.27; 95% 
CI 0.08-0.86, respectively). For salpingo-oophorectomy, no association with CBC risk was found (HR 
0.73; 95% CI 0.37-1.43) (Table 4).
No deleterious effect of radiotherapy for primary breast cancer, either after lumpectomy or after 
mastectomy, on CBC risk was found for the entire population (HR 0.84; 95% CI 0.46-1.55 and HR 
0.62; 95% CI 0.17-2.23, respectively) (Table 4). Adjusting for age, adjuvant chemotherapy, adjuvant 
endocrine therapy, and type of BRCA mutation in a multivariate analysis still showed no association of 
radiotherapy on CBC risk (HR 0.74; 95% CI 0.40-1.37 and HR 0.96; 95% CI 0.23-3.97, respectively). 
Table 3. Cumulative 5-, 10-, and 15-year risks of contralateral breast cancer.
Years after diagnosis Overall
% (n at risk)
BRCA1 mutation
% (n at risk)
BRCA2 mutation
% (n at risk)
Age <40
% (n at risk)
Age ≥40
% (n at risk)
5 8 (198) 9 (140) 5 (58) 11 (86) 6 (112)
10 19 (98) 21 (75) 15 (23) 32 (39) 10 (59)
15 32 (47) 35 (37) 15 (10) 40 (17) 23 (30)
Cumulative 5-, 10-, and 15-year risks of contralateral breast cancer in different subgroups of breast cancer patients 
(BRCA1 mutation carriers vs. BRCA2 mutation carriers and age at primary breast cancer <40 years vs. ≥40 years). 
Only those patients who underwent DNA testing for BRCA1/2 mutation before the diagnosis of contralateral breast 
cancer were included.
subgroup analyses of patient younger than 40 years at BC onset
Also in the subgroup of patients younger than 40 years at primary breast cancer diagnosis, no effect 
of radiotherapy for primary breast cancer, either after lumpectomy or after mastectomy, on CBC risk 
was found in univariate analysis (n = 211; HR 1.41; 95% CI 0.62-3.23 and HR 0.94; 95% CI 0.18-4.86, 
respectively), and this was maintained in multivariate analysis (HR 1.53; 95% CI 0.22-10.51 and HR 0.97; 
95% CI 0.41-2.30, respectively) (Figure 1; Table 4). Median time interval between primary breast cancer 
and CBC diagnoses was not significantly different between those treated with radiotherapy for primary 
breast cancer compared to those patients not receiving radiotherapy (5.5 vs. 4.9 years, p = 0.88).
During follow-up, the number of patients at risk substantially decreased because a large proportion 
of patients were censored as they underwent a contralateral risk-reducing mastectomy, developed a 
breast cancer recurrence or a second non-breast malignancy. In the group younger than 40 years at 
breast cancer onset, 165 of 325 patients (51%) were censored in the first 10 years of follow-up because 
of these three reasons (Figure 2). Furthermore, since a large proportion of patients had less than 10 
years of follow-up time, only 29 and 14 patients were available for the prospective analyses after 10 
and 15 years of follow-up in this age group, respectively.
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Treatment choices over time
Over the past decades, the proportion of patients at risk for radiation-induced CBC changed 
substantially as a result of an increased rate of mastectomy without radiotherapy instead of breast 
conserving therapy for primary breast cancer, and an increased rate of contralateral risk-reducing 
mastectomy (Figures 3 and 4). For example, patients aged younger than 40 years at diagnosis more 
often opted for mastectomy without radiotherapy instead of breast conserving therapy in 2010 
(reaching 50%), compared to less than 30% in 1995. The proportion of patients receiving radiotherapy 
following mastectomy was relatively stable over time being around 10-15% (Figure 3). Since 2010, 
more than 60% of patients younger than 40 years at primary diagnosis opted for contralateral risk-
reducing mastectomy, after primary breast cancer treatment, which was less than 40% in 1995 (Figure 4).
Table 4. Univariate and multivariate hazard ratios for risk of contralateral breast cancer associated with selected 
factors.
Overall Age <40 years
univariate analyses
number of patients: 
n = 418
Person years: 1105 years
hr (95% CI)
univariate analyses
number of patients: 
n = 211
Person years: 467 years
hr (95% CI)
Multivariate analysisa
number of patients: 
n = 211
Person years: 467 years
hr (95% CI)
Age at primary breast cancer
<40 years
≥40 years
2.42 (1.34-4.38)
1
Age at primary breast cancer
Continuous 0.94 (0.90-0.97) 0.93 (0.85-1.01) 0.96 (0.88-1.06)
BRCA mutation
BRCA1
BRCA2
2.32 (0.98-5.51)
1
3.52 (0.83-14.99)
1
2.33 (0.51-10.73)
1
Chemotherapy
No
Yes
1
0.45 (0.25-0.81)
1
0.51 (0.24-1.09)
1
0.52 (0.24-1.14)
Endocrine therapy
No
Yes
1
0.27 (0.08-0.86)
1
0.24 (0.06-1.02)
1
0.25 (0.05-1.23)
Salpingo-oophorectomy (time dependent)
No
Yes
 
1 
0.73 (0.37-1.43)
 
1 
1.22 (0.53-2.81)
Radiotherapy
No radiotherapy after mastectomy
Radiotherapy after mastectomy
Radiotherapy after lumpectomy
1
0.62 (0.17-2.23)
0.84 (0.46-1.55)
1
0.94 (0.18-4.86)
1.41 (0.62-3.23)
1
0.97 (0.41-2.30) 
1.53 (0.22-10.51)
HR: hazard ratio; CI: confidence interval
a The following variables were incorporated in the multivariate model: age at primary breast cancer (continuous 
variable), type of BRCA mutation (BRCA1 vs. BRCA2), adjuvant chemotherapy (yes vs. no), adjuvant endocrine 
therapy (yes vs. no) and radiotherapy (no radiotherapy after mastectomy vs. radiotherapy after mastectomy and 
vs. radiotherapy after lumpectomy).
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figure 1. Kaplan-Meier estimates of the contralateral breast cancer (CBC) risk in BRCA1/2 mutation carriers, younger 
than 40 years of age at primary breast cancer diagnosis. For this analysis, left truncation of analysis time at the DNA 
test date was applied, to correct for survival bias. Patients treated with radiotherapy (either after lumpectomy or 
after mastectomy) were compared to those not treated with radiotherapy at primary breast cancer diagnosis.
figure 2. Cumulative frequency of contralateral breast cancer or reasons for censoring event at study start and 
after 5, 10, 15, and 20 years of follow-up in all included patients who were younger than 40 years of age at primary 
breast cancer diagnosis. Recurrence includes both ipsilateral recurrence, a second ipsilateral primary tumor, and 
metastatic disease. End of FU (follow-up) comprises patients who did not reach the primary endpoint or other 
censoring event at data cut-off  or were lost to follow up.
(C)RRM: (contralateral) risk-reducing mastectomy; CBC: contralateral breast cancer.
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figure 3. Distribution of the choice of local therapy at primary breast cancer diagnosis by year of diagnosis among 
patients younger than 40 years of age with a BRCA1 or BRCA2 mutation. Regression line of best fi t and estimate of 
95% confi dence interval (gray). 
RT: Radiotherapy.
figure 4. Proportion of patients with a BRCA1 or BRCA2 mutation and breast cancer diagnosis below the age of 40 
opting for contralateral (or bilateral) risk-reducing mastectomy (either at primary breast cancer treatment or within 
the years after primary breast cancer) by year of breast cancer diagnosis. Regression line of best fi t and estimate of 
95% confi dence interval (gray).
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DIsCussIOn AnD COnClusIOn
The risk of CBC among breast cancer patients with a BRCA1/2 mutation is high, especially for younger 
patients. An association between adjuvant radiotherapy and the development of CBC in BRCA1/2-
associated breast cancer patients was not observed, neither in the entire cohort, nor in the subgroup 
of patients younger than 40 years at primary diagnosis. We found in this study that during follow-up 
the number of patients at risk for developing CBC substantially decreased due to either contralateral 
risk-reducing mastectomy or breast cancer recurrence (26 and 14%, respectively, within the first five 
years after primary BC among patients younger than 40 years). As a consequence, the number of 
patients at risk after 10 and 15 years of follow-up was too small to definitively exclude harmful effects 
of radiotherapy on the development of CBC among young BRCA1/2 mutation carriers.
A few other studies also reported on CBC risk in BRCA1/2-associated breast cancer patients treated 
with adjuvant radiotherapy compared to patients not treated with radiotherapy [13-15], and did not 
find an increased risk of CBC associated with adjuvant radiotherapy either. In the two multicenter 
retrospective cohort studies of breast cancer patients attending high-risk clinics [13,14], the numbers 
of young BRCA1/2 mutation carriers and follow-up periods were comparable to our study (145 out 
of 655 patients younger than 35 years with a median follow-up of eight years in the study of Pierce 
et al. [13], and 357 out of 810 patients younger than 40 years with a median follow-up of eleven 
years in the study of Metcalfe et al. [14]). However, subgroup analyses among these younger patients 
were not reported. Bernstein et al. performed a nested case control study within the WECARE study 
(Women’s Environmental Cancer and Radiation Epidemiology Study), which is a population-based 
study of patients with metachronous CBC [15], but again no results of subgroup analysis in younger 
patients were shown.
The main limitation of our study regarding the impact of radiotherapy on the CBC risk is the small 
number of patients at risk for CBC after 10-15 years of follow-up, as studies including sporadic patients 
suggest that a minimal latency period of 10-15 years is needed to develop radiation-induced BC 
[19,20]. It is, however, not known whether the latency period between exposure and development 
of a radiation-induced malignancy is similar for BRCA1/2 mutation carriers compared to sporadic 
patients. Even, if the latency period in BRCA1/2 mutation carriers is shorter, the number of patients at 
risk for CBC in our study group was too small to make definitive conclusions, especially since a large 
proportion of patients were already censored in the first five years. Given the number of events in 
patients younger than 40 years at primary breast cancer diagnosis, our study had 80% power to find 
an HR of at least 2.8 for adjuvant radiotherapy to be associated with increased risk of CBC.
In our total cohort, the 10-year cumulative risk of CBC in BRCA1/2 mutation carriers was 19%, while in 
the subgroup of patients younger than 40 years at breast cancer onset this risk was 32%. These risks 
are comparable to the risks reported in other studies [14,21,22]. Furthermore, the CBC risk was higher 
in BRCA1 compared to BRCA2 mutation carriers. Both the increased risk in younger patients and the 
increased risk in BRCA1- compared to BRCA2-associated breast cancer patients have been described 
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in other studies [14,21-23]. Additionally, in our cohort adjuvant systemic therapy for primary breast 
cancer, applying for both endocrine therapy and chemotherapy, was associated with a decreased 
risk of CBC. This effect, however, was only significant in the entire cohort and not in the subgroup of 
younger patients. Since the HRs were similar, this might be due to the lack of statistical power. The 
risk-reductive effect of adjuvant endocrine therapy on CBC risk in BRCA1/2 mutation carriers has been 
reported in previous studies [14,24,25]. Regarding chemotherapy, three studies have investigated the 
association between chemotherapy and CBC [14,23,26], whereby only Reding et al. found a significant 
association with a relative risk of 0.5. Although this latter association is biologically not totally clear, 
further research is certainly warranted. We did not find any impact of salpingo-oophorectomy on CBC 
risk, which is in contrast with previous reports [27,28], but is in line with more recent literature [29].
In our cohort, we found a growing preference over time for mastectomy without radiotherapy instead 
of breast conserving therapy including radiotherapy. At the same time, the rate of contralateral risk-
reducing mastectomy after primary breast cancer treatment has increased. Important reasons for the 
shift toward ablative breast surgery might be the improvements in and availability of (direct) breast 
reconstructive options, the increased awareness of the magnitude of the CBC risk and distress of 
screening, and the wish to avoid another treatment session for a second primary breast cancer. Finally, 
the important findings of Heemskerk et al. showing that contralateral risk-reducing mastectomy 
improves survival, mainly in younger patients and those with favorable primary tumor characteristics 
[30], might lead to an even larger proportion of younger patients opting for mastectomy without 
radiotherapy and contralateral risk-reducing mastectomy after primary breast cancer diagnosis in the 
nearby future. 
These trends in locoregional treatments eventually decreased the proportion of patients at risk for 
radiation-induced CBC over the past few decades. Nevertheless, the question whether adjuvant 
radiotherapy has deleterious effect on CBC risk still remains clinically important for a significant 
number of patients, who want to conserve their (ipsilateral and) contralateral breast. Moreover, in the 
nearby future a larger proportion of patients potentially might opt for breast conserving treatment 
and abstain from contralateral risk-reducing mastectomy, due to an increased use of endocrine 
therapy as chemoprevention, improved diagnostic imaging techniques for screening, and improved 
effectiveness of adjuvant systemic therapy (for example, in combination with PARP inhibitors) [31-33].
In the current study, we could not find an association between radiotherapy for primary breast cancer 
and risk of CBC in (young) BRCA1/2 mutation carriers compared to sporadic patients; however, the 
number of patients at risk after 10 and 15 years of follow-up was too small to definitively exclude 
harmful effects of adjuvant radiotherapy. An increase in the percentage of young patients with 
BRCA1/2-associated breast cancer choosing for conserving their (ipsilateral and) contralateral breast 
is not unlikely. Therefore, future research in larger study populations with minimal follow-up of 10 
years is needed to achieve a better understanding of the true effect of radiotherapy on the CBC risk in 
BRCA1/2-associated breast cancer patients. This will only be possible by combining study populations 
through collaborative efforts on a national or even international level. 
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ABsTrACT
Treatment with (neo)adjuvant chemotherapy for breast cancer, as currently given, causes cell damage 
by induction of double strand DNA breaks. Because BRCA1 and BRCA2 proteins play a role in the repair 
of DNA damage, the efficacy of (neo)adjuvant chemotherapy may be increased in BRCA1 and BRCA2 
(BRCA1/2)-associated breast cancer patients. As a downside, acute chemotherapy-related toxicity 
may also be increased. We selected all female patients who were treated at the Erasmus MC Cancer 
Institute, with (neo)adjuvant chemotherapy for primary or locoregional recurrence of breast cancer 
(PBC/LR) between January 1, 2004 and December 31, 2014. The primary outcome was the relative total 
dose intensity (RTDI), calculated for anthracyclines and taxanes separately. Secondary outcomes were 
the occurrence of febrile neutropenia, delay in chemotherapy administration, and switch to another 
chemotherapy regimen due to toxicity. In total, 701 patients treated for PBC/LR were eligible for data 
analyses, among which 85 BRCA1/2 mutation carriers (n = 67 BRCA1 and n = 18 BRCA2). The mean 
RTDI for anthracyclines was not significantly different between both groups (98.7% in the BRCA1/2 
and 96.6% in the sporadic group, p = 0.27). Also the mean RTDI for taxanes was not significantly 
different between the groups (93.6% in the BRCA1/2-associated and 90.0% in the sporadic group, p = 
0.12). Linear regression analysis revealed no significant effect of BRCA1/2 mutation carriership on the 
RTDIs. No significant differences were found in the percentages of patients presenting with febrile 
neutropenia, having a delay in chemotherapy administration or switching to an altered chemotherapy 
regimen. Additionally, the odds ratios showed no significant effect of BRCA1/2 mutation carriership 
on the secondary outcome variables. (Neo)adjuvant chemotherapy-related toxicity was not different 
between BRCA1/2-associated and sporadic breast cancer patients suggesting that the DNA damage 
repair mechanism of non-cancer cells with only one normal copy of either the BRCA1 or BRCA2 gene 
is sufficiently functional to handle acute chemotherapy-associated toxicity.
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InTrODuCTIOn
Carriers of a germline BRCA1 or BRCA2 (BRCA1/2) mutation face an increased lifetime risk of developing 
breast cancer, estimated to range from 47 to 66% for BRCA1 mutation carriers and from 40 to 57% for 
BRCA2 mutation carriers [1,2].
Carriers of a germline BRCA1/2 mutation, by definition, have one allele with a mutation in the BRCA1/2 
gene, while the gene on the other allele is intact. In normal cells, it seems that enough BRCA1 or 
BRCA2 protein is present for adequate functioning of cells in the various tissues of these women. 
However, BRCA1/2-associated breast cancers often have lost the wild type allele through somatic 
alterations during tumor development. As a consequence, there is no functional BRCA1 or BRCA2 
protein in these tumor cells. Since BRCA1 and BRCA2 proteins are essential in the repair of double 
strand DNA breaks by homologous recombination [3,4], treatments which cause double strand DNA 
breaks might be more effective in BRCA1/2-associated than in sporadic breast cancer patients, which 
tumor cells mostly have an intact homologous recombination repair system. The platinum derivates 
carboplatin and cisplatin, both strong inducers of double strand DNA breaks, indeed showed 
higher efficacy in BRCA1/2-associated compared to sporadic breast cancer patients [5-7]. Although 
less pronounced, anthracyclines are also known to induce indirect double strand DNA breaks by 
inhibiting topoisomerases, causing DNA interstrand cross-links and the generation of free radicals 
[8]. Accordingly, several clinical studies have shown increased sensitivity for anthracycline-containing 
chemotherapy in BRCA1/2 mutation carriers [9-11].
An important question is whether acute toxicity due to (neo)adjuvant chemotherapy is different in 
BRCA1/2 mutation carriers treated for breast cancer when compared with sporadic breast cancer 
patients. Since (neo)adjuvant chemotherapy induces massive DNA damage also in normal cells, 
one might argue that the amount of functional BRCA1 or BRCA2 protein in mutation carriers is too 
low to repair all the DNA damage created, compared to sporadic breast cancer patients, resulting in 
more toxicity. Thus far two studies investigated the acute toxicity of (neo)adjuvant chemotherapy in 
BRCA1/2-associated, compared to sporadic breast cancer patients, with inconsistent results [12,13]. In 
the retrospective study of Shanley et al., comparing 62 BRCA1/2 mutation carriers with breast cancer 
to 62 matched sporadic breast cancer cases, a large proportion of patients (80/124; 65%) was treated 
with older chemotherapy regimens without anthracyclines, while no patient was treated with taxanes. 
In BRCA2 mutation carriers, less hematological toxicity and dose alterations were observed compared 
to both BRCA1-associated and sporadic breast cancer patients, while no differences were seen for 
BRCA1-associated versus sporadic patients [12]. In the study by Huszno et al., comparing 41 BRCA1/2-
associated with 229 breast cancer patients without a BRCA1/2 mutation, all patients were treated 
with an anthracycline-based regimen and also patients treated with taxanes were included [13]. It 
was found that the proportion of patients with neutropenia at the planned start date of the second 
chemotherapy cycle was significantly higher in breast cancer patients with a BRCA1/2 mutation 
compared to patients without a BRCA1/2 mutation. Twelve patients (4.5%), all in the group of patients 
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without a BRCA1/2 mutation, required early termination of treatment due to chemotherapy toxicity, 
mostly because of grade 3-4 neutropenia. Nausea and vomiting were seen more often in patients 
without a BRCA1/2 mutation. There were no differences in the other investigated variables (anemia, 
diarrhea, and mucositis).
Nowadays, standard (neo)adjuvant chemotherapy regimens for breast cancer contain both 
anthracycline (either epirubicin or doxorubicin) and taxanes (either paclitaxel or docetaxel). In view 
of the sparse available data on toxicity of taxanes and currently used chemotherapy regimens in 
BRCA1/2 mutation carriers, we performed a larger single center retrospective cohort study to examine 
potential differences in (neo)adjuvant chemotherapy-associated toxicity between BRCA1/2-associated 
and sporadic breast cancer patients.
PATIenTs AnD MeThODs
Patient population
For this retrospective cohort study, we selected from the hospital pharmacy prescription registry all 
female patients who were treated at the Erasmus MC Cancer Institute, Rotterdam, The Netherlands, 
with adjuvant or neoadjuvant chemotherapy for primary breast cancer or local/locoregional recurrence 
(PBC/LR). Further eligibility criteria concerned: chemotherapy regimen consisting of anthracyclines 
and/or taxanes and chemotherapy treatment started between January 1, 2004 and December 31, 
2014. Patients who were previously treated with chemotherapy for either breast or another invasive 
cancer were not excluded, but subgroup analyses were performed with the exclusion of these 
patients, since pre-treated patient might have increased hematological toxicity. Patients treated with 
(neo)adjuvant chemotherapy twice in the time period of the study were included for both episodes 
of chemotherapy treatment. Eleven PBC/LRs were excluded because of missing data concerning 
chemotherapy administration, leaving a total of 704 PBC/LRs (in 701 patients) eligible for the primary 
analysis (Figure 1).
For eligible patients, data on tumor characteristics (type of histology, differentiation grade, estrogen 
receptor status, progesterone receptor status, HER2 status and stage) and treatment details (surgery, 
radiotherapy, and/or chemotherapy) were retrieved. We also collected specific data on chemotherapy 
treatment (treatment regimen, dosing, delays, alterations, and complications). Data on mutation 
status were collected from the institutional database of the family cancer clinic. Patients not tested for 
a BRCA1/2 mutation were considered as sporadic breast cancer patients.
Chemotherapy regimens
During the time period of the study, the chemotherapy regimens were not different for BRCA1/2 
mutation carriers and sporadic patients. Patients were treated with systemic therapy based on the 
national guidelines. For patients with HER2-negative breast cancer, the standard regimens at start of 
the study contained anthracyclines but no taxanes. From July 2008 till the end of the study, standard 
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regimen for node positive patients included taxanes (three-weekly docetaxel), while for node negative 
patients, taxanes (three-weekly docetaxel) were included in the standard regimen from October 2011 
onwards. Patients with HER2-positive breast cancer were treated with anthracyclines and no taxanes 
till August 2006. Trastuzumab was added to this regimen from September 2005 onwards. From August 
2006 till the end of the study, the standard regimen contained anthracyclines and taxanes (weekly 
paclitaxel) in combination with trastuzumab.
Some patients were treated with other schemes because of participation in a clinical trial, prior 
chemotherapy treatment, or comorbidities. Standard G-CSF (granulocyte colony-stimulating factor) 
prophylaxis was only used for six cycles of TAC (docetaxel, doxorubicin, and cyclophosphamide) and 
dose-dense regimens (AC, doxorubicin/cyclophosphamide, given every two weeks). In case of febrile 
neutropenia or persisting neutropenia at planned start of next chemotherapy cycle, G-CSF was added 
to the next treatment cycle. In case of febrile neutropenia or persisting neutropenia at planned start of 
next chemotherapy cycle in patients treated with G-CSF, dose reduction was considered. Furthermore, 
dose reduction and/or dose delay were considered based on the severity of hematological and non-
hematological toxicities.
19 
 
 
                Primary analysis 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Selection criteria: Primary breast cancer and/or local/locoregional recurrence, 
in female patients treated with (neo)adjuvant chemotherapy (anthracyclines 
and/or taxanes) between January 1, 2004 and December 31, 2014 
Selected: n = 715 (in 712 patients) 
Sporadic 
n = 627 
BRCA2 
n = 18 
BRCA1 
n = 70 
Missing data regarding 
chemotherapy doses and/or 
administration, n = 9 
Sporadic 
n = 618 
(in 616 patients) 
BRCA2 
n = 18 
(in 18 patients) 
BRCA1 
n = 68 
(in 67 patients) 
Missing data regarding 
chemotherapy doses and/or 
administration, n = 2 
figure 1. Study population.
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Toxicity outcomes
Primary outcome was the relative total dose intensity (RTDI), a measure of delivered (actual) total dose 
intensity (ATDI; i.e. administered dose over the total time course of treatment), relative to the planned total 
dose intensity (PTDI). The RTDI, therefore, expresses the effect of reductions, delays, as well as premature 
discontinuations of a treatment. The RTDI was calculated separately for anthracyclines and taxanes.
RTDI was calculated based on an adaptation of the formula described by Loibl et al. [14], and defined 
as the ratio of the ATDI and the PTDI, expressed as a percentage:
RTDI (%) = 
ATDI  
x 100
        PTDI
The ATDI was defined as the actual total dose intensity over the real treatment duration, expressed 
as percentage/day. In case of permanent treatment discontinuation, the remaining cycles were 
calculated with the planned length and zero dose:
ATDI (%/day) = 
sum of % of delivered dose per cycle
                  duration of therapy (days)
The PTDI was defined as the planned total dose intensity over the entire treatment duration, expressed 
as %/day:
PTDI (%/day) = 
100% x number of planned treatment cycles
                            planned duration of therapy (days)
The secondary outcomes were the occurrence of one or more episodes of febrile neutropenia, of 
one or more delays in chemotherapy administration (either due to anthracycline-related toxicity or 
taxane-related toxicity) and of switch to another chemotherapy regimen.
statistical analyses
We evaluated characteristics of patients, tumors and chemotherapy regimens, as well as outcome 
variables by comparing patients with proven BRCA1/2-associated breast cancer (BRCA1/2 group) with 
those with sporadic breast cancer (sporadic group). For categorical variables, Pearson’s χ2 square test 
was used to test for significant differences between the two groups, and the two-sample Wilcoxon 
rank-sum (Mann-Whitney) test was used for differences between continuous variables.
To quantify the effect of carrying a BRCA1/2 gene mutation on the RTDI of anthracyclines and taxanes, 
we performed univariate linear regression analyses. To estimate the effect of mutation carriership 
on the other endpoints (i.e. a delay in administration of chemotherapy, febrile neutropenia, and an 
alteration of the chemotherapy scheme due to toxicity), we used logistic regression models to obtain 
odds ratios (ORs) and accompanying 95% confidence intervals (CIs), using treatments for PBC/LRs in 
sporadic patients as the reference group. To adjust for other variables, we fitted multivariate regression 
models. We considered age at start of chemotherapy, previous chemotherapy, radiotherapy before 
chemotherapy, neoadjuvant chemotherapy, and number of administered chemotherapy cycles as 
potential confounders. We incorporated a variable in a regression model if (1) there was a significant 
difference in the median or in the distribution of the respective variable between the BRCA1/2-
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associated and the sporadic group and (2)—for linear regression models—univariate analysis of the 
respective variable showed a significant association with the outcome, or—for logistic regression 
models—the likelihood ratio test showed that the model including the respective variable was 
significantly different from the model without the variable.
All p values were two-sided, and a significance level α = 0.05 was used. Analyses were performed with 
STATA (version 13.1; StataCorp, College Station, TX, USA).
resulTs
In total, 701 patients were eligible for data analyses, of whom one BRCA1 mutation carrier and two 
sporadic patients were treated with two separate episodes of (neo)adjuvant chemotherapy for a 
PBC/LR during the study period. Tables 1 and 2 depict the patient and tumor characteristics, and 
the treatment features, respectively. Eighty-five patients (12%) were BRCA1/2 mutation carriers (n = 
67 BRCA1 and n = 18 BRCA2). The median age at start of chemotherapy was significantly lower in the 
BRCA1/2 group compared to the sporadic group (38 years [range 21-64] vs. 51 years [range 23-77], 
respectively, p <0.001). PBC/LRs in BRCA1/2 mutation carriers more often showed high differentiation 
grade (Bloom and Richardson grade 3), triple-negative tumors and negative lymph node status 
compared to PBC/LRs in sporadic patients. For a total of 492 PBC/LRs (70%), treatment with both 
anthracycline- and taxane-containing chemotherapy was applied, while chemotherapy consisted of 
anthracyclines with no taxanes for 193 PBC/LRs (27%) and for 19 PBC/LRs (3%) of taxanes with no 
anthracyclines. In the BRCA1/2 group, more patients were previously treated with chemotherapy for 
breast cancer or for another invasive malignancy (13 vs. 5% in the sporadic group, p = 0.004; Table 2).
Table 1. Patient and tumor characteristics.
BRCA1/2 mutation carriers 
(n = 85)
sporadic patients
(n = 616)
p-value
Year of birth, median (range) 1971 (1942-1990) 1957 (1936-1987) <0.001
Year of birth, n (%)
  1930-1939
  1940-1949
  1950-1959
  1960-1969
  1970-1979
  1980-1989
  1990-1999
0 (0)
4 (5)
15 (18)
18 (21)
30 (35)
17 (20)
1 (1)
8 (1)
130 (21)
205 (33)
188 (31)
66 (11)
19 (3)
0 (0)
<0.001
Ethnicity, n (%)
   East Asian
   Black
   White
   Other
0 (0)
6 (7)
79 (93)
0 (0)
17 (3)
36 (6)
557 (90)
6 (1)
0.33
BRCA mutation, n (%)
  BRCA1
  BRCA2
67 (79)
18 (21)
-
-
-
-
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Primary outcome
The mean RTDI for anthracyclines was high, without significant differences between the BRCA1/2 
and the sporadic groups (98.7 and 96.6%, respectively, p = 0.27; Table 3). The mean RTDI for taxanes 
was slightly lower than for anthracyclines, but again without significant differences between the two 
groups (93.6% in the BRCA1/2 group and 90.0% in the sporadic group, p = 0.12; Table 3). As illustrated 
in Figure 2, BRCA1/2 mutation carriers showed less variability in the RTDI than sporadic patients. As 
shown in Table 4, the linear regression models revealed no significant effect of BRCA1/2 mutation 
carriership on the RTDIs.
PBC/lrs in BRCA1/2 
mutation carriers 
(n = 86)
PBC/lrs in  
sporadic patients 
(n = 618)
p-value
Age at start chemotherapy, median (range) 38 (21-64) 51 (23-77) <0.001
Age at start chemotherapy, n (%)
  20-29 years
  30-39 years
  40-49 years
  50-59 years
  60-69 years
  70-79 years
12 (14)
34 (40)
23 (27)
12 (14)
5 (6)
0 (0)
15 (2)
61 (10)
179 (29)
221 (36)
136 (22)
6 (1)
<0.001
Body Surface Area (m2), median (range) 1.8 (1.4-2.3) 1.8 (1.4-2.6) 0.41
Histologic subtype, n (%)
  Ductal
  Lobular
  Other
  Unknown
74 (88)
1 (1)
9 (11)
2
521 (86)
58 (10)
30 (5)
9
0.005
Histologic grade (Bloom and Richardson), n (%)
  1
  2
  3
  unknown  
4 (5)
13 (16)
64 (79)
5
48 (8)
265 (46)
269 (46)
36
<0.001
Receptor status, n (%)
  Triple negative
  Estrogen receptor positive
  HER2 positive
51 (60)
32 (37)
4 (5)
101 (17)
466 (75)
135 (22)
<0.001
<0.001
<0.001
Lymph node status, n (%)
  N0
  N1
  N2
  N3
  Unknown
55 (65)
21 (25)
4 (5)
4(5)
2
228 (38)
254 (43)
78 (13)
37 (6)
21
<0.001
PBC/LR: primary breast cancer or local/locoregional recurrence.
Table 1. Patient and tumor characteristics (Continued).
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Table 2. Features of (neo)adjuvant chemotherapy and other treatments.
PBC/lrs in BRCA1/2 
mutation carriers 
(n = 86)
PBC/lrs in  
sporadic patients 
(n = 618)
p-value
Planned chemotherapy regimen, n (%)
- containing both anthracyclines and taxanes
     3xFE100C/3xD
     4xAC/12xP
     6xTAC
     Other
- containing anthracyclines and no taxanes
     5xFE90C
     6xFE90C
     4xAC
     Other
- containing taxanes and no anthracyclines
49 (57)
46 (53)
1 (1)
1 (1)
1 (1)
30 (35)
19 (22)
7 (8)
1 (1)
3 (3)
7 (8)
443 (72)
290 (47)
103 (17)
40 (6)
10 (2)
163 (26)
86 (14)
60 (10)
13 (2)
4 (1)
12 (2)
<0.001
Dose dense regimens, n (%) 3 (3) 1 (0.2) <0.001
Regimens with standard G-CSF prophylaxis, n (%) 4 (5) 41 (7) 0.48
Regimens with weekly chemotherapy, n (%) 1 (1) 104 (17) <0.001
Number of three-weekly chemotherapy cycles, median (range) 6 (3-10) 6 (1-8) 0.14
Previous chemotherapy, n (%) 11 (13) 31 (5) <0.01
Adjuvant radiotherapy before chemotherapy, n (%) 2 (2) 87 (14) <0.01
Neoadjuvant chemotherapy, n (%) 10 (12) 81 (13) 0.70
PBC/LR: primary breast cancer or local/locoregional recurrence; 3xFE100C/3xD: three cycles of three-weekly 
fluorouracil 500mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2, followed by three cycles of 
docetaxel 100 mg/m2; 4xAC/12xP: four cycles of three-weekly doxorubicin 60 mg/m2 and cyclophosphamide 600 
mg/m2, followed by twelve cycles of weekly paclitaxel 80 mg/m2; 6xTAC: six cycles of three-weekly docetaxel 75 
mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2; 5xFE90C: five cycles of three-weekly fluorouracil 
500mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 500 mg/m2; 6xFE90C: six cycles of three-weekly fluorouracil 
500 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 500 mg/m2; 4xAC: four cycles of three-weekly doxorubicin 
60 mg/m2 and cyclophosphamide 600 mg/m2; G-CSF: granulocyte colony stimulating factor.
Table 3. Primary and secondary outcome variables.
PBC/lrs in BRCA1/2 
mutation carriers 
(n = 86)
PBC/lrs in  
sporadic patients 
(n = 618)
p-value
Mean relative total dose intensity, % (SD)
     Anthracyclines
     Taxanes
98.7 (3.7)
93.6 (17.6)
96.6 (10.5)
90.0 (19.9)
0.27
0.12
Febrile neutropenia, n (%) 18 (21) 107 (17) 0.42
Delay of chemotherapy administration, n (%)
     Because of anthracyclines
     Because of taxanes
12 (15)
2 (4)
90 (15)
46 (10)
0.97
0.13
Alteration of chemotherapy scheme, n (%) 8 (9) 65 (11) 0.73
PBC/LR: primary breast cancer or local/locoregional recurrence; SD: standard deviation.
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figure 2. Relative total dose intensity (%) for (A) anthracyclines and (B) taxanes, separately for BRCA1/2-associated 
and sporadic breast cancer patients.
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Table 4. Linear regression analyses for mean relative total dose intensity.
univariate model Multivariate model
Coefficient (se) p-value Coefficient (se) p-value
Mean rTDI anthracyclines (%)
  BRCA1/2 versus sporadic 
  Age at start chemotherapy
  Previous chemotherapya
  Radiotherapy before chemotherapyb
1.69 (1.08)
-0.05 (0.03)
-1.09 (1.84)
-1.16 (1.00)
0.12
0.12
0.55
0.25
Not applicablec
Mean rTDI taxanes (%)
  BRCA1/2 versus sporadic 
  Age at start chemotherapy
  Previous chemotherapya
  Radiotherapy before chemotherapyb
3.94 (2.98)
-0.10 (0.08)
6.71 (4.17)
-6.77 (2.75)
0.19
0.22
0.11
0.01
3.33 (2.97)
-
-
-6.50 (2.76)
0.26
-
-
0.02
RTDI: relative total dose intensity; SE: standard error.
a versus no previous chemotherapy. 
b versus no radiotherapy before chemotherapy.
c none of the variables were associated with the outcome variable. 
Table 5. logistic regression analyses for secondary outcome variables.
univariate model Multivariate model
Odds ratio (95% CI) Odds ratio (95% CI)
febrile neutropenia 1.27 (0.71-2.27) 1.11 (0.59-2.07)a
Delay of chemotherapy administration
     Because of anthracyclines
     Because of taxanes
0.99 (0.50-1.97)
0.36 (0.08-1.54)
Not applicableb
Not applicableb
Alteration of chemotherapy scheme 0.80 (0.33-1.93) Not applicableb
Sporadic breast cancer patients as references vs. breast cancer patients with a BRCA1/2 mutation. 
CI: confidence interval. 
a adjusted for age at start chemotherapy. The other variables did not meet the criteria for incorporation in the 
multivariate model; 
b no variables did meet the criteria for incorporation in the multivariate model as described in the methods section. 
secondary outcomes
As shown in Table 3, no significant differences between the BRCA1/2-associated and sporadic 
groups were found in the percentage of patients presenting with febrile neutropenia (21 and 17%, 
respectively, p = 0.42), having a delay in chemotherapy administration due to chemotherapy toxicity 
(for anthracyclines: 15% in both groups, p = 0.97; for taxanes: 4% in the BRCA1/2-associated and 10% in 
the sporadic group, p = 0.13) or switching to an altered chemotherapy regimen due to chemotherapy 
toxicity (9% in the BRCA1/2-associated and 11% in the sporadic group, p = 0.73). Additionally, the ORs 
yielded by logistic regression showed no significant effect of BRCA1/2 mutation carriership on the 
secondary outcome variables (Table 5). 
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subgroup analyses
To exclude effect modification by differences in treatment regimens between the two groups on 
the outcome variables, we performed analyses with exclusion of certain chemotherapy regimens. 
Exclusion of the patients being treated with regimens administered with standard G-CSF prophylaxis 
(n = 4 treated with dose-dense regimens; n = 41 treated with TAC), with regimens consisting of weekly 
chemotherapy administration (n = 105) or with regimens containing taxanes with no anthracyclines 
(n = 19) did not significantly influence the results of both primary and secondary outcome variables 
(data not shown). Febrile neutropenia was then found in 25% of the BRCA1/2-associated and in 20% 
of the sporadic group, p = 0.57. Excluding the patients who were previously treated with adjuvant 
chemotherapy for breast cancer or for another invasive cancer (n = 42) also did not significantly 
influence the results of both primary and secondary outcome variables (data not shown). When taking 
the BRCA1/2-associated and the sporadic group together, the RTDI was not significantly different 
between patients previously versus not previously treated with chemotherapy (for anthracyclines 
RTDI: 96.8% in both groups, p = 0.80; for taxanes RTDI: 95.8 vs. 90.1%, p = 0.20).
DIsCussIOn
In this single center retrospective cohort study, we found no differences in RTDI of (neo)adjuvant 
chemotherapy (both for anthracyclines and taxanes) between BRCA1/2-associated and sporadic breast 
cancer patients. Furthermore, we found no differences in the occurrence of febrile neutropenia, in delay 
of chemotherapy administration or in alteration of the chemotherapy regimen due to toxicity between 
the two groups. Our observations on the absence of increased acute toxicity due to (neo)adjuvant 
chemotherapy in BRCA1/2 mutation carriers, compared to sporadic breast cancer patients, suggest that 
the DNA damage repair mechanism of non-cancer cells with only one normal copy of either the BRCA1 
or BRCA2 gene is sufficiently functional to handle acute chemotherapy-associated toxicity.
Our results have to be interpreted in the light of the two previously published studies on chemotherapy-
associated toxicity in BRCA1/2 mutation carriers. Huszno et al. found more neutropenia at the planned 
date of the second chemotherapy cycle in BRCA1/2-associated (n = 41) than in sporadic breast cancer 
patients (n = 229) [13]. It is unclear what the clinical relevance of this finding is, since they did not 
mention the proportion of patients needing dose reductions, experiencing delay in chemotherapy 
administration and febrile neutropenia. We choose to use more clinically relevant outcome measures 
such as dose intensity which is likely to be associated with efficacy [15] and febrile neutropenia that 
might have consequences for the subsequent cycle. The data of the study of Shanley et al., not finding 
increased chemotherapy-associated toxicity in BRCA1/2-associated (n = 62) compared to sporadic 
breast cancer patients (n = 62) [12], are hardly comparable to our study observations, since a large part 
of their patients were treated with older chemotherapy regimens.
To the best of our knowledge, our study is the largest published on this topic so far. We did not 
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find any differences in clinically relevant toxicity measures after treatment with anthracyclines and/or 
taxanes between BRCA1/2-associated and sporadic breast cancer patients. In both previous studies, 
as well as in our study, age at the start of chemotherapy was significantly lower in the BRCA1/2 
group than in the sporadic group. Although increased risk of myelosuppression at increased age of 
administration has been previously reported [16], in our study no difference was seen in mean RTDI 
comparing BRCA1/2 mutation carriers aged >50 years to BRCA1/2 mutation carriers younger than 50 
years (data not shown).
In the BRCA1/2 group more patients were previously treated with adjuvant chemotherapy than in 
the sporadic group, mainly for an earlier primary breast cancer. Since there is a maximum cumulative 
dose for anthracyclines, a relevant proportion of these patients did receive a non-anthracycline-
containing regimen. One might expect increased toxicity when patients are treated for a second time 
with chemotherapy. Leaving out all pre-treated patients, however, did not influence the results, and 
comparing previously treated patients with non-previously treated patients (irrespective of BRCA1/2 
mutation status) showed no significant differences in the RTDI, suggesting that previous treatment 
with chemotherapy does not increase acute chemotherapy-related toxicity. In the BRCA1/2-
associated group, fewer patients were treated with weekly chemotherapy regimens and with 
regimens containing standard G-CSF prophylaxis. However, exclusion of patients treated with these 
regimens did not significantly influence the results. The percentage of patients presenting with febrile 
neutropenia in the sporadic group increased in the subgroup analyses, compared to the percentage 
found in the primary analysis, which might be explained by the fact that in the sporadic group a larger 
proportion of patients were treated with regimens containing standard G-CSF prophylaxis.
We are aware of a number of shortcomings to be mentioned. Despite the fact that our study is the 
largest published on this topic with inclusion of 86 PBC/LRs in BRCA1/2-associated patients, being 
12% of the total study group, this number is still quite low. The numbers were too small to perform 
useful analyses for BRCA1 and BRCA2 mutation carriers separately, which would be of interest since 
BRCA1 and BRCA2 proteins have different roles in the DNA repair mechanism and the cell cycle. 
Nevertheless, it is unlikely that a clinically relevant difference will be found with higher numbers of 
patients, since the RTDI, especially for anthracycline is very high. In contrast to the study of Huszno 
et al., not all our patients were tested for a BRCA1/2 mutation, but we expect, if any, only a small 
proportion of BRCA1/2 mutation carriers in the sporadic subgroup, since at our institution (and in The 
Netherlands) patients are already tested with a low suspicion of BRCA1/2 mutation carriership. Further, 
in the current study, we did not include non-hematological toxicity as an outcome, since it is well 
known that these outcome variables are more prone to inter-observer variability and are less clinically 
relevant when they do not lead to dose delay or dose reduction [17]. For the same reason, we did not 
include hematological laboratory values measured at planned start of a new cycle, since these are 
only relevant when they lead to dose reduction, delay in chemotherapy administration, or alteration 
of chemotherapy regimen. It could have been of scientific interest to compare neutrophil nadir levels 
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between BRCA1/2 mutation carriers and sporadic patients. Unfortunately, due to the retrospective 
nature of our data, these data are lacking.
Recent data showed increased efficacy of platinum derivates in patients with triple-negative breast 
cancer and/or a BRCA1/2 mutation, leading to incorporation of carboplatin in standard (neo)adjuvant 
chemotherapy regimens in this population [5-7]. These studies did not report on differences in toxicity 
between BRCA1/2 mutation carriers and sporadic breast cancer patients. In our study, the number of 
patients treated with carboplatin was very low and no conclusions can be drawn hereon. Poly ADP-
ribose polymerase (PARP) inhibitors are an important new class of targeted anticancer drugs which 
induce double strand DNA breaks in tumors with homologous recombination deficiency due to, for 
example, a mutation in one of the BRCA genes. Recently, the first PARP inhibitor has been approved for 
the treatment of BRCA1/2-associated ovarian cancer, while trials in early and metastatic breast cancer 
are ongoing. Lederman et al. compared toxicity of the PARP inhibitor olaparib in BRCA1/2 mutation 
carriers and sporadic patients with ovarian cancer and found no differences in toxicity [18]. Both 
platinum derivates and PARP inhibitors have a much higher capacity to induce double strand DNA 
breaks, compared to anthracyclines. Therefore, further research on the toxicity of these regimens in 
BRCA1/2 mutation carriers compared to sporadic patients is warranted, especially since these drugs 
will be increasingly used in the treatment of BRCA1/2-associated breast cancer.
COnClusIOn
In conclusion, there seems no clinically relevant difference in toxicity of anthracycline- and taxane-
containing (neo)adjuvant chemotherapy regimens for BRCA1/2-associated compared to sporadic 
breast cancer patients, which suggests that the DNA damage repair mechanism of non-cancer cells 
with only one normal copy of either the BRCA1 or BRCA2 gene is sufficiently functional to handle acute 
chemotherapy-associated toxicity.
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ABsTrACT
The aim of this study was to investigate whether neutrophil-guided dose escalation of anthracycline-
cyclophosphamide-containing chemotherapy (ACC) for breast cancer is feasible, in order to optimize 
outcome. Breast cancer patients planned for three-weekly ACC were enrolled in this study. The first 
treatment cycle was administered in a standard body surface are (BSA)-adjusted dose. The absolute 
neutrophil count was measured at baseline and at day 8, 11 and 15 after administration of ACC. 
For patients with none or mild (CTC grade 0-2) neutropenia and no other dose limiting toxicity, we 
performed a 10-25% dose escalation of the second cycle with the opportunity to a further 10-25% dose 
escalation of the third cycle. Thirty patients were treated in the adjuvant setting with either FE100C 
(n = 23) or AC (n = 4), or in the palliative setting with FAC (n = 3). Two out of 23 patients (9%) treated 
with FEC did not develop grade 3-4 neutropenia after the first treatment cycle. Dose escalation was 
performed in these two patients (30% in one and 15% in the other patient). During dose escalation, 
there were no complications like febrile neutropenia. No patients treated with FAC or AC could be 
escalated, since all of them developed grade 3-4 neutropenia. We conclude that asymptomatic grade 
3-4 neutropenia is likely to be achieved in the majority of patients with breast cancer treated with 
ACC according to presently advocated BSA-based dose levels. Escalation of currently advocated ACC 
doses without G-CSF, with a target of grade 3-4 neutropenia, is feasible, but only possible in a small 
proportion of patients. 
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InTrODuCTIOn
Both anthracyclines and cyclophosphamide are highly effective drugs in the treatment of breast 
cancer [1,2]. According to international guidelines, anthracycline-cyclophosphamide-containing 
chemotherapy (ACC) is part of (neo)adjuvant treatment schedules for early stage or locally advanced 
breast cancer [3]. Furthermore, in the setting of metastatic disease, ACC is often used as palliative 
treatment [4,5].
Although highly effective, not all patients benefit from ACC. The cumulative dose of anthracyclines 
administered is important. From randomized controlled trials, it is clear that higher ‘standard dose’ of 
anthracyclines for early breast cancer improves patient survival compared to lower ‘standard dose’ 
[6]. On the other hand, a reason for differences in efficacy among patients who have had a similar 
dose of anthracyclines administered could be the large inter-individual (between patients) as well 
as the intra-individual (within patients) variability in pharmacokinetic parameters [7]. Interestingly, 
hematological toxicity is strongly associated with the absolute dose of anthracycline and might be 
useful as a surrogate measure of the anthracycline dose [6]. In accordance, some retrospective studies 
indeed have shown that breast cancer patients given adjuvant chemotherapy but not attaining at 
least moderate hematological toxicity have a worse prognosis compared to those with more toxicity 
[8-11].
The current standard of dosing ACC is guided by body surface area (BSA) with an a posteriori dose 
reduction of all component drugs in case of excessive toxicity (e.g. febrile neutropenia). Dose 
escalation among patients without toxicity is, however, no standard of care. The administration of an 
inappropriately low dose of chemotherapy is therefore not recognized, leaving patients that might 
benefit from an increased dose unidentified. The percentage of breast cancer patients receiving a 
suboptimal dose of ACC is unknown, as well as the amount of underdosing in these individuals.
In the present study, we addressed the feasibility of a simple tool for neutrophil-guided dose adaptation 
of ACC (without primary G-CSF support), among female breast cancer patients treated with ACC for 
either palliative or curative intention. The aim was to reach nadir absolute neutrophil count (ANC) of 
≤1.0 x 10e9/L with recovery to ≥1.5 x 10e9/L at the time of the planned next treatment cycle, without 
excessive hematological or non-hematological toxicity. In case successful dose escalation is possible 
in a substantial number of patients, this method is valid and should be further developed and refined 
to be ultimately tested on treatment efficacy in a prospective randomized trial of neutrophil-guided 
versus standard BSA-adjusted dosing.
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PATIenTs AnD MeThODs
Participants
Chemotherapy naive female breast cancer patients aged ≥18 years and planned for treatment with 
at least three cycles of ACC were identified at the Department of Medical Oncology, Ikazia Hospital, 
Rotterdam, The Netherlands. Both patients treated with curative as well as patients treated with 
palliative intention were eligible. Patients with the following chemotherapy regimens were eligible: 
FEC (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2), AC (doxorubicin 
60 mg/m2, cyclophosphamide 600 mg/m2) or FAC (fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, 
cyclophosphamide 500 mg/m2). Additionally, patients should have a WHO performance status 0-1, 
life expectancy >3 months, adequate peripheral blood cell counts (leukocytes ≥4.0 x 10e9/L and ANC 
≥2.0 x 10e9/L and platelet count ≥150 x 10e9/L), adequate renal function (defined as normal serum 
creatinine concentration and/or estimated creatinine clearance ≥60 mL/min), adequate liver function 
(defined as normal serum bilirubin concentration (≤17 µmol/L) and serum ASAT and ALAT ≤3 times the 
upper limit of normal (≤5 times the upper limit of normal in case of hepatic metastases)), normal serum 
albumin concentration (35-50 g/L) and given written informed consent. Women were excluded from 
participation if they had been treated with chemotherapy previously, were unable to consent with 
weekly follow-up for blood cell counts and toxicity assessment, had symptomatic brain metastasis, 
had a history of cardiac dysfunction, had uncontrolled arterial hypertension (blood pressure systolic 
≥180 mmHg and/or diastolic ≥110 mmHg) and/or unstable angina pectoris. Ethical approval for this 
study was obtained through the Institutional Review Boards, and all women signed the informed 
consent. The study was conducted in full accordance with the principles of the Declaration of Helsinki 
and local regulations. The trial adhered to the guidelines for good clinical practice and the European 
Union Clinical Trial Directive.
study design
This study was a prospective single center feasibility study. The first treatment cycle was given 
using standard BSA-adjusted dosing. Following the administration of ACC, ANC was evaluated in 
peripheral venous blood samples obtained at days 8 (±1), 11 (±1) and 15 (±1), day 1 being the day of 
chemotherapy administration. Hematological and non-hematological toxicities were assessed weekly 
according to the common toxicity criteria (CTC), version 3. Subsequent cycles of ACC were given at 
intervals of three weeks provided that the patient had sufficiently recovered from hematological and 
non-hematological toxicity. Sufficient recovery of hematological toxicity was defined as an ANC of 
≥1.5 x 10e9/L and a platelet count of ≥100 x 10e9/L, whereas sufficient recovery of non-hematological 
toxicity was defined as CTC grade ≤1 (with the exception of alopecia). In patients with nadir ANC ≥1.0 
x 10e9/L and maximum non-hematological toxicity CTC grade ≤2 during the first cycle of ACC, the 
dose of cyclophosphamide and the anthracycline (doxorubicin or epirubicin) was increased with 10, 
15 or 25% according to a predefined schedule based on ANC on day 8 and day 15. In patients treated 
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ACC cycle 1
Nadir ANC ≤ grade 2 and non-hematological toxicity ≤ grade 2 
Yes No
Dose escalation depending  
on ANC on days 8 and 15 
Further treatment according to 
standard practice 
ACC cycle 2 
Nadir ANC ≤ grade 2 and non-haematological toxicity ≤ grade 2  
Yes No
Further dose escalation depending 
on ANC on days 8 and 15 
No further dose escalation 
 
 
 
 
 
 
 
 
with chemotherapy schedules including fluorouracil (FAC or FEC), the dose of fluorouracil was not 
escalated due to its negligible contribution to hematological toxicity in these combination regimens 
[7]. Patients undergoing dose escalation of the second cycle of ACC were candidates for a further 
(and final) dose escalation of the third cycle of ACC following the same principles and according 
to the same predefined schedule. Patients experiencing excessive toxicity (i.e. febrile neutropenia, 
symptomatic thrombocytopenia and/or grade 3-4 non-hematological toxicity with the exception of 
nausea and vomiting) without previous dose escalation were treated according to standard clinical 
practice. In case of excessive toxicity after dose escalation, patients had to be retreated with standard 
BSA-adjusted dose during subsequent treatment cycles. Finally, all patients treated with ≥4 cycles of 
ACC received standard BSA-adjusted dosing from the fourth cycle onward. The study design is also 
outlined in Figure 1.
figure 1. Study design.
ACC: anthracycline-cyclophosphamide-containing chemotherapy; ANC: absolute neutrophil count.
Chapter 5
78
statistical analysis
This study was designed as a pilot feasibility study. Therefore, a useful sample size calculation was 
not appropriate. We aimed to enter 30 patients. Successful dose escalation of chemotherapy was our 
primary goal and was rather arbitrarily defined as a ≥15% increase in anthracycline-cyclophosphamide 
dose without excessive hematological (febrile neutropenia, grade 3-4 thrombocytopenia) or 
non-hematological (grade 3-4) toxicity. We stated that if successful dose escalation was possible 
in a significant proportion of patients (at least 3 out of 30 patients), our experimental method of 
neutrophil-guided dose escalation could be feasible in daily clinical practice and should be further 
developed and refined to be ultimately tested on treatment efficacy in a prospective randomized trial 
of neutrophil-guided versus standard BSA-adjusted dosing. If successful dose escalation turned out to 
be possible in less than 3 out of 30 patients, it is unlikely that this method of dose escalation will have 
significant impact on treatment efficacy, and this method should not be further explored.
Furthermore inter-individual variation in ANC after administration of the chemotherapy was assessed 
as coefficient of variation (CV) for nadir ANC and for cumulative neutrophil count (expressed as the 
sum of CTC grades of neutropenia (0-4) on day 8, 11 and 15), addressing the duration of neutropenia.
resulTs
A total of 30 patients were entered in this study between November 2010 and December 2013. 
Baseline characteristics are outlined in Table 1. Median age was 55 years (range 37-74 years). The 
majority of the patients were treated for early breast cancer with either FEC (77%) or AC (13%). Three 
patients (10%) were treated with first line palliative chemotherapy in the form of FAC. 
Table 1. Baseline characteristics.
Median age, years (range) 55 (36-74)
Chemotherapy regime, n (%)
              FEC
              FAC
              AC
23 (77)
3 (10)
4 (13)
Tumor stage, n (%)
             Early
             Metastatic
27 (90)
3 (10)
WHO performance score, n (%)
             WHO 0
             WHO 1
25 (83)
5 (17)
Median height, cm (range) 170 (155-184)
Median weight, kg (range) 75 (53-100)
Median body surface are, m2 (range) 1.9 (1.5-2.1)
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Dose escalation was feasible in two patients. Both patients were treated with FEC for early breast 
cancer. So, 2 out of 23 (9%) of patients treated with FEC could be escalated, while no patients treated 
with FAC or AC could be escalated. Both of the escalated patients developed only grade 2 neutropenia 
(ANC 1.00-1.49 x 10e9/L) at day 15 of the first cycle and were escalated with 15% during the second 
cycle. One of these patients reached grade 3 neutropenia (ANC 0.50-0.99 x 10e9/L) in the second cycle, 
and no further escalation was performed. The other patient developed only grade 2 neutropenia after 
the second cycle and was further escalated with another 15% in cycle 3 (Figure 2; Table 2). During 
dose escalation, there were no complications like febrile neutropenia, grade 3-4 thrombocytopenia or 
increase in non-hematological toxicity. There were no relevant differences in baseline characteristics 
between escalated and non-escalated patients (Table 2).
figure 2. Absolute neutrophil counts (ANC) over time in the two escalated patients.
For the whole group of patients, mean ANC at baseline was 5.32 x 10e9/L (range 2.66-10.52), on day 8 
was 3.72 x 10e9/L (range 2.02-9.60), on day 11 was 0.80 x 10e9/L (range 0.05-2.11) and on day 15 was 
0.53 x 10e9/L (range 0.03-3.94). Nadir mean was 0.41 x 10e9/L (range 0.03-1.28) and was reached on 
day 11 in 7 patients and on day 15 in 23 patients. Coefficient of variation (CV) for mean ANC nadir was 
0.77. Grade 3 neutropenia (ANC 0.50-0.99 x 10e9/L) or grade 4 neutropenia (ANC 0.50 x 10e9/L) after 
the first treatment cycle was observed in 28 of the 30 patients. Two of them had febrile neutropenia 
and were hospitalized. All patients had recovery of ANC to ≥1.5 x 10e9/L at the time of the planned 
next treatment cycle. Duration of neutropenia expressed as mean cumulative neutrophil count (the 
sum of CTC grades of neutropenia on day 8, 11 and 15) was 6.4 with a CV of 0.24 (Table 3).
Incidence of grade 3-4 neutropenia was lower after the second and third cycle of chemotherapy 
compared to after the first cycle (proportion of grade 3-4 neutropenia in first, second and third cycle 
respectively, 94, 77 and 75%, non-significant, Table 4). In these figures, patients who underwent dose 
escalation or used secondary G-CSF prophylaxis were excluded.
Figure 2. Absolute neutrophil counts (ANC) over time in the two escalated patients.
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Table 2. details of escalated patients.
Patient A Patient B
Escalations 15% in first cycle
15% in second cycle
15% in first cycle
No further escalation in second cycle
Age (years) 47 55
Chemotherapy regime FEC FEC
Body surface are, m2 1.9 1.8
Weight (kg) 75 75
Cycle 1 ANC baseline 7.05 9.35
Cycle 1 ANC nadir 1.28 1.21
Cycle 1 ANC nadir, day reached 15 11
Cycle 2 ANC baseline, x 10e9/L 3.13 6.88
Cycle 2 ANC nadir, x 10e9/L 1.19 0.59
Cycle 2 ANC nadir, day reached 15 15
ANC: absolute neutrophil count.
Table 3. laboratory values, first cycle, all patients.
Mean ANC 
    baseline, x 10e9/L (range)
    day 8, x 10e9/L (range)
    day 11, x 10e9/L (range)
    day 15,  x 10e9/L (range)
5.32 (2.66-10.52)
3.72 (2.02-9.60)
0.80 (0.05-2.11)
0.53 (0.03-3.94)
Mean ANC nadir, x 10e9/L (range)
Coefficient of variation 
0.41 (0.03-1.28)
0.77
ANC nadir, n (%)
       day 8
       day 11
       day 15       
0 (0)
7 (23)
23 (77)
Neutropenia nadir, n (%)
       CTC grade 0
       CTC grade 1
       CTC grade 2
       CTC grade 3
       CTC grade 4       
0 (0)
0 (0)
2 (7)
8 (27)
20 (67)
Mean cumulative neutrophil counta  
Coefficient of variation
6.4
0.24
Febrile neutropenia, n (%) 2 (7)
ANC: absolute neutrophil count.
a expressed as the sum of CTC grades of neutropenia (0-4) on day 8, 11 and 15.
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DIsCussIOn
The ANCHOR study was designed based on the improved survival found in a number of retrospective 
studies among patients treated with adjuvant chemotherapy for early breast cancer, who achieved 
a higher degree of hematological toxicity [6,9-11]. In this pilot feasibility study among breast cancer 
patients treated with currently advocated doses of ACC, neutrophil-guided dose escalation was 
feasible. Dose escalation was possible in 2 out of 23 patients (9%) treated with FEC, while dose 
escalation was possible in none of the patients treated with FAC or AC. Asymptomatic grade 3-4 
neutropenia was achieved in the majority of patients after the first cycle of ACC. It seems therefore 
not useful to proceed with a large randomized controlled trial on neutrophil-guided dose escalation 
among patients with currently advocated doses of ACC.
Previously, two other studies have also investigated the feasibility of dose escalation of ACC, although 
they are hardly comparable with our current study. In the first study of tailored fluorouracil, epirubicin 
and cyclophosphamide (FEC) with primary granulocyte colony-stimulating factor (G-CSF) support, 
the dose of epiriubicin and cyclophosphamide could be escalated by 50% or more in more than 
half of the patients. Starting dose in this study was fluorouracil 600 mg/m2, epirubicin 75 mg/m2 
and cyclophosphamide 900 mg/m2. Treatment with nine cycles of tailored FEC with G-CSF support 
(median cumulative dose of epirubicin was 780 mg/m2) was, however, associated with an increased 
Table 4. ANC nadir in first three cycles of ACC, all patients.
Cycle 1 (n = 30) Cycle 2 (n = 21a) Cycle 3 (n = 16b)
Mean ANC nadir, x 10e9/L (range) 0.41 (0.03-1.28) 0.66 (0.09-1.50) 0.63 (0.06-1.57)
ANC nadir, n (%)
       day 8
       day 11
       day 15
0 (0)
7 (23)
23 (77)
0 (0)
2 (10)
19 (90)
0 (0)
5 (31)
11 (69)
Neutropenia nadir, n (%)
       CTC grade 0
       CTC grade 1
       CTC grade 2
       CTC grade 3
       CTC grade 4       
0 (0)
0 (0)
2 (7)
8 (27)
20 (67)
0 (0)
0 (0)
5 (24)
10 (48)
6 (29)
0
1 (6)
3 (19)
4 (25)
8 (50)
ANC: absolute neutrophil count.
a exclusion of escalated patients (n = 2), patients with febrile neutropenia after the first cycle (n = 2) and patients 
with missing data (n = 5). Besides the escalated patients, there were no patients with dose alterations in the second 
cycle.
b exclusion of escalated patients (n = 2), patients with febrile neutropenia after the first cycle (n = 2) and patients 
with missing data (n = 10). There were no patients with febrile neutropenia after the second cycle. Besides the 
escalated patients, there were no patients with dose alterations in the third cycle.
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risk of acute myeloid leukemia and myelodysplastic syndrome. There were also more cardiac side 
effects in the tailored FEC group. Tailored FEC with G-CSF support can therefore not be advocated 
for clinical practice [12]. In our study, the two patients in whom escalation of ACC was feasible had a 
cumulative dose of epirubicin of 347 and 330 mg/m2, respectively. In the second study by Edlund et 
al., the study design was comparable with our study; however, the ‘standard dose’ of epirubicin used 
in this study was substantially lower than in our study (60 mg/m2 vs. 100 mg/m2, respectively). In this 
study (n = 1,535), patients who did not reach leukopenia CTC grade 3 or 4 after a first cycle of standard 
FEC (in this study fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) 
were randomized to a total of six courses of standard dosed FE(60)C (n = 526) or a total of six cycles of 
FEC with doses tailored to achieve grade 3 leukopenia (n = 521). The relative dose intensity (defined 
as the given dose delivered in the originally expected time/the expected dose in the expected time) 
was increased by a factor of 1.31. Median cumulative dose of epirubicin in the tailored dose group was 
520 mg/m2. There was no excess of acute non-hematological toxicity [13].
It is important to mention that both these studies used lower ‘standard doses’ of epirubicin compared 
to our study (75 and 60 mg/m2, respectively). It can be concluded based on these and our study that 
neutrophil-guided dose escalation might be feasible in older regimens with lower ‘standard dose’ of 
epirubicin. With currently advocated doses (epirubicin 100 mg/m2 and doxorubicin 50-60 mg/m2), it 
is, however, not feasible to escalate a relevant proportion of patients.
Interestingly, the two patients, who were escalated, were both treated with epirubicin, while none 
of the patients treated with doxorubicin could be escalated. This might be due to chance. A real 
difference in hematological toxicity between these two anthracyclines can, however, not be excluded. 
When taking only the patients treated with epiriubicin into account, dose escalation was possible 
in 9% of patients, not reaching the predefined 10% which was considered worthwhile enough for 
further exploration.
Furthermore, a trend was seen in a decreased proportion of patient with grade 3-4 neutropenia 
over the subsequent cycles. In our study, dose escalation was only permitted when no grade 3-4 
neutropenia was seen after the first cycle. When we also had allowed patients to escalate based on 
ANC nadir after the second cycle, five more patients could have been escalated in the third cycle. One 
of the currently advocated (neo)adjuvant chemotherapy regimens consists of three cycles FEC (5FU 
500 mg/m2; epiriubicin 100 mg/m2 and cyclophosphamide 500 mg/m2), followed by three cycles 
docetaxel 100 mg/m2. In this regimen, cumulative anthracycline dose is relatively low, with a low risk 
of cardiotoxicity [14]. Since only three cycles of ACC are given, it is of utmost importance to dose these 
cycles as high as possible without unacceptable side effects. Further research should therefore focus 
mainly on patients treated in (neo)adjuvant setting and allow escalation also in subsequent cycles.
For most classical anticancer drugs, BSA-guided dosing is still standard practice in clinical oncology. 
BSA-based dosing of chemotherapy has largely resulted from its use in the extrapolation of drug 
doses used in experimental animals to those considered safe as starting doses for phase 1 clinical 
trials. However, a proper scientific rationale for BSA-based dosing of anticancer drugs in human 
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adult cancer patients is lacking [15-17]. Furthermore, the use of BSA does not reduce inter-individual 
variability in pharmacokinetic parameters for the majority of investigated anticancer drugs [18]. For 
irinotecan, it has been shown that flat-fixed dosing does not result in increased pharmacokinetic/
pharmacodynamic variability and could be safely used [19]. Furthermore, for carboplatin, glomerular 
filtration rate-adjusted dosing has been widely accepted as standard [20]. Although knowledge 
on pharmacogenetics has rapidly been expanding, this had not led to many practically applicable 
dosing algorithms for classical anticancer drugs, while exposure to chemotherapy is influenced by 
many other interacting factors [21,22]. For fluoropyrimidines, it has been suggested to adjust the 
dose based on dihydropyrimidine dehydrogenase (DPYD) genotype tests [23]. The method of dose 
adjustment guided by plasma drug concentrations (therapeutic drug monitoring, TDM) has not been 
used as standard practice, which is largely due to the obscure relationship between plasma drug 
concentrations and treatment effects [24,25]. However, for the vast majority of classical anticancer 
agents, BSA-guided dosing remains still standard practice. For most (oral) targeted agents, flat-fixed 
dosing and a posteriori dose reduction in case of severe toxicity is a standard practice. For these 
agents, the relation between dose and outcome (both efficacy and safety) is even less clear, compared 
to classical chemotherapy, due to both differences in molecular characteristics of the tumor as well as 
in environmental and genetic factors.
COnClusIOn
In conclusion, inter-individual variability in hematological toxicity with currently advocated doses of 
ACC in breast cancer patients is limited. Escalation of currently advocated ACC doses without G-CSF, 
with a target of grade 3-4 neutropenia, is feasible, but only possible in a relatively small proportion of 
patients. Since no other dosing algorithms are available for ACC, BSA-guided dosing remains standard 
practice at this moment.
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ABsTrACT
The aim of this study was to validate an earlier developed high-performance highly sensitive ultra 
performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method for 
quantification of tamoxifen and its three main metabolites (N-desmethyl-tamoxifen, 4-hydroxy-
tamoxifen and 4-hydroxy-N-desmethyl-tamoxifen) in scalp hair. This non-invasive method might, 
by segmental analysis of hair, be useful in the determination of the concentration of drugs and 
its metabolites over time, which can be used to study a wide variety of clinical relevant questions. 
Hair samples (150-300 hair strands, cut as close to the scalp as possible from the posterior vertex 
region of the head) were collected from female patients taking tamoxifen 20 mg daily (n = 19). The 
analytes were extracted using a liquid-liquid extraction procedure with carbonate buffer at pH 8.8 
and a mixture of n-hexane/isopropranol method, followed by UPLC-MS/MS chromatography, based 
on an earlier validated method. The calibration curves were linear in the range of 1.00-200 pmol for 
tamoxifen and N-desmethyl-tamoxifen, with lower limit of quantitation (LLQ) of 1.00 pmol and 0.100-
20.0 pmol with LLQ of 0.100 pmol for endoxifen and 4-hydroxy-tamoxifen. Assay performance was fair 
with a within-run and between-run variability less than 9.24 at the three quality control samples and 
less than 15.7 for the LLQ. Importantly, a steep linear decline was observed from distal to proximal hair 
segments. Probably, this is due to ultraviolet (UV) exposure as we showed degradation of tamoxifen 
and its metabolites after exposure to UV light. Furthermore, higher concentrations of tamoxifen 
were found in black hair samples compared to blond and brown hair samples. We conclude that 
measurement of the concentration of tamoxifen and its main metabolites in hair is possible, with the 
selective, sensitive, accurate and precise UPLC-MS/MS method. However, for tamoxifen, it seems not 
possible to determine exposure over time with segmental analysis of hair, probably largely due to the 
effect of UV irradiation. Further research should therefore focus on quantification of other anticancer 
drugs, in segmented scalp hair, that are less sensitive to UV irradiation.
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InTrODuCTIOn
Tamoxifen, a selective estrogen receptor modulator, is an important drug in the treatment of hormone 
receptor positive breast cancer. In early stage breast cancer, tamoxifen reduces the risk of recurrence, 
the risk of mortality and the risk of contralateral breast cancer [1-3]. In advanced hormone receptor 
positive breast cancer, tamoxifen improves progression free and overall survival over observation [4,5]. 
Tamoxifen also significantly reduces the risk of breast cancer in women at high risk to develop breast 
cancer [6]. However, not all women benefit from tamoxifen therapy, while treatment-related adverse 
reactions also vary greatly between patients. Inter-individual variability in metabolism of tamoxifen, 
which is influenced by both genetic and environmental factors, contributes to the differences in 
efficacy and toxicity of tamoxifen [7-9]. Since tamoxifen often has to be used for a longer period of 
time, therapy adherence, change in environmental factors and possibly resistance mechanisms might 
influence the systemic exposure over time [10,11].
Tamoxifen is a pro-drug and undergoes biotransformation into several active metabolites, including 
N-desmethyl-tamoxifen, which is the most abundant metabolite, and its potent metabolites 
4-hydroxy-tamoxifen and 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) [12]. Chemical structures 
of tamoxifen and its main metabolites are shown in Figure 1. Endoxifen and 4-hydroxytamoxifen 
have equivalent anti-estrogenic potencies and are 30-100 times more active as anti-estrogens than 
tamoxifen and N-desmethyltamoxifen. Because of the higher plasma concentrations of endoxifen 
compared to 4-hydroxytamoxifen, endoxifen is believed to be the principal active metabolite [13-15]. 
Even low concentrations of tamoxifen and its main metabolites can be quantified in plasma with 
highly sensitive, selective, accurate and precise UPLC-MS/MS methods [16-19]. 
One option to monitor drug exposure and to adjust treatments would be by implementing therapeutic 
drug monitoring (TDM) as a dosing strategy. For most anticancer drugs, however, TDM is still not 
common practice due to undefined thresholds, and practical problems incorporating this in clinical 
practice due to logistical constraints. Additionally, since plasma concentrations only give information 
about the systemic concentration at a particular time point, several samples over time should be taken. 
As a result, most reliable TDM can be achieved with serial measurements of plasma concentrations of 
drugs and/or metabolites, which will increase the complexity and the costs of TDM [20]. 
Methods, which give (in retrospect) information about the course of concentrations of anticancer 
drugs and/or its metabolites over time would therefore be of great interest. A potential method, 
which is also feasible for clinical practice, could be to measure these concentrations in scalp hair. Hair 
is a strong and stable tissue and has the major advantage over traditional matrices (e.g. blood or urine) 
of giving the opportunity to study long term exposure to drugs, clearly depending on the length of 
hair collected. Scalp hair grows with an average rate of one centimeter per month, therefore, one 
centimeter of scalp hair could represent drug levels of one month [21]. So segmental analysis of hair 
allows the determination of the historic pattern of drug concentrations making serial venous blood 
collections unnecessary.
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 Early experience with measurement of drugs in (scalp) hair was build up in toxicology and forensic 
medicine [22]. A validation of a method for screening and quantification of 96 drugs from different 
pharmacologic groups in hair by UPLC-MS/MS was performed by Montesano et al. [23]. Few clinical 
studies have been performed using measurement of drug concentrations in hair. In HIV infected 
figure 1. Chemical structures and multiple reaction monitoring (MRM) chromatograms of hair samples spiked at 
the concentration of the lower limit of quantitation (A) and a human scalp hair sample of a patient collected after 
20 mg daily tamoxifen administration containing 9.44 pmol/mg tamoxifen, 0.694 pmol/mg endoxifen, 0.231 pmol/
mg 4-hydroxy-tamoxifen and 14.2 pmol/mg N-desmethyl-tamoxifen (B).
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patients on antiretroviral therapy, it has been shown that concentration of the antiretroviral drug 
atazanavir in hair is one of the best predictors of suppression of viral load, even when adjusting 
for the other known important predictors [24]. Furthermore, there is increasing experience with 
measurement of the steroid hormone cortisol in scalp hair. Concentrations of cortisol in hair segments 
correspond with clinical course in patients with (cyclic) Cushing syndrome and can be used for 
monitoring of therapy [25,26]. So far, no studies have been performed with measuring of anticancer 
drugs or its metabolites in hair. Obviously, when measurement of concentrations of (metabolites of ) 
anticancer drugs in hair is feasible this could open an important new way to study a wide variety of 
clinical relevant questions in patients suffering from cancer. We have here developed and validated an 
UPLC-MS/MS assay for measurement of tamoxifen and its metabolites in scalp hair. Furthermore, we 
investigated whether or not segmental analysis of hair can be used to determine the historic pattern 
of drug concentrations.
MATerIAls AnD MeThODs
Chemicals
Pure Z (cis)-isomers of tamoxifen, N-desmethyl-tamoxifen and 4-hydroxy-tamoxifen, the stable labeled 
deuterated internal standards tamoxifen-d5, N-desmethyl-tamoxifen-d5, 4-hydroxy-tamoxifen-d5 
and a racemic mixture of the Z- and E-isomers (1:1) of 4-hydroxy-N-desmethyl-tamoxifen-d5 and 
4’-hydroxy-tamoxifen, the stable labeled deuterated internal standard 4’-hydroxy-tamoxifen-d6 and 
N-desmethyl-4’-hydroxy-tamoxifenwere obtained from Toronto Research Chemicals (North York, 
ON, Canada). The pure Z (cis)-isomer of 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) was kindly 
provided by Jina Pharmaceuticals Inc. (Libertyville, IL). All chemicals were of analytical grade or 
higher. Acetonitrile, methanol and water were from Bio-solve BV (Valkenswaard, The Netherlands). 
Dimethylsulphoxide (DMSO), ammonium carbonate and 2-propanol were purchased from Merck 
(Darmstadt, Germany), n-hexane was purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands), 
and formic acid from J.T. Baker (Deventer, The Netherlands). Blank human scalp hair was obtained from 
healthy volunteers.
Preparation of stock solutions, calibration standards and quality control samples
Stock solutions containing 1.00 mM free base of tamoxifen, N-desmethyl-tamoxifen, 4-hydroxy-
tamoxifen, 4΄-hydroxy-tamoxifen, N-desmethyl-4΄-hydroxy-tamoxifen and endoxifen in DMSO 
were prepared individually and stored at T <-70°C. Individual stock solutions of tamoxifen and its 
metabolites were used for the preparation of a working stock solution, containing 200 µM tamoxifen, 
200  µM N-desmethyl-tamoxifen, 20 µM4-hydroxy-tamoxifen, 20 µM 4΄-hydroxy-tamoxifen, 20 µM 
N-desmethyl-4΄-hydroxy-tamoxifen and 20 µM endoxifen in DMSO. The working stock solution was 
divided into 150  µL aliquots, which were used for the construction of calibration curve standards 
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during the validation. Separate stock solutions of tamoxifen and its metabolites were used for the 
preparation of the pools of quality control (QC) samples. The variation between the stock solutions of 
tamoxifen and its metabolites used for the construction of the calibration standards and QC samples 
was in all cases <5%.
Deuterated internal standards were dissolved in DMSO separately, to obtain internal standard stock 
solutions at a concentration of 1 mg/mL free base, which subsequently were aliquotted and stored at 
T <-70°C. Aliquots of 10 µL of the individual stock solutions were concurrently 10,000-fold diluted in 
acetonitrile, resulting in an internal standard working solution containing 100 ng/mL tamoxifen-d5, 
N-desmethyl-tamoxifen-d5,4-hydroxy-tamoxifen-d5, 4-hydroxy-N-desmethyl-tamoxifen-d5 and 4΄- 
hydroxy-tamoxifen, which was stored at T <8°C for a maximum of three months. 
Calibration curve standards were freshly prepared for each run, by addition of 10  µL aliquots of 
appropriate dilutions of the working stock solution in acetonitrile/DMSO (1:1, v/v) to 190  µL aliquots 
of 10 mg overnight extracted scalp hair in methanol at the following amounts: 1.00, 2.00, 10.0, 20.0, 
50.0, 100, 180, and 200 pmol for tamoxifen and N-desmethyl-tamoxifen and 0.100, 0.200, 1.00, 2.00, 
5.00, 10.0, 18.0, and 20.0 pmol for 4-hydroxy-tamoxifen, 4΄-hydroxy-tamoxifen, N-desmethyl-4΄-
hydroxy-tamoxifen and endoxifen. 
A total of four pools of quality control (QC) samples were prepared by spiking appropriate dilutions 
of stock solutions of tamoxifen and its metabolites to blank extracted scalp hair at amounts of 1.00 
pmol (lower limit of quantification, LLQ), 3.00 pmol (QC-Low), 80.0 pmol (QC-Middle) and160 pmol 
(QC-High) for tamoxifen and N-desmethyl-tamoxifen and at 0.100 pmol (LLQ), 0.300 pmol (QC-Low), 
8.00 pmol (QC-Middle) and 16.0 pmol (QC-High) for 4-hydroxy-tamoxifen, 4΄-hydroxy-tamoxifen, 
N-desmethyl-4΄-hydroxy-tamoxifen and endoxifen. Pools of QC samples were aliquotted and stored 
at T <-70°C until analysis. 
Aliquots of 50 µL of internal standard working solution and 750  µL methanol was added to 200 µL 
of calibration curve standards and QC samples in 2-mL micro centrifuge tubes and shaken for 24h at 
ambient temperature. Hereafter, the organic phase was transferred to a clean 2-mL micro centrifuge 
tube and evaporated to dryness under nitrogen at T = 60°C. The residues were reconstituted in 200 
µL aliquots of sodium carbonate buffer (pH 8.8) and 1 mL aliquots of hexane/2-propanol (95:5, v/v). 
The samples were vortexed and centrifuged at 18,000 × g at ambient temperature for ten minutes. 
Aliquots of 800  µL of the organic phase were transferred into 4.5 mL glass tubes and evaporated 
to dryness under nitrogen at T = 60°C. Hereafter the residues were reconstituted in 100 µL aliquots 
of acetonitrile/water/formic acid (40:60:0.1, v/v/v) and centrifuged for five minutes at 4,000 × g. The 
supernatants were transferred into 350 µL 96-well plates, which were placed into a chilled (T = 10°C) 
autosampler, from which aliquots of 5 µL were injected onto the UPLC column.
hair sample preparation
Root ends of hair samples (150-300 hair strands) were divided into sections of 1 cm and subsequently 
cut into pieces of approximately 1 mm in length. Aliquots of 50  µL of internal standard working 
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solution and 950  µL of methanol were added to 10-30 mg of hair samples in 2 mL micro centrifuge 
tubes and shaken for 24h at ambient temperature, protected from light. Subsequently, the organic 
phase was transferred to a clean 2 mL micro centrifuge tube and evaporated to dryness under nitrogen 
at T = 60°C. The residues were reconstituted in 200 µL aliquots of sodium carbonate buffer (pH 8.8) and 
1 mL aliquots of hexane/2-propanol (95:5, v/v). Hereafter, the samples were vortexed and centrifuged 
at 18,000 × g at ambient temperature for ten minutes. Aliquots of 800  µL of the organic phase were 
transferred into 4.5 mL glass tubes and evaporated to dryness under nitrogen at T = 60°C. Hereafter, 
the residues were reconstituted in 100 µL aliquots of acetonitrile/water/formic acid(40:60:0.1, v/v/v) 
and centrifuged for five minutes at 4,000 × g. The supernatants were transferred into 350 µL 96-well 
plates, which were placed into a chilled (T = 10°C) autosampler, from which aliquots of 5 µL were 
injected onto the UPLC column.
equipment
The UPLC-MS/MS system was composed of a Waters Aquity UPLC Sample Manager coupled to a 
Waters TQ Detector (Waters, Etten-Leur, The Netherlands). The MassLynx V4.1 SCN627 software 
package was used for the acquisition and processing of data. Quantification was performed using 
QuanLynx as implemented in the MassLynx software.
Chromatographic conditions
Analytes including 4΄-hydroxy-tamoxifen and N-desmethyl-4΄-hydroxy-tamoxifen were separated on 
an Aquity UPLC®BEHC 18 column 1.7  µm, 100 mm × 2.1 mm, (Waters, Etten-Leur, The Netherlands) 
and thermostatted at T = 50°C. Aqueous ammonium formate (0.2 mM) and acetonitrile, both acidified 
with 0.1% formic acid, were used as mobile phase A and mobile phase B, respectively. A linear gradient 
at a flow-rate of 0.300 mL/min was achieved with 30-80% of mobile phase B from 0 to 6 min, then 
80-30% of mobile phase B over 2 minutes, which was held for 2 minutes for re-equilibration of the 
system. An autosampler (at 10°C) injected volumes of 5 µL onto the UPLC column. The overall run 
time was ten minutes. The needle of the autosampler was washed using a strong needle wash 
solvent (acetonitrile/methanol/2-propanol/water/formic acid, 25:25:25:25:0.1 v/v/v/v/v) and a weak 
needle wash solvent (30% acetonitrile in water). The column effluent was introduced to the mass 
spectrometer and monitored.
Mass spectrometry
Tandem mass spectrometry was performed in the positive ion electrospray ionization mode. Mass 
transitions of m/z were optimized for tamoxifen, its metabolites and the deuterated internal standards 
of tamoxifen and its metabolites by infusion of the respective analytes in acetonitrile/water/0.1% 
formic acid (40:60:0.1, v/v/v) via combined infusion. Optimal MS settings were adjusted manually. 
The desolvation gas was set at 800 L/h, the cone gas at 25 L/h (nitrogen) and the ionspray voltage 
was kept at 1.50 kV. We used a source temperature of T = 150°C and desolvation temperature of T 
Chapter 6
94
= 350°C. The dwell times were set at 20 ms and the inter-channel delay at 10 ms. Multiple reaction 
monitoring (MRM) mode was applied for the quantitation with the parameters as presented in Table 
1. The collision cell pirani pressure was set at ~5e−3 mbar (argon).
Table 1. MS/MS settings.
Analyte scan window 
(minutes)
Parent (m/z) Daughter (m/z) Collision (V) Cone voltage (V)
Tamoxifen
Tamoxifen-d5
3.00-5.50
3.00-5.50
372
377
72
72
25
25
45
45
N-desmethyl-tamoxifen
N-desmethyl-tamoxifen-d5
3.00-5.50
3.00-5.50
358
363
58
58
21
21
42
42
N-Desm.-4’hydroxy-tamoxifen 2.50-5.00 374 58 23 45
4-OH-tamoxifen
4-OH-tamoxifen-d5
2.00-5.00
2.00-5.00
388
393
72
72
25
25
47
47
4’OH-tamoxifen
4’OH-tamoxifen-d6
2.50-5.00
2.50-5.00
388
394
72
78
25
25
47
47
Quantitation
Calibration curves were constructed by plotting the peak area ratios of the components to internal 
standards versus the known amount with a weight factor of 1/concentration2.
Patients and hair sampling
Hair samples from 19 female breast cancer patients, aged from 33 to 73 years were collected for the 
study. Hair samples (150-300 hair strands) were cut, as close to the scalp as possible, from the posterior 
vertex region of the head, since this region of the scalp is associated with least variation in growth rate. 
All patients received 20 mg tamoxifen daily for a period of six months up to five years, at the moment 
of participation in this study. All patients reported that they were compliant with the medication. 
The hair samples were cut into segments of one centimeter length starting from the hair root which 
corresponds to one month growth. The study was approved by the local ethical board (METC Erasmus 
MC, study number MEC14-346).
Method validation
The UPLC-MS/MS method was validated for tamoxifen and the three main metabolites, 4-hydroxy-
tamoxifen, endoxifen and N-desmethyl-tamoxifen in agreement with the Guidance for Industry, 
Bioanalytical Method Validation, as specified by the FDA [27]. Blank human hair samples of ten different 
healthy volunteers were analyzed to determine the potential presence of endogenous contaminating 
compounds that may interfere with the assay. 
For the determination of the LLQ, blank human hair samples of ten healthy volunteers were spiked at 
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an amount of 1.00 pmol for tamoxifen and N-desmethyl-tamoxifen and 0.100 pmol for endoxifen and 
4-hydroxy-tamoxifen and analyzed during one run. Accuracy (ACC), within-run precision (WRP) and 
the between-run precision (BRP) were determined by analyzing five replicates of pools of LLQ and QC 
samples independently over a three-run period. The ACC, WRP and BRP at the level of the LLQ and QC 
samples were calculated by one-way analysis of variance, using the run as the variable as described 
earlier [28]. Reproducibility of the method was performed by measuring one hair segment of one 
patient on five separate occasions.
Matrix effect and recovery
Recovery was determined by comparing the areas of the peak from spiked hair before extraction 
to spiked hair after extraction. The matrix effect was measured by comparing the areas of the peak 
from spiked hair after extraction to spiked methanol at the same concentration. Concentrations of 
5.00 pmol and 16.0 pmol for recovery and matrix effect were used for tamoxifen and N-desmethyl-
tamoxifen and 0.500 pmol and 1.60 pmol for endoxifen and 4-hydroxy-tamoxifen.
stability of tamoxifen and its metabolites in hair to ultraviolet (uV) irradiation
Hair samples obtained from patients receiving 20 mg tamoxifen daily were used to investigate the 
influence of UV irradiation from an UV lamp (254 nm). One group of hair samples was protected from 
light, while the second group was exposed to UV light (254 nm) for one hour. The two groups of hair 
samples were analyzed by UPLC-MS/MS using the conditions described in the experimental sections.
relationship between hair concentration and pigmentation
To investigate the relationship between hair pigmentation and tamoxifen concentration in root hair 
samples, hair samples with different hair color were analyzed according to the protocol. Patients who 
had bleached their hair less than one month before were excluded for this analysis. A total of seven 
hair samples were divided into three groups of natural hair color, i.e. two hair samples were classified 
as blond, three hair samples were classified as brown and two hair samples were classified as black. 
One of these patients had permed her hair more than two months before collection of the hair sample 
while five patients painted their hair less than three months before collection.
resulTs AnD DIsCussIOn
uPlC-Ms/Ms conditions and method development
The presented method for the determination of tamoxifen and its main metabolites in human scalp 
hair is based on the validated method described by Binkhorst et al. [16]. The selected product ions, 
cone voltages and collision energies of tamoxifen, its metabolites and their respective deuterated 
internal standards are presented in Table 1. The validation of 4’-hydroxy-tamoxifen and N-desmethyl-
4’-hydroxy-tamoxifen failed for accuracy described in the Guidance for Industry, Bio-analytical 
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Method Validation, as specified by the FDA. Good baseline separation and separation from early 
eluting hydrophilic, potentially interfering matrix components was achieved for all compounds 
while maintaining a relative short injection to injection time of ten minutes with elution times of 2.6 
minutes for endoxifen, 2.7 minutes for 4-hydroxy-tamoxifen, 2.9 minutes for N-desmethyl-4’-hydroxy-
tamoxifen, 3.0 minutes for 4’-hydroxy-tamoxifen, 3.6 minutes for N-desmethyl-tamoxifen and 3.7 
minutes for tamoxifen (Figure 1).
Adequate management of the scalp hair samples before performing the analyses is of great 
importance in the development of an analytical method. Remaining endogenous compounds may 
cause ion-suppression or ion-inducement and can negatively affect the sensitivity of the assay. A 
variety of extraction procedures have been described for drug analysis in human scalp hair depending 
on the chemical structure of the compounds of interest. The first step in hair analysis is the removal 
of the drug from the hair. Several methods have been described and include alkaline digestion, 
acidic extraction, enzymatic digestion and simple extraction with methanol. The use of methanol 
for the removal of tamoxifen and its metabolites from the hair showed to be effective. Almost all 
drug was extracted within 24h of incubation of cutted hair with methanol at ambient temperature. 
No significant increase of drug was observed between 24h and 30h incubation of cutted hair with 
methanol at ambient temperature. Extraction of hair with methanol alone leads to extracts with 
potential interfering endogenous products. A variety of methods have been described that lead 
to more purified extracts. This includes several solid phase extractions and liquid-liquid extraction. 
Solid phase extraction has, if not automated, disadvantages including poor reproducibility and is, 
compared to liquid-liquid extraction, relatively laborious [29-33].
In this validated method, a liquid-liquid extraction procedure was applied with carbonate buffer 
at pH 8.8 and a mixture of n-hexane/isopropanol, which resulted in clean extracts. Reproducibility 
was investigated by analyzing one segment of one hair sample on five separate occasions. On one 
occasion, the concentration of tamoxifen and its main metabolites was substantial higher than the 
mean concentration of the measurements on the other four occasions (>400%). This measurement 
was excluded for further calculations. The mean concentration of tamoxifen, endoxifen, 4-hydroxy-
tamoxifen and N-desmethyl-tamoxifen was 1.15 ± 0.0980 pmol/mg, 0.0931 ± 0.00604 pmol/mg, 
0.0471 ± 0.00694 pmol/mg and 1.46 ± 0.113 pmol/mg, respectively. The concentration of tamoxifen 
and its metabolites in the scalp hair sample measured on five executive days are presented in Table 2.
Assay performance
Each validation run includes calibration curves prepared induplicate containing eight standards 
per calibration curve. Weighted (1/concentration2) linear regression analysis of peak area ratios of 
analytes and Internal Standard, versus concentration of analytes were used for the quantitation. The 
method results were linear (r2 ≥0.9979) in the range of 1.00-200 pmol for tamoxifen and N-desmethyl-
tamoxifen and of 0.100-20.0 pmol for 4-hydroxy-tamoxifen and endoxifen in human scalp hair and 
none of the blank scalp hair samples showed potential interference for tamoxifen, N-desmethyl-
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Table 2. Measurements of tamoxifen and its metabolites in a scalp hair sample during five occasions.
Day Tamoxifen 
(pmol/mg)
endoxifen 
(pmol/mg)
n-desmethyl-tamoxifen 
(pmol/mg)
4-Oh-tamoxifen 
(pmol/mg)
1 1.20 0.0874 1.46 0.0412
2 5.16a 0.564a 5.73a 0.542a
3 1.24 0.0965 1.47 0.0451
4 1.01 0.100 1.31 0.0449
5 1.17 0.0886 1.59 0.0571
Mean 1.15 0.0931 1.46 0.0471
SD 0.0980 0.00604 0.113 0.00694
CV 8.5% 6.5% 7.7% 14.7%
SD: standard deviation; CV: coefficient of variation. 
a Excluded from calculation.
tamoxifen, 4-hydroxy-tamoxifen, endoxifen or any of the deuterated internal standards.
The LLQ was validated at 0.100 pmol for 4-hydroxy-tamoxifen and endoxifen and at 1.00 pmol for 
tamoxifen and N-desmethyl-tamoxifen. The LLQ has been validated in separate runs. In one validation 
run, analytes were spiked to ten different lots of human scalp hair. In three other runs, a pool of LLQ 
samples was processed as QC-samples. For tamoxifen, the amount in all independently spiked scalp 
hair samples fell within the acceptable range of accuracy of 80-120%, with an average measured 
concentration of 1.00 ± 0.0378 pmol. The measured amount of N-desmethyl-tamoxifen for all ten 
independent human scalp hair samples fell within the acceptable range of accuracy, with an average 
observed concentration of 0.995 ± 0.0499 pmol. The average amount for 4-hydroxy-tamoxifen in the 
ten independent samples (nine in acceptable range) was 0.0941 ± 0.0120. For endoxifen, measured 
amount in all independent samples fell within the acceptable range of accuracy, with an average 
concentration of 0.100 ± 0.0131 pmol.
The within-run and between-run precisions and the accuracies at five tested concentrations, including 
at the level of the LLQ, are summarized in Table 3, and all fell within the accepted ranges as specified 
by the FDA [34]. 
The extraction recovery (RE) and matrix effect (ME) were determined in six different lots of human 
blank hair samples, spiked with tamoxifen and its metabolites in a concentrations of 5 pmol and 
16 pmol for tamoxifen and N-desmethyl-tamoxifen and 0.500 pmol and 1.6 pmol for endoxifen and 
4-hydroxy-tamoxifen. The mean measured extraction efficiencies and matrix effects are presented in 
Table 4. The average recovery of tamoxifen was 93% at 5.0 pmol and 82% at 16 pmol. The recovery for 
the metabolites ranged from 69% for endoxifen at 0.500 pmol to 99% for 4-hydroxy-tamoxifen. Matrix 
effect was near 100% but a slight enhancement was observed for endoxifen.
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Table 3. Calculations of the between-run and within-run precisions and the average accuracy of the LLQ and QC 
samplesa.
sample spiked 
(pmol)
GM (pmol) ACC (%) WrP (%) BrP (%) nc
Tamoxifen
LLQ
Low
Middle
High
1
3
80
160
0.882
2.82
75.8
152
88.2
94
94.8
94.8
6.65
5.03
3.74
3.07
#b
#b
#b
0.923
13 of 15
15 of 15
15 of 15
15 of 15
N-desmethyl-tamoxifen
LLQ
Low
Middle
High
1
3
80
160
0.996
3.04
83
156
99.6
101.3
103.8
97.8
5.42
4.07
2.79
3.78
4.34
3.78
3.11
#b
15 of 15
15 of 15
15 of 15
15 of 15
4-OH-tamoxifen 
LLQ
Low
Middle
High
0.1
0.3
8
16
0.094
0.3
7.84
16
94
100
98
100
8.56
5.51
3
4.16
3.73
0.822
#b
#b
14 of 15
15 of 15
15 of 15
15 of 15
Endoxifen
LLQ
Low
Middle
High
0.1
0.3
8
16
0.101
0.306
8.08
16.4
101.4
102
101
102.8
15.7
9.24
4.46
3.96
8.08
3.96
3.16
0.891
13 of 15
12 of 15
15 of 15
15 of 15
LLQ: lower limit of quantitation; QC: quality control; GM: grand mean; WRP: within-run precision; BRP: between-run 
precision; ACC: average accuracy.
a n = 5 in four separate runs (three runs at the LLQ).
b No additional variation observed by performing the assay in different runs.
c Number of individual samples falling within acceptable range of accuracy of 85-115% (80-120% at LLQ).
Table 4. Extraction recovery (RE) and matrix effect (ME) in hair from six different lots spiked with tamoxifen 
and N-desmethyl-tamoxifen at a concentration of 5.00 pmol and 16.0 pmol and 0.500 pmol and 1.60 pmol for 
endoxifen and 4-hydroxy-tamoxifen.
Analyte 5.00/0.500 pmol 16.0/1.60 pmol
Me (%) re (%) Me (%) re (%)
Tamoxifen 86 ± 3.6 93 ± 3.6 84 ± 2.2 82 ± 17.6
N-Desmethyl-tamoxifen 91 ± 5.9 79 ± 8.7 86 ± 3.2 76 ± 16.6
4-OH-tamoxifen 101 ± 6.0 99 ± 11.1 98 ± 3.0 99 ± 7.7
Endoxifen 114 ± 9.5 69 ± 14.3 111 ± 4.3 82 ± 13.2
Data presented as mean ± standard deviation (n = 6).
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stability of tamoxifen and its metabolites in hair along the hair shaft
As shown in Figure 2, reduction on concentrations of tamoxifen and its metabolites was shown 
from the hair segment starting from the hair root to the following segments. The decline of hair 
tamoxifen and its metabolites along hair shaft was probably attributed to hair washing and other 
treatments. Also exposure to sunlight could contribute to the decline of tamoxifen and its metabolites 
in hair. An average linear decline rate of 0.0203 pmol/segment, 0.0111 pmol/segment, 0.00370 pmol/
segment and 0.371 pmol/segment was observed for tamoxifen, endoxifen, 4-hydroxy-tamoxifen and 
N-desmethyl-tamoxifen, respectively.
stability of tamoxifen and its metabolites in hair to uV irradiation
It is well known that tamoxifen and its metabolites are light sensitive and exposure to UV light leads 
to degradation [16]. To investigate if exposure of hair to UV light leads to degradation of tamoxifen 
and its metabolites, the extent of degradation of tamoxifen, N-desmethyl-tamoxifen, 4-hydroxy-
tamoxifen and endoxifen under UV light was determined. Hair samples from patients receiving 20 
mg of tamoxifen daily were divided into two groups. One group of hair samples was protected from 
light, the second group was exposed for 1h to UV light (254 nm). Tamoxifen and its metabolites were 
very light sensitive under UV light (254 nm). No degradation of tamoxifen or its metabolites was 
observed when the samples were protected from light (Figure 3). As hair is always exposed to the 
environmental light, including UV, photo-degradation of tamoxifen and its metabolites seems the 
main limiting factor in the determination of the historic pattern of drug concentrations by segmental 
hair analysis.
relationship between hair concentration and pigmentation
Higher concentrations of tamoxifen were found in black hair than in blond and brown hair samples. 
Mean concentration (range) in, respectively, black, blond and brown hair was 6.95 (4.47-9.44) pmol/
mg, 2.23 (1.02-2.77) pmol/mg and 0.726 (0.663-0.789) pmol/mg. The decline of the concentration of 
tamoxifen and its metabolites along the hair shaft was independent of hair pigmentation. Several 
publications indicate that there is a good relation between drug levels and that of melanin in hair 
[35,36]. Hair color complicates the interpretation of hair testing in humans.
Analysis of tamoxifen and its metabolites in patients scalp hair samples
To demonstrate the applicability of the assay, segmented scalp hair samples of eight patients 
receiving 20 mg tamoxifen daily for at least six months were analyzed. As a result of the long term use 
of tamoxifen, the patients were at steady-state. The results are shown in Table 5 and clearly show the 
decrease of concentration of tamoxifen and its metabolites in scalp hair segments of one centimeter 
from root to distal end. Decline in concentration is independent of hair color. This method is sensitive 
and accurate enough for measuring tamoxifen and metabolites in human scalp hair.
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figure 2. Concentration of tamoxifen (A), endoxifen (B), 4-hydroxy tamoxifen (C) and N-desmethyl-tamoxifen (D) 
in scalp hair, showing reduction on concentrations of tamoxifen and its metabolites from the hair segment starting 
from the hair root to the following segments, represented on the x-axis with distances in centimeter (cm). Gray line 
represent the mean profile of all hair samples (n = 8).
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figure 3. Accuracy of tamoxifen (A), endoxifen (B), 4-hydroxy-tamoxifen (C) and N-desmethyl-tamoxifen (D) after 
hair exposure to UV light source (- -) and hair protected from light (- -).
COnClusIOn
There are currently no published LC-MS/MS methods for quantification of any anticancer drug in 
hair. In this study, we are the first to show the UPLC-MS/MS method to be a selective, sensitive, 
accurate and precise method for the simultaneous analysis of tamoxifen and its three main phase I 
metabolites, N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and endoxifen, in human scalp hair. One 
of the potential advantages for measuring drug concentrations in scalp hair samples is the possibility 
to perform segmental analysis of hair, allowing the determination of the historic pattern of drug 
concentrations. However, for tamoxifen and its main metabolites, a steep linear decline was observed 
from distal to proximal hair segments probably mainly due to the effect of UV irradiation. Further 
research should therefore focus on quantification of other anticancer drugs in segmented scalp hair, 
that are less sensitive to UV irradiation, with taking into account also influencing factors like the role 
of hair pigmentation.
21 
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Table 5. Concentration of tamoxifen and its metabolites in segmented human scalp hair of eight patients 
receiving 20 mg tamoxifen daily for at least six months. Segments of one centimeter were used and segments 
were numbered from root (segment 1) to distal end.
Concentration (pmol/mg)
   segment
subject Age Color 1 2 3 4 5 6
Tamoxifen
1
2
3
4
5
6
7
8
38
69
70
60
46
70
53
52
Blond
Brown
Blond
Blond
Brown
Blond
Gray
Black
0.807
2.77
0.789
0.663
1.02
0.362
1.42
9.44
0.333
1.97
0.785
0.451
0.621
0.186
1.15
6.40
0.0904
1.85
0.684
0.29
0.296
0.0855
0.820
0.0443
1.62
0.213
0.191
0.0643
0.0310
1.24
0.191
0.0913
Endoxifen
1
2
3
4
5
6
7
8
38
69
70
60
46
70
53
52
Blond
Brown
Blond
Blond
Brown
Blond
Gray
Black
0.0750
0.0102
0.106
0.0394
0.0292
NQ
0.0684
0.694
0.0447
0.00705
0.110
0.0285
0.0233
NQ
0.0562
0.556
0.0169
0.00593
0.0725
0.0179
0.0131
NQ
0.0389
0.00856
0.00504
0.0163
0.00784
NQ
0.00685
0.00277
0.0134
0.00495
4-Hydroxy-tamoxifen
1
2
3
4
5
6
7
8
38
69
70
60
46
70
53
52
Blond
Brown
Blond
Blond
Brown
Blond
Gray
Black
0.0184
0.0696
0.0163
0.0071
0.00994
NQ
0.0327
0.231
0.00806
0.0389
0.0179
0.0047
0.00719
NQ
0.0341
0.178
0.033
0.0145
NQ
0.00287
NQ
0.0196
0.024
NQ
0.00176
NQ
0.0165
NQ
N-desmethyl-tamoxifen
1
2
3
4
5
6
7
8
38
69
70
60
46
70
53
52
Blond
Brown
Blond
Blond
Brown
Blond
Gray
Black
1.47
3.84
1.83
0.758
1.38
0.445
1.26
14.2
0.925
2.75
1.83
0.521
0.858
0.246
1.12
11.0
0.320
2.37
1.37
0.318
0.402
0.118
0.909
0.123
2.31
0.297
0.254
0.0794
0.078
1.71
0.199
0.0577
0.0717
0.0472
NQ: not quantifiable. 
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ABsTrACT
To explore the role of bevacizumab and a chemotherapy-free approach, the authors evaluated the 
combination of bevacizumab, trastuzumab, and paclitaxel (HAT) and the regimen of trastuzumab and 
bevacizumab (HA) with the addition of paclitaxel after progression (HA-HAT) as first line treatment for 
patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. In 
a non-comparative phase 2 trial, patients were randomized between HAT and HA-HAT. The primary 
endpoint was the progression free rate at 1 year (1-year PFR). In the HA-HAT group, progression free 
survival (PFS) was separately established for HA (PFS1) and HAT (PFS2). Eighty-four patients received 
HAT (n = 39) or HA-HAT (n = 45). The 1-year PFR was 74.4% (95% confidence interval [CI], 61.8-89.4%) 
and 62.2% (95% CI 49.6-89.4%) in the HAT and HA-HAT arms, respectively. The median PFS was 19.8 
months (95% CI 14.9-25.6 months) in the HAT arm and 19.6 months (95% CI 12.0-32.0 months) in the 
HA-HAT arm. In the HA-HAT arm, the median PFS1 was 10.4 months (95% CI 6.2-15.0 months), and the 
median PFS2 was 8.2 months (95% CI 7.0-12.6 months). The number and severity of adverse events 
were comparable between the arms. Both HAT and HA-HAT have promising activity in patients with 
HER2-positive metastatic breast cancer. In particular, starting with only targeted agents and delaying 
chemotherapy is worth further exploration. 
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InTrODuCTIOn
Patients with metastatic breast cancer overexpressing human epidermal growth factor receptor 2 (HER2) 
have poor outcomes in the absence of HER2-targeted treatments [1,2]. The advent of HER2-targeting 
agents, such as trastuzumab and lapatinib, and, more recently, pertuzumab and trastuzumab-emtansine, 
has substantially improved outcomes [3-9]. Trastuzumab as a single agent yielded a progression free 
survival (PFS) of 3.5 to 3.9 months [10,11], but, particularly when combined with taxanes, trastuzumab-
based regimens exert considerable antitumor activity. Consequently, until recently, the combination of 
trastuzumab with a taxane was standard first line therapy for these patients [3,4].
Despite these improvements, not all patients benefit from first line trastuzumab combined with 
chemotherapy and, eventually, most if not all patients experience resistance. In addition, the combination 
of trastuzumab and taxanes is accompanied by chemotherapy-induced toxicities, such as bone marrow 
suppression and neurotoxicity, impairing quality of life. For these reasons, new treatment options are 
needed to improve outcomes for this patient category. One strategy to do so is to enhance antitumor 
activity by adding novel agents. Another approach is to reduce the toxicity from treatment by exploring 
strategies in which chemotherapy is being withheld while maintaining efficacy.
Based on both preclinical and clinical data, bevacizumab might be a potentially useful drug to be 
added to trastuzumab and chemotherapy. Bevacizumab is a fully humanized monoclonal antibody 
against vascular endothelial growth factor (VEGF). In addition to playing a key role in angiogenesis, 
it is also thought that VEGF confers chemotherapy resistance [12]. In HER2-overexpressing breast 
cancer cell lines, VEGF production was enhanced, and results suggested that it was causally related 
to the more aggressive phenotype compared with HER2-negative tumors [12,13]. It is noteworthy 
that targeting both VEGF and HER2 inhibited tumor growth more than either agent alone in HER2-
overexpressing preclinical models [13]. In a single arm phase 2 study, the combination of trastuzumab 
and bevacizumab revealed a median time to progression of 9.2 months (95% confidence interval 
[CI], 5.4-20.4 months), which compared favorably with the time to progression achieved with the 
combination of trastuzumab and paclitaxel [3,14].
In addition to trastuzumab, bevacizumab also enhances the antitumor effect of chemotherapy, 
as demonstrated in several tumor types; and there is mounting evidence that the added value of 
bevacizumab depends on the schedule and chemotherapeutic agents with which it is concomitantly 
received [15]. This may also be true for metastatic breast cancer, in which bevacizumab seems to 
enhance the activity of weekly paclitaxel to a greater extent than when combined with docetaxel 
every three weeks [16,17]. 
To investigate the potential value of bevacizumab in patients with HER2-positive metastatic breast 
cancer and to explore the feasibility of an upfront chemotherapy-free approach, we performed 
a randomized, non-comparative phase 2 trial. This design gave us the opportunity to test two 
experimental treatment arms in parallel, which is advantageous when several interesting regimens 
exist that warrant screening for antitumor activity in a phase 2 setting.
Chapter 7
110
Randomization was used to reduce various types of bias, including patient selection and controlling 
for possible baseline imbalances across the treatment arms. This facilitates the choice which regimen 
emerging from a phase 2 study should warrant further investigation and be pursued in a phase 3 study 
[18,19]. We randomized patients between the combination of bevacizumab, trastuzumab, and weekly 
paclitaxel and a regimen consisting of a chemotherapy- free approach with upfront trastuzumab and 
bevacizumab treatment with the addition of paclitaxel at the time of disease progression.
PATIenTs AnD MeThODs
study design
The HAT Study was an open-label, randomized, non-comparative phase 2 trial of concomitant 
trastuzumab, bevacizumab, and paclitaxel (HAT) versus trastuzumab and bevacizumab (HA) followed 
by the combination of trastuzumab, bevacizumab, and paclitaxel at progression (HA-HAT) as first 
line treatment in patients with metastatic breast cancer with HER2 overexpression (Figure 1). The 
primary objective was to establish whether HAT and/or HA-HAT show sufficient efficacy to be studied 
further. The primary endpoint was the progression free rate at 1 year after randomization (1-year 
PFR). Secondary endpoints included PFS, overall survival (OS), the best overall response, the objective 
response rate (ORR) (i.e. partial responses [PRs] and complete responses [CRs]), the clinical benefit rate 
(CBR) (i.e. CRs, PRs, and stable disease for >6 months), duration of response, safety, and tolerability.
Randomization
Trastuzumab + Bevacizumab (HA)
Paclitaxel (T)
Trastuzumab + Bevacizumab (HA)
Paclitaxel (T)
(added after PD on HA)
Off study
Off study
PFS1 PFS2
PFS
PFS
figure 1. The study design is illustrated. Patients were randomized at a 1:1 ratio between combined bevacizumab, 
trastuzumab, and paclitaxel (HAT) (trastuzumab 6 mg/kg [the first dose was 8 mg/kg] plus bevacizumab 15 mg/kg 
every three weeks, both until progressive disease developed; and paclitaxel 90 mg/m2 on days 1, 8, and 15 every 
four weeks for a maximum of six cycles) versus trastuzumab and bevacizumab (HA) plus HAT (HA-HAT) (doses 
of trastuzumab and bevacizumab were the same those in the HAT regimen with paclitaxel for a maximum of six 
cycles added at the time of disease progression). Progression-free survival (PFS) is illustrated separately for HA 
(PFS1) and HAT (PFS2).
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The protocol was approved by an accredited medical research ethical committee (Netherlands Cancer 
Institute, Amsterdam). The trial was registered upfront in the Netherlands Trial Register (NTR1349) 
and was conducted in full accordance with the principles of the Declaration of Helsinki and local 
regulations. All participants provided written informed consent.
Patient Population
Patients who had measurable or evaluable locally recurrent or metastatic, HER2-positive breast cancer 
(LR/MBC) were eligible whenever they required first line chemotherapy. Prior endocrine therapy 
for metastatic disease was allowed. Positive HER2 status was defined as score of 3+ assessed by 
immunohistochemistry and/or gene amplification using in situ hybridization of the primary tumor 
or a metastatic lesion. Eligible patients had an Eastern Cooperative Oncology Group performance 
status 0 or 1; were aged ≥18 years; had adequate cardiac, hematologic, hepatic, and renal function; 
and had no known central nervous system metastases. Patients who had received trastuzumab in 
the adjuvant setting were eligible only when they had received at least ten months of therapy with 
trastuzumab and ≥6 months had elapsed since their last adjuvant administration of trastuzumab. 
Patients who had received (neo)adjuvant chemotherapy were only eligible if they had received their 
last dose ≥6months before randomization and their taxane-associated toxicities had resolved to less 
than grade 2.
random Assignment and Treatment
Patients were randomized by the trial office of the Dutch Breast Cancer Research Group and were 
stratified by participating center at a 1:1 ratio between the HAT arm (trastuzumab 6 mg/kg [the first 
dose was 8 mg/kg] plus bevacizumab 15 mg/kg every three weeks and paclitaxel 90 mg/m2 on days 
1, 8, and 15 every four weeks) and the HA-HAT arm (with doses of trastuzumab and bevacizumab 
the same as in the HAT regimen and paclitaxel added at the time of disease progression). Paclitaxel 
was planned for six cycles, unless unacceptable toxicity or disease progression mandated earlier 
discontinuation. Both trastuzumab and bevacizumab were administered until disease progression 
(in the HA-HAT arm, this was defined as progression after the addition of paclitaxel), unacceptable 
toxicity, or withdrawal of consent. Adding endocrine therapy was not allowed for the duration of the 
study.
study Assessments
Metastatic lesions were assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.0 at baseline and every twelve weeks thereafter, at the onset of clinical signs suggesting 
progression, or in case of premature discontinuation of study treatment. Local investigators performed 
tumor response assessments. Adverse events (AEs) were recorded at every cycle and for 30 days after 
the last receipt of any of the study drugs. AEs were graded according the National Cancer Institute-
Common Toxicity Criteria version 3. Quality of life was assessed using the European Organization for 
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Research and Treatment of Cancer (EORTC) quality-of-life questionnaire (EORTC QLQ-C30, version 3) 
at baseline, every twelve weeks thereafter, and at the time of disease progression.
statistical design
For the 1-year PFR, all patients in the HAT arm who were without progression within 1 year after 
randomization, all those in the HA-HAT arm who were without progression within 1 year after 
randomization and had received treatment with trastuzumab and bevacizumab, and all those who 
progressed during HA and started treatment with HAT but did not experience disease progression 
during this triple combination were considered “progression free” with respect to the primary 
endpoint. The rationale for the definition of 1-year PFR in the HAHAT group was that the objective of 
this study was to test whether it was possible to delay the initiation of chemotherapy without losing 
efficacy.
Secondary endpoints included PFS, measured as the time from randomization to the first documented 
disease progression or death from any cause in the HAT group. For the HA-HAT group, PFS was 
measured as the time from randomization to either the first documented disease progression after 
paclitaxel treatment was added to bevacizumab and trastuzumab or death from any cause. This means 
that documented disease progression during treatment with trastuzumab and bevacizumab (without 
paclitaxel) was ignored as an event if treatment with paclitaxel was started. In addition, for the HA-HAT 
group, a PFS1 and PFS2 were established, with PFS1 defined as the time from randomization to first 
documented disease progression or death from any cause and PFS2 defined as the time from starting 
treatment with HAT to subsequent documented disease progression or death from any cause. OS was 
measured as the time from randomization to either death from any cause or the date of last follow-up.
For this study, a regimen that yielded a 1-year PFR of approximately 40% was deemed to be worth 
further exploration (p1). A Fleming one stage design was applied to both arms, with p0 = 20%, α = 
0.05, and β = 0.10, indicating that, if a treatment yielded >14 of 42 patients were progression free 
1 year after randomization, then the treatment was considered worth further exploration. For that 
reason, a total sample size of 84 patients (42 in both arms) was chosen. PFS, PFS1, PFS2, and OS were 
estimated using the Kaplan-Meier method for both arms. The estimated 1-year PFR and the median 
PFS, PFS1, PFS2, and OS values were calculated with their 95% CIs.
resulTs
Patient population
Between April 2009 and September 2013, 84 patients were enrolled at 16 centers in the Netherlands 
and were randomly assigned to HAT or HA-HAT (Figure 2). A slight imbalance occurred in the 
treatment arm allocation (39 patients in the HAT arm and 45 patients in the HA-HAT arm) because 
of stratification for participating centers. One patient allocated to the HA-HAT group did not begin 
treatment because brain metastases became symptomatic before treatment was started. The cutoff 
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date for data collection for the current analysis was one year after the last patient had been enrolled. 
The median follow-up for the entire group was 42 months. Patients’ baseline characteristics were 
well balanced between the treatment arms (Table 1, [20]).
efficacy
The 1-year PFR was 74.4% (95% CI 61.8-89.4%) in the HAT arm and 62.2% (95% CI 49.6-89.4%) in the 
HA-HAT arm. The median PFS for the HAT arm was 19.8 months (95% CI 14.9-25.6 months), and the 
median overall PFS in the HA-HAT arm was 19.6 months (95% CI 12.0-32.0 months) (Figure 3A). In the 
HA-HAT arm, the median PFS1 was 10.4 months (95% CI 6.2-15.0 months) (Figure 3B), and the median 
PFS2 was 8.2 months (95% CI 7.0-12.6 months). The median OS was 36.8 months (95% CI 29.1 months 
to not applicable [NA]) in the HAT group and 54.0 months (95% CI 37.4 months to NA) in the HA-HAT 
group (Figure 3C).
In the HAT arm, 39 patients started with HAT. The median number of paclitaxel cycles was six (range, 
1-7 cycles; mean, 5.26 cycles). 29 of 39 patients completed all six cycles of paclitaxel, and six patients 
progressed during paclitaxel-based therapy.
In the HA-HAT arm, among those who experienced disease progression while receiving HA, paclitaxel 
was not added in six patients (17%) because of toxicity (n = 4; proteinuria, decrease of left ventricular 
ejection fraction, neuropathy, and/or fatigue) or patient request (n = 2). One patient had already 
started HAT based on growth of liver metastases but did not formally meet the criteria for progression 
Patients randomized (n = 84)
Allocated to HAT arm (n = 39)
Received HAT (n = 39)
Off study (n = 27)
- Progression (n = 27)
On study at date collection cut off (n = 12)
- On treatment (n = 8)
- In follow-up (n = 4)
Allocated to HA-HAT arm (n = 45)
Received HA (n = 44)
Progression (n = 36)
- Started HAT (n = 30)
- Off study (n = 6)
- Toxicity (n = 4)
- Patient wish (n = 2)
Started HAT before progression (n = 1)
Started HAT (n = 31)
Off study (n = 23)
- Progression (n = 22)
- Died due to toxicity (n = 1)
On study at data collection cut off (n = 8)
- On treatment (n = 5)
- In follow-up (n = 3)
On treatment at date collection cut off (n = 7)
figure 2. This is a Consolidated Standards of Reporting Trials (CONSORT) diagram of enrollment, intervention 
allocation, and follow-up in the current study. 
HA: trastuzumab and bevacizumab; HAT: bevacizumab, trastuzumab, and paclitaxel.
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Table 1. Patient demographic and baseline characteristics.
hAT (n = 39)   hA-hAT (n = 45) Total (n = 84)
Age, median (range) 57 (35-76) 55 (29-80) 55 (29-80)
ECOG Performance status 
       0, n (%)
       1, n (%)
27 (69)
12 (31)
33 (73)
12 (27)
60 (71)
24 (29)
Hormone receptor status
       ER positive, n (%)
       ER negative, n (%)
       PR positive, n (%)
       PR negative, n (%)
       ER or PR positive, n (%)
       ER and PR negative, n (%)
24 (62)
15 (38)
13 (33)
25 (64)
25 (64)
13 (33)
27 (60)
18 (40)
21 (47)
23 (51)
28 (62)
16 (36)
51 (61)
33 (39)
34 (40)
48 (57)
53 (63)
30 (36)
Involved tumor site
       Lung, n (%)
       Liver, n (%)
       Bone, n (%)
12 (31)
16 (41)
26 (67)
16 (36)
22 (49)
32 (71)
28 (33)
38 (45)
58 (69)
Number of different metastatic sitesa
       1, n (%)
       2, n (%)
       3, n (%)
       4, n (%)
10 (26)
15 (38)
12 (31)
2 (5)
8 (18)
19 (42)
14 (31)
4 (9)
18 (21)
34 (40)
26 (31)
6 (7)
Disease-free interval ≥12 monthsb, n (%) 22 (56) 33 (73) 55 (56)
Primary metastatic disease, n (%) 16 (41) 12 (27) 28 (33)
Prior endocrine therapy 
       Adjuvant, n (%)       
       Metastatic, n (%)
12 (31)
9 (23)
16 (36)
12 (27)
28 (33)
21 (25)
Prior adjuvant chemotherapy, n (%) 12 (31) 17 (38) 29 (35)
Prior adjuvant trastuzumabc, n (%) 6 (15) 8 (18) 14 (17)
ECOG: Eastern Cooperative Oncology Group; ER: estrogen receptor; PR: progesterone receptor. 
a Different metastatic sites included lung, liver, bone and other. 
b The disease-free interval was defined as the time from histologic diagnosis of primary breast cancer to the 
diagnosis of locally recurrent or metastatic disease.
c The receipt of prior adjuvant trastuzumab was based on the assumption that all patients who received with 
adjuvant treatment for human epidermal growth factor 2-positive disease after August 2005 also received with 
adjuvant trastuzumab (see De Munck et al, 2011 [20]).
according to RECIST. In total, 31 patients started with HAT. The median number of paclitaxel cycles was 
six (range, 1-6 cycles; mean 4.68 cycles). 22 of 31 patients completed all six cycles of paclitaxel, and 
three patients progressed during paclitaxel-based therapy.
The investigator-assessed ORR (i.e. CRs plus PRs) was 58% in the HAT arm and 44% in the HA-HAT 
arm during HA. Among patients in the HA-HAT group who experienced disease progression while 
receiving HA, the addition of paclitaxel induced objective responses in 50%. The CBR was 87% in 
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figure 3. Kaplan-Meier survival estimates are shown. (A) Estimated progression free survival (PFS) is illustrated 
in patients who received concomitant trastuzumab, bevacizumab, and paclitaxel (HAT arm) versus those who 
received trastuzumab and bevacizumab (HA) followed by HAT at progression (HA-HAT arm). (B) Estimated PFS 
is compared between patients who received only HA in the HA-HAT arm (PFS1) versus those who received 
concomitant HAT. (C) Estimated overall survival is illustrated for patients in the HAT arm versus those who received 
HA followed by HAT at progression (HA-HAT arm).
A
B
C
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the HAT arm and 58% in the HA-HAT arm during HA. Among patients in the HA-HAT group who had 
disease progression during HA, adding paclitaxel led to a clinical benefit in 62% of patients. In the HAT 
arm, among patients who had an objective response, the median response duration was 22.2 months 
(95% CI 16.0 months to NA). In the HA-HAT arm, among those who had an objective response who 
received only trastuzumab and bevacizumab (n = 19), the median response duration was 26.1 months 
(95% CI 22.6 months to NA). Baseline characteristics were comparable between patients with a PFS1 
<24 months (n = 38) and patients with a PFS1 >24 months (n = 7) (data not shown).
Toxicity
The safety population, defined as patients who had received at least one administration of study 
drug(s), included 83 patients. Grade ≥3 AEs were reported in 84% of patients. Most grade ≥3 AEs 
were attributable to bevacizumab, with grade ≥3 hypertension and proteinuria in 36 and 13% of 
patients, respectively, and with no differences between treatment arms. The toxicity profiles of the 
two regimens during the whole period of study treatment were comparable (Table 2). Neutropenia, 
febrile neutropenia, infection, peripheral neuropathy, stomatitis, and diarrhea were reported less 
frequently during HA treatment than during HAT treatment. One patient in the HA-HAT arm who had 
been receiving treatment with bevacizumab for four months died from a perforation of a sigmoid 
diverticulum shortly after starting paclitaxel.
Quality of life
Quality-of-life questionnaires were collected every twelve weeks until the end of treatment. Responses 
to the EORTC QLC-C30 questionnaire were available from 73 patients (87%) at baseline, from 61 at 
twelve weeks, and from 23 after first progression. There were no relevant differences in reported 
quality of life when HAT treatment in the HAT arm was compared with HA treatment in the HA-HAT 
arm (data not shown).
DIsCussIOn
In this randomized, non-comparative phase 2 study in which two experimental treatments were tested 
in parallel, both HAT and HA-HAT were active first line treatment regimens in patients with HER2-positive 
LR/MBC, yielding a 1-year PFR (the primary endpoint of the study) of 74.4 and 62.2%, respectively. The 
median PFS was 19.8 months in the HAT arm and 19.6 months in the HA-HAT arm, with durable OS in 
both arms. This implies that both treatments have met the predefined criteria for further study. On the 
basis of comparison with the landmark trial of Slamon et al, data from the current study suggest that 
bevacizumab strongly enhances the antitumor activity of combined paclitaxel and trastuzumab [3].
Our results from the addition of bevacizumab to combined paclitaxel and trastuzumab have to be 
compared with those from the ‘Study of Avastin [Bevacizumab] in Combination With Herceptin 
[Trastuzumab]/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer’ (AVEREL) trial, a 
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phase 3 study in patients with HER2-positive LR/MBC who received docetaxel and trastuzumab with 
or without bevacizumab in which no significant difference in median PFS was observed between 
treatment arms (PFS 16.5 vs. 13.7 months, respectively) [21]. It is noteworthy that docetaxel every three 
weeks was used in that study, whereas preclinical evidence indicates that not every chemotherapeutic 
drug will have its efficacy enhanced by the addition of a VEGF-targeting drug. Paclitaxel is one of the 
drugs which antitumor activity is augmented when combined with bevacizumab [15]. Accordingly, 
in patients with HER2-negative LR/MBC, the absolute PFS benefit from bevacizumab added to weekly 
paclitaxel over paclitaxel alone in the Eastern Cooperative Oncology Group 2100 study (PFS 11.8 vs. 
5.9 months; hazard ratio 0.60; p <0.001) was greater than the gain achieved from bevacizumab added 
to docetaxel versus docetaxel alone, as reported in the ‘Avastin and Docetaxel’ (AVADO) study (PFS 10.1 
vs. 8.2 months; hazard ratio 0.77; 95% CI 0.64-0.93) [16,17], suggesting greater activity of bevacizumab 
when added to weekly paclitaxel than when added to docetaxel every three weeks.
Along with the AVEREL study, two other (although much smaller), single-arm phase 2 trials have 
investigated the efficacy and safety of adding bevacizumab to combinations of trastuzumab and 
chemotherapeutic agents in the first line treatment of patients with advanced, HER2-positive breast 
cancer [22,23]. Those two studies combined trastuzumab and bevacizumab with vinorelbine and 
Table 2. Summary of main adverse events. 
All grades grade 3 and higher
hAT arm
during hAT
(n = 39)
n (%)
hA-hAT arm hAT arm
during hAT
(n = 39)
n (%)
hA-hAT arm
during hA
(n = 44)
n (%)
during hAT
(n = 31)
n (%)
during hA
(n = 44)
n (%)
during hAT
(n = 31)
n (%)
Nausea 18 (46.2) 18 (40.9) 13 (41.9) - - 1 (3.2)
Vomiting 7 (17.9) 10 (22.7) 5 (16.2) 1 (2.6) - 1 (3.2)
Stomatitis 12 (30.8) 9 (20.5) 10 (32.3) 2 (5.1) - -
Diarrhea 19 (48.7) 12 (27.2) 15 (48.4) 3 (7.7) - 3 (9.7))
Edema 12 (30.8) 10 (22.7) 4 (12.9) - - -
Infection 26 (66.7) 13 (29.5) 14 (45.2) 6 (15.4) 2 (4.5) 6 (19.4)
Fatigue 32 (82.1) 27 (61.4) 23 (74.2) 2 (5.1) - 3 (9.7)
Neutropenia 12 (30.8) 1 (2.3) 13 (41.9) 8 (20.5) - 5 (16.1)
Febrile neutropenia 1 (2.6) - - 1 (2.6) - -
Peripheral neuropathy 28 (71.8) 10 (22.7) 17 (54.8) 1 (2.6) 1 (2.3) -
Hypertension 29 (74.4) 25 (56.8) 11 (35.5) 16 (41.0) 13 (29.5) 5 (16.1)
Proteinuria 13 (33.3) 12 (27.2) 7 (22.6) 4 (10.3) 6 (13.6) 4 (12.9)
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capecitabine, respectively, and demonstrated a lower median PFS compared with that in our study 
(PFS 9.9 and 14.4 months, respectively). The study on vinorelbine was closed early because of toxicity. 
The study on capecitabine met the primary endpoint of that study, although the combination with 
capecitabine is not standard first line treatment for LR/MBC.
In the adjuvant setting, the ‘Bevacizumab and Trastuzumab Adjuvant Therapy’ (BETH) trial, a phase 
3 study of the addition of bevacizumab to a standard regimen with docetaxel, carboplatin, and 
trastuzumab, did not demonstrate a benefit from the addition of bevacizumab [24]. Recently, phase 
2 neoadjuvant trials demonstrated high pathologic complete response rates (range 54-64%) when 
bevacizumab was added to standard neoadjuvant regimens [25,26]. However, the results from those 
perioperative studies cannot be extrapolated to the treatment of metastatic disease.
Another way to improve outcome is by reducing treatment-induced toxicity. Therefore, we also 
explored the option of delaying the start of chemotherapy by beginning with trastuzumab and 
bevacizumab and adding paclitaxel only at the time of disease progression. In that analysis, we 
demonstrated that a significant proportion of patients who received treatment with monoclonal 
antibodies alone could achieve a durable PFS, i.e. a median PFS1 of 10.4 months and a median response 
duration of 26.1 months among those who had an objective response to treatment with trastuzumab 
and bevacizumab only. The median PFS1 is in line with the previously mentioned phase 2 study of 
combined trastuzumab and bevacizumab, which demonstrated a median time to progression of 9.2 
months (95% CI 5.4-20.4 months) [14]. By comparison, studies on trastuzumab monotherapy as first 
line treatment for patients with HER2-positive LR/MBC reported a median PFS of only 3.5 to 3.9 months 
[10,11], stressing that bevacizumab probably adds to the activity of trastuzumab in an advanced 
setting. To the best of our knowledge, no other studies have been published on a chemotherapy-
free approach with the combination of trastuzumab and bevacizumab. Several non-first line phase 
2 studies in the metastatic setting have been performed on dual HER2 blockade using trastuzumab 
in combination with either pertuzumab or lapatinib, all of which demonstrated a median PFS of ≥6 
months [27-30].
It is noteworthy that, although ORR, CBR, and PFS values appeared to be lower when we started 
treatment with trastuzumab and bevacizumab versus combined trastuzumab, bevacizumab, and 
paclitaxel, adding chemotherapy at the time of disease progression in the HA-HAT arm yielded a similar 
total PFS compared with that in the HAT arm. Furthermore, in a substantial number of patients who 
progressed while receiving trastuzumab and bevacizumab, adding paclitaxel re-induced objective 
responses. Currently, follow-up duration is too short to draw conclusions on OS results.
The toxicity profiles of both regimens seem to be in favor of beginning treatment with bevacizumab 
and trastuzumab only and delaying the start of cytotoxic chemotherapy, thereby postponing 
chemotherapy-associated toxicities. The large majority of grade ≥3 AEs in this study were attributable 
to treatment with bevacizumab and mainly consisted of hypertension and proteinuria, which, 
overall, were easily manageable. Bevacizumab-related toxicities, as demonstrated in other studies, 
do not result in decreased quality of life for most patients [31]. One patient died from a spontaneous 
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bowel perforation, which is a known complication of bevacizumab, although its reported incidence 
in bevacizumab-treated patients with advanced breast cancer is <1% [32]. We did not observe any 
suggestion of a difference in quality of life between the two groups. Less therapy-associated toxicity 
during HA compared with HAT might have led to decreased quality of life during HAT. Conversely, the 
response rates under HA were lower than under HAT, which might lead to decreased quality of life 
during HA. These compensatory explanations might have outweighed each other. Furthermore, the 
number of returned questionnaires was quite low for unknown reasons. This hampers our ability to 
draw firm conclusions.
Adding endocrine therapy to the combination of trastuzumab and bevacizumab was not allowed in 
our study. The results might have been even better if endocrine therapy had been added for patients 
with hormone receptor positive disease.
With publication of the ‘Clinical Evaluation of Pertuzumab and Trastuzumab’ (CLEOPATRA) trial 
indicating a median overall survival benefit of 15.7 months for the combination of trastuzumab, 
pertuzumab, and docetaxel compared with combined trastuzumab and docetaxel, this regimen has 
become the standard first line therapy for patients with HER2-positive metastatic breast cancer [9]. 
When taking into account the solid phase 3 data from the CLEOPATRA trial and the favorable toxicity 
profile of pertuzumab, compared with bevacizumab, it is unlikely that further phase 3 trials on the 
combination of bevacizumab, trastuzumab, and chemotherapy will be performed. The results from 
our study, however, indicate that the concept of starting with a chemotherapy-free approach using 
only biologics is an approach that deserves further study. New trials of chemotherapy-free treatments 
should incorporate newer HER2-targeted agents, such as pertuzumab, trastuzumab-emtansine, 
novel agents, and also endocrine therapy in hormone receptor positive patients. Preclinical evidence 
suggests that the combination of trastuzumab, pertuzumab, and bevacizumab is very active [33]. 
Obviously, randomized controlled trials investigating combinations of targeted agents (with and 
without bevacizumab) and endocrine therapy (in hormone receptor positive patients) followed 
by the addition of chemotherapy at the time of progression as first line treatment for patients with 
HER2-positive metastatic breast cancer would be interesting. Results on the efficacy of combined 
trastuzumab and pertuzumab without chemotherapy will follow from the ongoing PERNETTA 
trial (a randomized phase 2 trial of pertuzumab in combination with trastuzumab with or without 
chemotherapy, both followed by trastuzumab emtansine, in patients with HER2-positive MBC; 
clinicaltrials.gov no. NCT01835236) and GCC 1303 trial (trastuzumab and pertuzumab with hormone 
therapy or chemotherapy in women aged ≥60; clinicaltrials.gov no. NCT02000596).
Chapter 7
120
COnClusIOn
In summary, both the HAT combination and the sequential treatment starting with a chemotherapy-
free approach using HA followed by adding paclitaxel at progression seem to be active regimens in 
patients who have HER2-positive metastatic breast cancer. The results from this study strongly suggest 
that bevacizumab adds clinically relevant antitumor activity to certain trastuzumab-based regimens. 
In particular, a sequential approach with bevacizumab and trastuzumab and delaying the start of 
cytotoxic chemotherapy is worth further exploration in studies that incorporate newer HER2-targeted 
agents along with endocrine therapy in patients who have hormone receptor positive disease.
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ABsTrACT
The bone is the most common site to which breast cancer metastasises. Recently, denosumab, a fully 
human monoclonal antibody that binds to receptor activator of nuclear factor kappa-B ligand (RANKL) 
has been developed as a new targeted bone therapy. In a large randomized phase 3 study with a head-
to-head comparison of denosumab to zoledronic acid in patients with bone metastases of breast 
cancer, denosumab significantly delayed the time to first skeletal related event. In the adjuvant setting 
denosumab significantly increased bone mineral density compared to placebo in a phase 3 study in 
patients treated with aromatase inhibitors. Preclinical data suggest an effect of denosumab on tumor 
growth and even on carcinogenesis. This review describes the current indications for denosumab 
in the various settings of breast cancer treatment, with special attention for efficacy, short and long 
term toxicity and other relevant issues for clinical practice. Furthermore possible and necessary future 
research questions are proposed.
C
h
ap
te
r  
8
Denosumab in breast cancer treatment
127
InTrODuCTIOn
The bone is the most common site to which breast cancer metastasises (up to 70%) [1]. Although 
bone metastases can be asymptomatic for years, the occurrence of skeletal related events (SREs), 
which are defined as pathological fractures, necessity for radiation or surgery due to (threaten) spinal 
cord compression or hypercalcemia due to bone metastases, has a negative impact on patients’ 
quality of life and generally portends a worse prognosis [2,3]. Since the life expectancy of metastatic 
breast cancer patients has increased over the years, preventing SREs have become a major challenge 
in optimizing the care for these patients.
For years, bisphosphonates have been the cornerstone for the prevention and management of SREs, 
especially in patients with metastatic breast cancer. Recently, denosumab, a fully human monoclonal 
antibody that binds with high affinity and high specificity to receptor activator of nuclear factor 
kappa-B ligand (RANKL), has been developed as a new targeted bone therapy [4]. In this review we 
will describe denosumab within the breast cancer population in more detail, with special attention 
for efficacy, short and long term toxicities and other issues relevant for clinical practice. Furthermore, 
possible and necessary research questions are proposed.
The rAnK-rAnKl system in bone metastases
In physiological circumstances, the bone undergoes constant remodeling, resulting from the 
tightly controlled balance between osteoblast and osteoclast activity. The ratio between RANKL 
and its physiological antagonist osteoprotegerin is crucial in maintaining this balance and thereby 
controls bone health. RANKL is a member of the tumor necrosis factor (TNF) superfamily and is 
produced by the osteoblasts. After releasing into the bone micro-environment, RANKL binds to its 
receptor RANK, which is expressed by immature osteoclasts and initiates maturation to activating 
osteoclasts by signaling through the nuclear factor kappa-B and Jun N-terminal kinase pathways [4]. 
As a consequence of RANKL production, bone resorption will occur. On the contrary, excessive bone 
resorption is prevented by the decoy receptor osteoprotegerin, also produced by osteoblasts, that 
binds to RANKL thereby preventing its binding to RANK [5]. The extent of bone resorption is thus 
regulated via osteoclast formation and activity through the coordinated expression of RANKL and 
osteoprotegerin.
In patients with a solid tumor and bone metastases, increased expression of both RANKL and 
osteoprotegerin can occur [6]. This increased expression of RANKL or osteoprotegerin is induced by 
osteotropic factors, produced by cancer cells, such as parathyroid hormone, parathyroid hormone 
related peptide, 1,25-dihydroxyvitamin D3, and prostaglandins. The local balance between RANKL 
and osteoprotegerin determines whether bone metastatic lesions have a lytic or blastic appearance 
on radiographic images [6]. A disproportional high level of RANKL will lead to lytic lesions, while a 
disproportional high level of osteoprotegerin will lead to blastic lesions.
Bone metastases in breast cancer are predominantly osteolytic [7]. The reason for that is that 
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parathyroid hormone related peptide is probably the most important factor produced by breast 
cancer cells, which leads to increased RANKL expression that activates osteoclasts causing enhanced 
bone resorption [8]. Besides bone resorption, activated osteoclasts also activate release of growth 
factors from the bone matrix that stimulate tumor growth and bone destruction [9]. This reciprocal 
interaction between breast cancer cells and the bone micro-environment results in a vicious circle 
that increases both bone destruction and the tumor burden (Figure 1).
BONE
osteoblast                                osteoclastincreased RANKL
decreased OPG         
PTHrP and other 
osteotropic 
factors
Osteoprotegerin
RANKL 
RANK
bone derived  
growth factors
Breast tumor cells
BONE
osteoblast                                  osteoclast
Osteoprotegerin
RANKL 
RANK
Denosumab
Bone resorption
Breast tumor cells
figure 1. The vicious circle of bone metastases in breast cancer. Breast cancer cells (BC) produce parathyroid 
hormone related peptide (PTHrP) and other osteotropic factors which lead to increased expression of RANKL and 
decreased expression of the decoy receptor osteoprotegerin (OPG) by osteoblasts, resulting in increased binding 
of RANKL to the RANK receptor, which is expressed by immature osteoclasts. Increased RANK-RANKL interaction 
leads to increased activation of osteoclasts which has a direct effect on bone resorption (lytic lesions), but also 
activates production and release of bone derived growth factors, which stimulate tumor growth.
figure 2. Working mechanism of denosumab. Denosumab specifically binds to RANKL. Like osteoprotegerin, this 
prevents binding of RANKL to RANK on osteoclasts and inhibits the downstream signaling that induces osteoclast 
activation, leading to reduction of bone resorption and disruption of the vicious circle of bone metastases.
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Denosumab
Denosumab is a fully human monoclonal antibody (IgG2) that specifically binds to human RANKL. 
Like osteoprotegerin, this prevents activation of the receptor RANK on osteoclasts and inhibits the 
downstream signaling that induces osteoclast activation, migration and differentiation and so reduces 
bone resorption [4] (Figure 2).
Denosumab has been developed for subcutaneous (sc) administration, and shows a non-linear, dose-
dependent pharmacokinetic, so that the drug is detected in peripheral blood samples within one 
hour and up to nine months after one single dose [10,11]. This leads to a mean elimination half-life of 
denosumab of 28 days and a steady state which is reached by six months (Amgen Inc. Denosumab: 
full prescribing information. http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf (accessed 22 
June 2012)).
Compared to denosumab, bisphosphonates differ greatly in terms of the administration route 
as well as the pharmacokinetics. Although oral administration of bisphosphonates is possible, the 
poor absorption makes intravenous administration necessary to ensure sufficiently high dose of 
bisphosphonates to prevent SREs in the advanced setting. Once in the circulation, bisphosphonates 
are directly cleared from the blood by binding to hydroxyapetite in the bone matrix. As a consequence, 
24h after a single dose of zoledronic acid, less than 1% can be measured in the blood.
DenOsuMAB In ADVAnCeD BreAsT CAnCer
efficacy and tolerability of denosumab in advanced breast cancer patients
Denosumab was originally approved for the treatment of postmenopausal osteoporosis as well as 
bone loss in patients receiving adjuvant aromatase inhibitor therapy for early breast cancer or androgen 
deprivation therapy for non-metastatic prostate cancer. Recently, three large randomized phase 3 
studies with a head-to-head comparison of denosumab to zoledronic acid in patients with bone 
metastases of breast, prostate and all other solid tumors (and multiple myeloma), showed denosumab 
to be non-inferior to zoledronic acid for preventing first on-study SREs [12-14]. In the study on breast 
cancer patients with bone metastases (n = 2,046), denosumab (120 mg every four weeks) significantly 
delayed time to first on-study SRE by 18% (HR 0.82; 95% CI 0.71-0.95, p = 0.01 (superiority)) compared to 
zoledronic acid (4 mg every four weeks). The median time to first on study SRE was 26.4 months for the 
zoledronic acid group and had not yet been reached for the denosumab group. Denosumab was also 
superior compared with zoledronic acid in delaying time to first and subsequent on-study SREs (HR 0.77; 
95% CI 0.66-0.89, p = 0.001) [14]. No differences in overall survival or disease progression were observed 
between the two study groups. Although the study was initially designed as a non-inferiority study with 
time to first on-study SRE as primary endpoint, superiority criteria were prespecified in the protocol [14].
In general the tolerability of denosumab was acceptable and quite well comparable with the side 
effects of zoledronic acid. Acute-phase reactions characterized by fever, myalgia and bone pain within 
the first three days of treatment were observed in a slightly lower percentage of patients treated with 
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denosumab (8.7%) compared to those treated with zoledronic acid (20.0%) [12-14]. Hypocalcemia 
was more frequent with denosumab than with zoledronic acid (9.6% vs. 5.0%), despite the fact that all 
patients were encouraged to take calcium and vitamin D supplements. Although, most episodes of 
hypocalcemia were generally mild, easily managed and rarely required hospital admission, fatal cases 
of hypocalcemia have been reported. Therefore it is advised to correct pre-existing hypocalcemia 
prior to the start of denosumab treatment and to monitor calcium levels while on treatment and 
administer calcium, magnesium, and vitamin D if necessary (Amgen Inc. Denosumab: full prescribing 
information. http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf (accessed 22 June 2012)). 
Moreover, the calcium levels should be monitored more frequently when denosumab is administered 
in combination with calcium lowering drugs or in patient with pre-existent impaired renal function 
due to an increased risk of hypocalcemia.
The most important adverse event associated with the use of bisphosphonates in oncology is 
osteonecrosis of the jaw (ONJ). This seems also the case for denosumab. In the three large prospective 
phase 3 studies among patients with metastatic bone disease, comparing denosumab with zoledronic 
acid, regular oral assessment was incorporated [12-14]. In all three studies, a similar proportion of 
denosumab-treated and zoledronic acid-treated patients developed ONJ (1.8 vs. 1.3%, respectively) 
[15]. In total, 89 confirmed cases of ONJ occurred among 5,677 patients who received one or more 
doses of either agent. However, the median time period of patient participation in the study was only 
approximately two years. Since studies have shown that ONJ can still occur after a longer duration of 
bisphosphonate treatment and that the incidence seems to increase with time to exposure [16,17], the 
low percentages of ONJ described by Saad et al. [15] could be an underestimation. As a consequence, 
longer follow-up is necessary to draw final conclusions.
ONJ is a serious complication which is a real challenge for the physician who has seldom experience 
with this rare event. Detailed recording of the severity and the course of the ONJ by Saad et al. [15] 
gave relevant information on the true incidence and outcome of this condition. ONJ was diagnosed 
as early as four months after the start of the bone-targeting agents or at 30 months at the latest. Over 
half of the patients (54%) were treated conservatively using analgesics or antibiotics. Approximately 
41% of the patients underwent limited surgical intervention (sequestrectomy, extraction or superficial 
debridement) with only 4 of 89 patients (4%) requiring resection of the necrotic bone. The symptoms 
lasted a median duration of 14 months and resolved (defined as mucosal coverage of the exposed 
bone) in 36% of patients (29.7% for zoledronic acid and 40.4% for denosumab) [15].
In the search for potential risk factors, tooth extraction (while on treatment) was a major risk factor for 
developing ONJ among patients treated with denosumab. As a consequence, it is currently advised to 
perform an oral examination and appropriate preventive dentistry prior to the initiation of denosumab 
treatment as well as periodically during denosumab treatment. Patients must be informed about oral 
hygiene practices and invasive dental procedures should be avoided whenever possible (Amgen Inc. 
Denosumab: full prescribing information. http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf 
(accessed 22 June 2012)).
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A key difference between the safety profiles of denosumab and zoledronic acid is the lack of renal 
toxicity of denosumab. Since denosumab is a monoclonal antibody, clearance is likely to occur via 
the reticulo-endothelial system, resulting in normal dosing of denosumab in the presence of renal 
(or hepatic) failure. In the randomized phase 3 trial comparing denosumab with zoledronic acid in 
advanced breast cancer patients the incidence of renal toxicity was less frequent with denosumab 
than with zoledronic acid (adverse events potentially associated with renal toxicity 4.9 vs. 8.5%, 
respectively and serious renal adverse events 0.9 vs. 1.5%, respectively). Moreover, in patients with 
baseline renal clearance between 30-60 ml/min, the renal adverse events were only 5.9% with 
denosumab compared to 20% with zoledronic acid [14]. Denosumab can thus be administered in 
case of renal impairment and can be administered concomitantly with nephrotoxic chemotherapy. 
Moreover, it does not require dose-adjustment for reduced creatinine clearance and obviates the 
need for assessment of the patient’s renal function before each denosumab dose (Amgen Inc. 
Denosumab: full prescribing information. http://pi.amgen.com/united_states/xgeva/xgeva_pi.pdf 
(accessed 22 June 2012)).
remaining issues to be addressed
From the currently published data, denosumab as a bone modifying agent seems to be a valuable 
drug in the aim to prevent SREs in breast cancer patients suffering bone metastases. Nevertheless, 
many questions still remain.
The first issue concerns the optimal duration of denosumab treatment. Until now, the phase 3 
trials in patients with bone metastases examined a monthly dose of 120 mg denosumab with the 
longest median duration on treatment 17 months [14]. A possible concern could be the risk of long 
term toxicity. Potential benefits should be weighed against potential side effects from continuing 
denosumab beyond two years of treatment until more mature data are available.
Second, the question what the optimal treatment is after developing a SRE while on denosumab 
treatment. In the current studies, denosumab has just been continued, however, it could be argued 
that in these patients the activated RANK/RANKL system is not repressed well enough. Patient-tailored 
treatment (see below) might be an option to further explore this possibility. Alternatively, other 
mechanisms than the activated RANK/RANKL pathway could be responsible for developing SREs, Src 
activation being one of these. Src is a membrane-associated non-receptor tyrosine kinase with a pivotal 
role in all kinds of cellular functions and also plays an essential role in the activation of osteoclasts [18]. 
Dasatinib, an oral tyrosine kinase inhibitor, which targets among others Src tyrosine kinase has shown 
potent anti-resorptive bone activity as well as inhibition of osteoclast proliferation in rat models. 
Moreover, two trials are currently ongoing to evaluate the role of dasatinib either alone or in combination 
with zoledronic acid among breast cancer patients with bone metastases (http://www.clinicaltrials.gov. 
Identifiers NCT00566618 and NCT00410813). Thus, further study is needed to find the optimal treatment 
once patients have developed SREs while on monthly denosumab treatment.
Third, the issue whether denosumab can be used directly after pre-treatment with bisphosphonates. 
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Breast cancer patients with bone metastases are nowadays almost always treated with intravenous 
bisphosphonates. In case renal function deteriorates, a switch to denosumab could theoretically 
be considered. Since both drugs have a long elimination half-life, the question is whether a switch 
from a bisphosphonate to denosumab would lead to increased toxicity which for example has been 
described for patients treated with intravenous pamidronate who were switched to intravenous 
zoledronic acid (e.g. increased percentages of ONJ) [17].
Recently the results of the two year open label extension treatment phase of the earlier mentioned 
phase 3 trial in bone metastatic breast cancer were reported [19]. All patients who remained on 
treatment after a median time on study in the phase 3 trial of 17 months were offered open-label 
denosumab in a prespecified two year extension treatment phase (n = 752). Eighty-nine per cent of 
the patients chose to receive open label denosumab. Patients who did not participate in the open-
label treatment were followed for survival every twelve weeks for up to two years after their last dose 
of investigational product in the double-blinded treatment phase. The total median cumulative 
denosumab exposure was 19.3 months (range 0.9-59.8 months). Adverse events were comparable 
between the two groups. An additional 20 patients in the denosumab group and 18 patients in the 
group, who received zoledronic acid in the double-blinded phase of the study, reported osteonecrosis 
of the jaw, resulting in a cumulative incidence for the entire study period of 4.7% for denosumab 
treated patients and 3.5% for patients treated with denosumab after treatment with zoledronic acid. 
Overall survival was similar between groups over the entire study.
Based on these data, switching from bisphosphonates to denosumab treatment seems to be safe and 
well tolerated, although the number of patients treated are small and the treatment duration was only 
short. Therefore, abstention in switching patients from bisphosphonates to denosumab is advised, 
until more mature safety and efficacy data are available in this particular setting.
Finally, the theoretical concern that denosumab could be associated with an increased risk of 
opportunistic infections. Besides the expression in bone, RANKL and RANK are also expressed by 
activated T- and B-lymphocytes, and dendritic cells and is thereby involved in the regulation of the 
immune system [20,21]. Since denosumab binds to RANKL in general, it could be hypothesised that 
inhibition of RANKL expressed by cells of the immune system could alter the immune function. 
Preclinical data have indeed suggested that the RANKL-RANK interaction modifies immune responses 
in specific tissues such as the skin. A recent meta-analysis of three randomized clinical trials among 
postmenopausal women with low bone mass treated with denosumab or placebo (total number of 
patients: n = 996) reported a significantly increased risk of infections, that required hospitalisation (OR 
4.5; p = 0.03) for those women treated with denosumab [22-24]. This meta-analysis did not incorporate 
safety data on the large pivotal FREEDOM trial, which randomized postmenopausal women with low 
bone mass to denosumab or placebo [25]. In a post hoc analysis, the incidence, type, and details 
in individual subjects (n = 7,808 women) of adverse events of infections were investigated [26]. 
The overall incidence as well as percentage of serious infections was similar between the placebo 
and denosumab groups (54.4 vs. 52.9%; p = 0.17 and 3.4 vs. 4.1%; p = 0.14 respectively). However, 
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serious adverse events in terms of cellulitis and erysipelas resulting in hospitalisation occurred more 
frequently with denosumab compared to placebo, although the number of events was low (n = 15 
(0.4%) vs. n = 3 (<0.1%); p <0.05) [26].
In the three large prospective phase 3 studies among patients with metastatic bone disease, comparing 
zoledronic acid with denosumab, in which the concentration of denosumab is much higher (120 mg 
every month continuously) than compared to doses given for osteoporosis, special attention was paid 
to the occurrence of infectious adverse events. In the trial with advanced breast cancer patients there 
were no differences between the zoledronic acid and denosumab group in percentage of infectious 
adverse events (48.8 vs. 46.4, respectively) as well as percentage of infectious serious adverse events 
(8.2 vs. 7.0, respectively), however skin infections were not separately mentioned [14]. The same holds 
through for the other two phase 3 trials [12,13]. Taken together, there is no increased risk of infections 
in general in patient with bone-metastatic solid tumors treated with denosumab 120 mg monthly 
compared to zoledronic acid. However, based on the results of the larger series with lower doses of 
denosumab in the treatment of osteoporosis the risk of serious infectious of the skin at higher doses 
is still a matter of uncertainty.
Patient-tailored treatment
Currently, the main aim of using denosumab in breast cancer patients with bone metastases is to 
prevent SREs by suppressing osteoclast activity, thereby impairing bone resorption. Although 
complete inhibition of osteoclast activity might be considered most effective in preventing SREs, a 
patient-tailored denosumab treatment with a more controlled inhibition of osteoclast activity seems 
far more desirable. By such an approach, less denosumab might be necessary for many patients 
thereby ameliorating adverse events and decreasing costs.
Non-invasive measuring of bone resorption markers, such as N-telopeptide and C-telopeptide, might 
be useful tools both for identifying patients at risk of developing SREs and for monitoring response to 
therapy. The levels of bone markers in patients with breast cancer seem to correlate with response to 
bone modifying agents, the risk of developing SREs, bone metastases progression and prognosis [27-29]. 
Moreover, among breast cancer patients normalization of bone markers with zoledronic acid within 111 
days of follow-up reduces the risk of SREs (RR = 0.51; 95% CI 0.33-0.78) and overall survival (RR = 0.52; 95% 
CI 0.34-0.78) compared to those patients in which bone markers did not normalise [30].
Since the bone resorption marker urinary N-telopeptide (uNTx) normalized for urinary creatinine 
(uNTx/Cr) correlates with osteoclast activity, this marker has been used to provide the optimal 
dose of denosumab for clinical use. Model-based pharmacodynamic analyses from six clinical trials 
investigating denosumab for the prevention of SREs in patients with cancer and bone metastases, 
came up with denosumab 120 mg administered every 4 weeks as the standard dose because this 
resulted in a normalizations of uNTx/Cr (i.e. <50 nM/mM) in over 95% of the subjects [31]. Interestingly, 
approximately 56% of the subjects with denosumab 30 mg administered every four weeks had an 
undetectable low uNTx/Cr (i.e. <1 nM/mM), compared to 64% for those administered denosumab 
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120 mg. This suggests that in more than half of the patients a 30 mg dose is enough to inhibit 
osteoclast activity sufficiently.
Moreover, in a study in which 111 patients with breast, prostate or other solid cancers were randomized 
to subcutaneous denosumab 180 mg every four weeks or every twelve weeks, or continued 
intravenous bisphosphonate therapy (every four weeks) for 25 weeks, all patients had elevated uNTx 
levels at screening despite ongoing treatment with intravenous bisphosphonates [32]. After twelve 
weeks, the proportion of patients achieving normalized uNTx levels (defined as an uNTx/Cr <50 nM/
mM) was significantly greater among individuals who received denosumab every four weeks (78%; 
p <0.001) and every twelve weeks (64%; p ≤0.005) than in those treated with bisphosphonates (29%) 
[32]. These data suggest that at least for a substantial proportion of the patients (64%) a longer (twelve 
weeks) interval in between denosumab administrations is feasible. Finally, the duration of suppression 
was dose dependent. In a phase 1 study in cancer patients with bone lesions, a single subcutaneous 
dose of denosumab (0.1, 0.3, 1.0 and 3.0 mg/kg) led to a decrease in uNTx/Cr levels of up to 58% in 
patients with breast cancer one day after dosing. Administration of doses of >0.3 mg/kg provided 
sustained reductions throughout the study period of twelve weeks [11]. Taken together these data 
plead for patient-tailored approach with the use of biochemical markers to monitor the degree of 
bone resorption to guide denosumab treatment rather than treating all patients with the currently 
licensed and recommended fixed once monthly dose of 120 mg subcutaneous denosumab. This 
should however first be tested in a randomized clinical trial to ensure similar efficacy in reducing SREs 
of both dose schedules.
DenOsuMAB In eArlY BreAsT CAnCer
Denosumab effective against cancer-therapy induced bone loss (CTIBl)?
Patients with breast cancer often develop bone loss secondary to cancer treatment itself. Several 
mechanisms of bone loss due to cancer treatment have been identified. Firstly, there is bone loss as 
a result of estrogen deprivation. In premenopausal women bone density loss averages 8% in the first 
year of treatment with premature ovarian suppression due to chemotherapy induced amenorrhea 
[33]. Secondly, there is bone loss due to endocrine anticancer therapies. The effects of tamoxifen, 
a selective estrogen receptor modulator (SERM), on bone are dependent on the actual physiologic 
estrogen concentration. Tamoxifen causes bone loss in premenopausal women, but is bone 
protective in postmenopausal women [34]. Aromatase inhibitors in postmenopausal women lower 
the estrogen level by suppressing the conversion of androstenedione to estradiol. As a consequence 
of the estrogen deprivation, on average a 2.6% loss of bone density in the first year of breast cancer 
treatment has been found [35]. In contrast, bone loss during natural menopause is typically 1% per 
year. Finally, chemotherapies and supportive drugs, such as steroids, affect bone density directly or do 
so indirectly. Chemotherapy treatment causes bone loss by directly damaging bone architecture or 
inducing early menopause in premenopausal women.
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The role of denosumab in preventing aromatase inhibitor induced bone loss has been studied in 
the Hormone Ablation Bone Loss Trial in Breast Cancer (HALT-BC) study [24]. This trial examined the 
efficacy of denosumab (60 mg sc every six months for two years) vs. placebo for preventing bone loss 
among 252 postmenopausal women with early-stage breast cancer who were receiving an aromatase 
inhibitor. After 24 months of follow-up, a significant difference of 7.6% in lumbar spine bone density of 
patients treated with denosumab compared to placebo was found. Similarly, a significant difference 
of 4.7% was detected in total hip bone density in advantage of the denosumab treated group. 
Although the results of this trial were promising, the results of the large Austrian Breast and Colorectal 
Cancer Study Group Trial 18 (ABCSG18-trial; http://www.clinicaltrials.gov. Identifier: NCT00556374) 
have to be awaited. In this ongoing trial approximately 3,460 postmenopausal breast cancer patients 
receiving adjuvant aromatase inhibitor therapy will be randomized between denosumab (60 mg sc 
every six months) and placebo, with time to first clinical fracture as the primary endpoint. This study 
will provide the essential information on fracture rates, disease recurrence, and long term data safety 
to decide whether or not denosumab treatment could be given in this setting.
Denosumab effective in preventing (bone)metastases?
The “seed and soil” hypothesis of cancer metastases was proposed over a century ago, and stated that 
cancer cells (the seed) are only able to become metastases in organs where the micro-environment 
(the soil) permissive the growth of these cancer cells (the seed) [36]. Osteotropic cancer cells express 
several proteins that are thought to specifically adhere to surface markers expressed by bone marrow 
endothelial cells. One of these proteins is supposed to be RANK by which it interacts with the 
RANKL expressed on bone stromal cells. Interestingly, RANKL may also be involved in the epithelial-
mesenchymal transitions, invasion and homing of tumor cells to bone [37].
It could therefore be speculated that by altering the micro-environment of the bone by interfering 
the RANKL/RANK system, the development of bone metastases could be postponed or even be 
prevented and maybe also dissemination to other organs. Denosumab is a specific inhibitor of the 
RANKL pathway for osteoclast activation and function but is primate-specific and thus cannot be 
tested in rat models of bone metastases. In animal models, inhibition of RANKL activity is achieved by 
binding to recombinant antibody constructs of either osteoprotegerin-Fc or RANK-Fc [38]. In animal 
models with advanced breast cancer, RANKL inhibition reduces the burden of tumor in bone [39]. 
Moreover, in another breast cancer mouse model, inhibition of the RANKL pathway prevented tumor 
progression and increased survival [40]. Finally, treatment of transgenic mice with RANK-Fc significantly 
decreased development of spontaneous lung metastases [41]. As such denosumab administration in 
humans could reduce rates of distant metastases by manipulating the bone micro-environment or 
potentially by a direct antitumor effect.
A large phase 3 randomized controlled trial among men (n = 1,432) with castration resistant prostate 
cancer indeed showed that denosumab (120 mg sc every four weeks) significantly delayed the onset 
of detectable bone lesions compared to placebo (33.2 vs. 29.5 months; HR 0.85; 95% CI 0.73-0.98; p = 
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0.028) [42]. Progression free and overall survival did not differ between the groups, suggesting that 
inhibiting bone resorption alone might be insufficient to prevent the subsequent development of 
metastases outside the bone. Denosumab is also being evaluated in the adjuvant setting among 
breast cancer patients in an ongoing trial (D-CARE trial; http://www.clinicaltrials.gov. Identifier: 
NCT01077154). In this trial 4,500 women with high-risk early breast cancer (stages II and III) will be 
randomized to denosumab or placebo for five years. The primary endpoint compares bone metastases 
free survival between denosumab and placebo. Secondary endpoints include disease free and overall 
survival and distance recurrence-free survival. The D-CARE trial has accrued more than 4,000 patients 
thus far, with no significant safety concerns to date, and will provide more data on the possible role of 
denosumab as adjuvant therapy to prevent bone metastases as well as potential adverse events with 
longer term treatment.
Of particular interest would be to test the efficacy of denosumab in a group of patients at high risk 
of developing bone metastases. Accordingly, in the near future a non-randomized phase 2 study 
will be started in women with early breast cancer with a significant number of disseminated tumor 
cells in the bone marrow after (neo)adjuvant chemotherapy (http://www.clinicaltrials.gov. Identifier: 
NCT01545648). These patients will receive denosumab for one year. Primary endpoint is reduction of 
bone marrow disseminated tumor cells at six and twelve months of treatment, compared to baseline. 
Another possibility of preselecting a group of patients with a high risk of developing bone metastases 
could be by using a genetic signature of the primary tumor [43].
DenOsuMAB effeCTIVe AGAInsT BreAsT CArCInOGenesIs?
Progesterone is an important risk factor for breast carcinogenesis. From large epidemiological studies 
it became clear that postmenopausal women on hormone replacement therapy have an increased 
risk of developing breast cancer when taking combined estrogens and progestins, however not 
when taking estrogens alone [44]. The precise mechanism through which progesterone could case 
carcinogenesis is however unclear. Recently, preclinical research has shed new light on this issue, by 
the observation that progesterone was found to play an indirect role in carcinogenesis via the RANKL/
RANK system.
Normal breast development in the mouse involves hormonal stimulation of a differentiated 
progesterone-receptor positive luminal epithelial cell population, as well as a progesterone-
receptor negative (basal) stem cell population [45,46]. Progesterone-receptor positive luminal cells 
express RANKL in response to progesterone. RANKL on its turn binds to RANK on progesterone 
negative (basal) stem cells causing proliferation of these stem cells, i.e. increasing their number 
as well as their regenerating activity. By using a combination of progesterone derivate (progestin 
medroxyprogesterone acetate) and a well-known mutagenic agent (7,12-dimethylbenz(a) anthracene 
(DMBA)), mammary carcinomas could be induced in mice, a process fully regulated by the RANKL-
RANK system. Overexpression of RANK by means of a mouse mammary tumor virus (MMTV)-driven 
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transgenic accelerated hyperplasia but also tumor formation. Pharmacological inhibition of RANKL in 
the mammary epithelium decreased incidence and delayed onset of carcinogenesis in this system 
[38]. An important question is whether denosumab has an anti-carcinogenesis effect in the clinical 
setting, as is reported in preclinical models for recombinant antibody constructs of RANK-Fc in animals. 
Immunostainings of human breast cancers reveal that RANKL is expressed in 11% of human tumors, 
whereas RANK was detected in 6% of tumors. There is no evidence for co-localization within the 
epithelium for receptor and ligand but expression of RANKL is found in some stromal cells [41]. This 
raises the possibility that the scenario is more complex in human breast cancer than in the present 
mouse tumor models with infiltrating immune cells providing the ligand.
In the earlier mentioned meta-analysis of three randomized clinical trials among post-menopausal 
women (n = 996) with low bone mass no significant decrease in cancer risk was seen in the patients 
treated with denosumab compared to placebo [22]. Also in the FREEDOM trial (n = 7,868), comparing 
denosumab with placebo in postmenopausal women with low bone mineral density, no differences 
were seen between the group in the incidence of malignancies [25]. Similarly, in the HALT-BC trial (n = 
252), comparing denosumab vs. placebo in women with non-metastatic breast cancer and low bone 
mass who were receiving adjuvant aromatase inhibitor therapy, no new primary breast cancers were 
seen in both groups [24]. Finally, in the earlier mentioned trial among patients with bone metastases 
of breast cancer and the trial of bone metastases from other solid tumors or multiple myeloma, 
comparing denosumab with zoledronic acid, again no significant differences in the development of 
new primary cancer were seen (respectively 0.5 vs. 0.5% and 0.3 vs. 0.6%; p = 0.73) [13,14].
Taken together, the potential effects of denosumab on the carcinogenesis of the breast are currently 
unknown. However, based on the current clinical (indirect) evidence the preventive effect of 
denosumab on carcinogenesis, if any, seems relatively small. Further maturation of the safety data of 
the above mentioned trials and the results of the earlier mentioned currently ongoing ABCSG-18 and 
D-CARE study have to be awaited before definite conclusions can be drawn.
COnClusIOn
Denosumab is an interesting new member in the group of the bone-modifying agents with very 
promising results in breast cancer patients with bone metastases. Nevertheless, several questions 
still remain which have been discussed in this review. The most urgent question for tomorrows’ 
daily practice is where to place denosumab relating to bisphosphonates. The ASCO clinical practice 
guidelines has recently been updated and recommend either denosumab or bisphosphonate therapy 
and state that there is currently insufficient evidence to demonstrate that one bone-modifying agent 
is to be preferred over the other [47]. Since no difference in survival was reported in breast cancer 
patients treated with denosumab compared to zoledronic acid, the benefit will need to be considered 
in reducing morbidity by reducing the risk of SREs and increasing patients’ quality of life measured by 
diminished side effects and a more convenient way of administration compared to bisphosphonates. 
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Clearly, costs will also be an important factor to consider. Denosumab is significantly more expensive 
than e.g. zoledronic acid and might therefore be not cost-effective compared to treatment with 
zoledronic acid in preventing SREs [48]. Further research will be essential and investigating whether 
patient-tailored denosumab treatment for breast cancer patients with bone metastases is as effective 
as fixed dose denosumab is of great value.
Whether the indications for denosumab treatment could be expanded to secondary prevention 
(preventing the development of bone metastases) and maybe to anticancer treatment or primary 
prevention (prevent development of breast cancer) also, is currently under investigation. The results 
of the ABCSG-18 and D-CARE study are eagerly awaited.
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suMMArY AnD GenerAl DIsCussIOn 
Introduction 
In the Western world, breast cancer is the most commonly diagnosed cancer and the second most 
common cause of cancer death in women [1]. The high incidence and prevalence of this disease 
makes this disease extremely suitable for scientific research and major advances have been made in 
the past decades. Both for early and metastatic breast cancer many new treatment options became 
available in the recent years. Unfortunately, all treatment modalities are associated with the risk of 
acute and/or late toxicity. Acute toxicity of chemotherapy could for example be manifest as bone 
marrow suppression, nausea and vomiting; long term toxicity could manifest as the development of 
other (breast) cancers, cardiotoxicity, premature postmenopausal state and osteoporosis. One of the 
major challenges in breast cancer research is to increase efficacy of anticancer treatments without 
increasing clinical relevant toxicity or to decrease toxicity of anticancer treatment without decreasing 
its efficacy. 
Impaired DnA repair mechanism related to increased treatment-associated toxicity
BRCA1 and BRCA2 (BRCA1/2) mutation carriers have decreased levels of functional BRCA1 and BRCA2 
proteins, leading to homologous recombination deficiency, resulting in inadequate repair of double 
strand DNA breaks. Both ionizing radiation and various chemotherapeutic agents induce DNA damage 
by several mechanisms including induction of double strand DNA breaks. Patient with BRCA1/2-
associated breast cancer might therefore be at increased risk for treatment-associated toxicity. 
Ionizing radiation
BRCA1/2 mutation carriers are at increased risk for the development of breast cancer and once they 
developed breast cancer they are at increased risk for the development of a second ipsilateral or 
contralateral new primary breast cancer [2-4]. This makes that a possibly increased risk of developing 
(primary or second primary) breast cancer as a result of ionizing radiation might be proved easier in 
this population.
In Chapter 2 we provide an overview and interpretation of the literature about the risk for the 
development of a first and second primary breast cancer as late toxicity of diagnostic and/or 
therapeutic ionizing radiation, with special attention for BRCA1/2 mutation carriers. There is a clear 
positive radiation dose-risk relation, which is modified by age, whereby young age at exposure is 
associated with an increased breast cancer risk. Furthermore, studies suggest a minimal latency period 
of 10-12 years before an increased breast cancer risk becomes apparent. For sporadic breast cancer 
patients, diagnosed above the age of 45 years, there is no reason to withhold radiotherapy in adjuvant 
setting. For younger sporadic patients, however, no definite conclusion can be drawn based on the 
current data. Data on the deleterious effects of radiation for the subgroup of BRCA1/2 mutation carriers 
are sparse. Nevertheless, for screening purposes there seems to be enough evidence to incorporate 
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mammography in breast cancer screening programs for BRCA1/2 mutation carriers, only after the age 
of 30 years. For those BRCA1/2 mutation carriers who developed breast cancer above the age of 30 
years and opting or breast conserving therapy, there are no hard data regarding a possibly increased 
carcinogenic effect of adjuvant radiotherapy with respect to a second primary breast cancer. Caution 
with regard to breast conserving surgery and radiotherapy seems warranted in BRCA1/2 mutation 
carriers, aged <30 years at breast cancer diagnosis.
We added new data to the important topic of the possible deleterious effects of adjuvant radiotherapy 
by increasing the risk of ipsilateral and contralateral breast cancer in BRCA1/2 mutation carriers. In 
Chapter 3 we present the results of a single center retrospective cohort study from the Rotterdam 
Family Cancer Clinic database. In this study we include all proven or obligate BRCA1/2 mutation carriers 
treated at the Erasmus MC Cancer Institute for early stage breast cancer diagnosed between January 
1, 1980 and January  1, 2013 (n = 790). Objective of this study was to estimate the influence of adjuvant 
radiotherapy for primary breast cancer on the risk of contralateral breast cancer in BRCA1/2 mutation 
carriers. Additionally, tendencies in locoregional treatments and rates of contralateral risk-reducing 
mastectomy over time were explored. No association between radiotherapy for primary breast cancer 
and risk of contralateral breast cancer was observed in the total group, nor in the patients irradiated 
before the age of 40 years. Importantly, the number of patients at risk for developing contralateral 
breast cancer decreased substantially over time since a large proportion of patients were censored 
after contralateral risk-reducing mastectomy or breast cancer recurrence. As a consequence, the 
number of patients at risk after 10 and 15 years of follow-up was too small to definitively exclude 
harmful effect of radiotherapy on the development of contralateral breast cancer among young 
BRCA1/2 mutation carriers. Over the years, increasing preference for mastectomy without radiotherapy 
was found ranging from less than 30% in 1995 to almost 50% after 2010. The rate of contralateral risk-
reducing mastectomy increased over the past decades from less than 40% in 1995 to more than 60% 
after 2010. Further increase in patients choosing for risk-reducing mastectomy is expected, due to 
the increased awareness of breast cancer risks and risk-reducing possibilities in this population, also 
called the Angelina Jolie effect [5,6]. These trends in locoregional treatments eventually decreased the 
proportion of patients at risk for radiation-induced contralateral breast cancer. 
Nevertheless, the question whether adjuvant radiotherapy has deleterious effect on contralateral 
breast cancer risk is still important for those patients who want to conserve their (ipsilateral and) 
contralateral breast. Moreover, in the nearby future a larger proportion of patients potentially might 
opt for breast conserving treatment and abstain from contralateral risk-reducing mastectomy, due to 
an increased use of endocrine therapy as chemoprevention, improved diagnostic imaging techniques 
for screening and improved effectiveness of adjuvant systemic therapy. Future research in larger study 
populations with minimal follow-up of 10 years is needed to achieve a better understanding of the 
true toxic effect of radiotherapy on the contralateral breast cancer risk in BRCA1/2-associated breast 
cancer patients. 
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Chemotherapy
Besides the possibly increased toxicity of ionizing radiation in BRCA1/2 mutation carriers, one could 
also argue that the toxicity of chemotherapy might be increased in these patients, since chemotherapy 
causes cell damage by induction of double strand DNA breaks. In Chapter 4 we describe the results 
of a single center retrospective cohort study on differences in (neo)adjuvant chemotherapy related 
toxicity between BRCA1/2 mutation carriers and sporadic breast cancer patients. For this study we 
selected all female patients who were treated at the Erasmus MC with adjuvant or neoadjuvant 
chemotherapy for primary breast cancer or local/locoregional recurrence (PBC/LR). Further eligibility 
criteria concerned: chemotherapy regimen consisting of anthracyclines and/or taxanes, chemotherapy 
treatment started between January 1, 2004 and December 31, 2014. In total, 701 patients were 
eligible for data-analyses, of whom one BRCA1 mutation carrier and two sporadic patients were 
treated with two separate episodes of (neo)adjuvant chemotherapy for a PBC/LR during the study 
period. 85 patients (12%) were BRCA1/2 mutation carriers (n = 67 BRCA1 and n = 18 BRCA2).  Primary 
outcome was the relative total dose intensity (RTDI), a measure of delivered (actual) dose-intensity 
(i.e. administered dose over the total time course of treatment), relative to the planned dose intensity. 
The RTDI therefore expresses the effect of reductions, delays as well as premature discontinuations of 
a treatment. We found no differences in RTDI (both for anthracyclines and taxanes) between breast 
cancer patients with a BRCA1/2 mutation and sporadic breast cancer patients. Furthermore, we found 
no differences in the occurrence of febrile neutropenia, in delay of chemotherapy administration 
or alteration of the chemotherapy regimen due to toxicity between these groups. This absence of 
increased acute toxicity due to (neo)adjuvant chemotherapy in BRCA1/2 mutation carriers, compared 
to sporadic breast cancer patients, shows that the DNA damage repair mechanism of non-cancer 
cells with only one normal copy of either the BRCA1 gene or the BRCA2 gene is sufficiently functional 
to handle acute chemotherapy-associated toxicity of currently used chemotherapy regimens. Both 
platinum derivatives and PARP inhibitors are increasingly used in BRCA1/2-associated breast cancer 
[7-11]. These drugs have a much higher capacity in inducing double strand DNA breaks, compared to 
anthracyclines and might therefore induce more toxicity in BRCA1/2 mutation carriers. Further data 
on the toxicity of these regimens in BRCA1/2 mutation carriers compared to sporadic patients should 
follow from currently ongoing and new studies.
Could toxicity be used to optimize treatment?
Interestingly, toxicity might be associated with efficacy and might therefore be used to increase 
efficacy by increasing systemic therapy dose in patients without or with only limited toxicity. Especially 
the amount of hematological toxicity in breast cancer patients treated with chemotherapy seems to 
be related to efficacy [12-14]. The amount of toxicity could thus be used as a marker in dose escalation 
studies. In Chapter 5 we describe the results of a single center prospective study on the feasibility of 
neutrophil-guided dosing of anthracycline-cyclophosphamide containing chemotherapy in sporadic 
breast cancer patients. Thirty-two patients planned for three-weekly anthracycline-cyclophosphamide 
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containing chemotherapy, either in adjuvant or metastatic setting, were enrolled in this study. The first 
treatment cycle was administered in a standard BSA (body surface area)-adjusted dose. For patients 
with none or mild (CTC grade 0-2) neutropenia and no other dose limiting toxicity, we performed a 
10-25% dose escalation of the second cycle with the opportunity to a further 10-25% dose escalation 
of the third cycle. Two out of 23 patients (9%) treated with FEC (fluorouracil 500 mg/m2, epirubicin 
100 mg/m2 and cyclophosphamide 500 mg/m2) did not develop grade 3-4 neutropenia after the 
first treatment cycle. Dose escalation was performed in these two patients (30% in one and 15% in 
the other patient). During dose escalation, there were no complications like febrile neutropenia. No 
patients treated with FAC (fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 
mg/m2) or AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) could be escalated, since 
all of them developed grade 3-4 neutropenia. We conclude that asymptomatic grade 3-4 neutropenia 
is likely to be achieved in the majority of patients with breast cancer treated with anthracycline-
cyclophosphamide-containing chemotherapy according to presently advocated BSA-based dose 
levels. Escalation of currently advocated doses of anthracycline-cyclophosphamide-containing 
chemotherapy without G-CSF, with a target of grade 3-4 neutropenia, is feasible, but only possible 
in a small proportion of patients. Since no other dosing algorithms are available for anthracycline-
cyclophosphamide-containing chemotherapy, BSA-guided dosing remains standard practice at this 
moment. For the vast majority of classical cytotoxic anticancer agents, BSA-guided dosing remains 
still standard practice. Further research on neutrophil-guided dosing might be useful for other 
chemotherapeutic agents. For a number of (oral) targeted agents, flat-fixed dosing and a posteriori 
dose reduction in case of severe toxicity is a standard practice. For a small number of targeted 
anticancer agents an association between toxicity and efficacy has been found. Increased skin toxicity 
of anti-EGFR antibodies is associated with increased response rates in metastatic colorectal cancer 
[15]. For adjuvant endocrine therapy it has been suggested that development of toxicity might be 
used as a biomarker of better response to therapy [16].
Treatment related toxicity, compliance and therapeutic drug monitoring
Bothersome toxicity of anticancer agents, influencing quality of life, might be a reason for early 
discontinuation of treatment. For adjuvant endocrine therapy, which often has to be used for 
years, it has been found that, despite their proven benefit, adherence to and persistence with 
the medications is poor [17]. Therapy adherence, change in environmental factors and possibly 
resistance mechanisms might influence the systemic exposure over time. The best way forward for 
individualization of tamoxifen therapy seems to be therapeutic drug monitoring (TDM). The often 
used method of TDM by serial measurements of plasma concentrations of drugs and/or metabolites 
over time might be difficult to incorporate in clinical practice. A method, which gives (in retrospect) 
information about the course of concentrations of anticancer drugs (and its metabolites) over time, 
could be the measurement of these concentrations in scalp hair, which gives the opportunity to 
study the historic pattern of drug concentrations (depending on the length of hair collected), which 
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makes serial venous blood collections unnecessary [18]. In Chapter 6 we describe the validation of 
an earlier developed high-performance highly sensitive ultra performance liquid chromatography/
tandem mass spectrometry (UPLC-MS/MS) method for quantification of tamoxifen and its three main 
metabolites (N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen, and 4-hydroxy-N-desmethyl-tamoxifen) 
in scalp hair. In that study we conclude that measurement of the concentration of tamoxifen and 
its main metabolites in hair is possible, with the selective, sensitive, accurate and precise UPLC-MS/
MS method. However for tamoxifen, it seems not possible to determine exposure over time with 
segmental analysis of hair, probably largely due to the effect of UV irradiation. Further research 
should therefore focus on quantification of other anticancer drugs, in segmental scalp hair, that are 
less sensitive to UV irradiation. For studies on therapeutic drug monitoring in patients treated with 
tamoxifen, measurement of endoxifen concentrations in plasma remains gold standard.
Prevention and treatment of toxicity
One of the important toxicities of breast cancer treatment is premature bone loss. This therapy-
induced bone loss can develop by a variety of mechanisms: premature ovarian failure due to adjuvant 
chemotherapy and/or adjuvant endocrine therapy, lower levels of estrogens by aromatase inhibitors 
and the direct influence of chemotherapy and supportive drugs, such as steroids. Furthermore, the 
bone is the most common site to which breast cancer metastasizes [19]. The occurrence of skeletal 
related events, defined as pathological fractures, necessity for radiation or surgery due to (threaten) 
spinal cord compression or hypercalcemia due to bone metastases, has a negative impact on patient’s 
quality of life and generally portends a worse prognosis. 
For years, bisphosphonates have been the cornerstone for the prevention and management of 
both skeletal related events in metastatic breast cancer and cancer-treatment induced bone loss 
in early breast cancer [19,20].  Denosumab, a fully human monoclonal antibody that binds to the 
receptor activator of nuclear factor kappa-B ligand (RANKL) has been developed as a new targeted 
bone therapy, which can be used both in early and metastatic breast cancer [21-23]. In Chapter 7 
we describe the current indications for denosumab in the various settings of breast cancer treatment 
and concludes that there are still a number of questions to be answered such as where to place 
denosumab relating to bisphosphonates, whether patient-tailored dosing, for example based on 
markers of bone turnover, is possible and whether there is a place for denosumab in the prevention 
of bone metastases or even in the prevention of the development of breast cancer. Important 
information on the value of denosumab in the (neo)adjuvant setting will follow from the D-CARE 
study (https://clinicaltrials.gov/ct2/show/NCT01077154).
Postponing (cyto)toxic therapy an option in her2-positive metastatic breast cancer?
Once patients develop metastatic breast cancer or local recurrence without surgical or radiotherapeutic 
options, treatment is aimed at maintaining or improving quality of life and improving progression 
free and overall survival. When treating patients with metastatic breast cancer minimizing toxicity 
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is therefore an important goal. For the subgroup of HER2-positive breast cancer, the combination of 
trastuzumab and a taxane (either docetaxel or paclitaxel) was standard first line treatment until recently 
[24,25]. Progress in this subgroup of patients might be made in different ways. One way could be to 
increase efficacy of treatment by adding a new agent, with limited toxicity. Another option could be 
to try to decrease toxicity by delaying the start of chemotherapy by adding a second targeted agent 
with limited toxicity to trastuzumab and only start chemotherapy at progression under this regimen. 
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), could be one 
of the possible agents to be used in these strategies [26,27].
In Chapter 8 we describe the results of an open label, randomized, non-comparative, phase 2 
study, in which 84 patients were randomized (1:1) between HAT (the combination of bevacizumab, 
trastuzumab and weekly paclitaxel) and HA-HAT (the regimen of upfront trastuzumab and 
bevacizumab and adding weekly paclitaxel after progression). The progression free rate at 1 year 
was 74.4% (95% confidence interval, CI 61.8-89.4) and 62.2% (95% CI 49.6-89.4) in the HAT and HA-
HAT arm, respectively. The median progression free survival in the HAT arm was 19.8 months (95% 
CI 14.9-25.6), and the median overall progression free survival in the HA-HAT arm was 19.6 months 
(95% CI 12.0-32.0). In the HA-HAT arm the median progression free survival for treatment with only 
bevacizumab and trastuzumab was 10.4 months (95% CI 6.2-15.0) and the median progression free 
survival for treatment with trastuzumab, bevacizumab and paclitaxel after first progression was 8.2 
months (95% CI 7.0-12.6). The median overall survival was 36.8 months (95% CI 29.1 to not applicable) 
in the HAT group and 54.0 months (95% CI 37.4 to not applicable) in the HA-HAT group. Number and 
severity of adverse events were comparable between the arms and were in favor of starting with only 
bevacizumab and trastuzumab. 
Based on comparison with historical controls, the data suggest that bevacizumab enhances the 
antitumor activity of the trastuzumab-based regimens as applied in this study. With the publication 
of the CLEOPATRA trial showing median overall survival benefit of 15.7 months for the combination 
of trastuzumab, pertuzumab and docetaxel compared to the combination of trastuzumab and 
docetaxel, this regimen has become the standard first line therapy in patients with HER2-positive 
metastatic breast cancer [28,29]. When taking this solid data and the favorable toxicity profile of 
pertuzumab, compared to bevacizumab into account, it is unlikely that further phase 3 trials on the 
combination of bevacizumab, trastuzumab and chemotherapy will be performed. The results from 
our study however shows that the concept of starting with a less toxic chemotherapy-free approach 
with only biologicals is an approach deserving further study. From a quality of life viewpoint, it would 
be of great interest to develop treatment schedules starting with less toxic therapies. New trials about 
chemotherapy-free treatments should therefore also incorporate newer HER2-targeted agents such 
as pertuzumab, trastuzumab-emtansine and novel agents, but also endocrine therapy in hormone 
receptor positive patients. 
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Conclusion
Altogether we may conclude that, despite all the improvements in the treatment of both early and 
metastatic breast cancer, the disease remains a serious health problem with high morbidity and 
mortality. Unfortunately, all treatments are associated with toxicity and one of the important goals in 
breast cancer research should be decreasing treatment-associated acute and long term toxicity. It is 
therefore essential to continue preclinical and clinical trials as well as prospective and retrospective 
observational studies. For future studies it is more and more important to design studies in subgroups 
of patients with specific patient and tumor characteristics. For example, for patients with a BRCA1/2 
gene mutation it is extremely important to design studies specific for these subgroups since they 
might differ in both efficacy and toxicity of systemic therapy but also the baseline risk for the 
development of primary and second primary ipsilateral and contralateral breast cancer are increased 
compared to the sporadic population. This will only be possible by combining study populations 
through collaborative efforts on a national, or even international level. Furthermore future research 
should not only incorporate possible biomarkers that better predict which patients will benefit from a 
certain treatment, but also which patients will or will not develop toxicity from that treatment.
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sAMenVATTInG
Inleiding 
Borstkanker is de meest voorkomende kankersoort bij vrouwen in de westerse wereld. Daarnaast is 
het de op één na belangrijkste oorzaak van overlijden aan kanker onder vrouwen. Het aantal nieuwe 
patiënten met borstkanker is de afgelopen jaren gestegen. Dit kan voor een deel verklaard worden 
door de toegenomen levensverwachting en de toenemende vergrijzing. In Nederland is het risico 
voor vrouwen om borstkanker te krijgen in de loop van het leven opgelopen tot bijna 14%. Door 
wetenschappelijk onderzoek is de laatste jaren duidelijke vooruitgang geboekt in de behandeling van 
borstkanker. Zowel voor vroegstadium (niet uitgezaaide) borstkanker als voor uitgezaaide borstkanker 
zijn nieuwe behandelmogelijkheden beschikbaar gekomen. 
Vroegstadium borstkanker
Borstkanker wordt bij vrouwen meestal in een vroeg stadium ontdekt, waarbij de ziekte niet 
uitgezaaid is voorbij de regionale lymfklierstations. De behandeling is dan gericht op genezing en 
bestaat uit lokale behandeling (operatie en in veel gevallen nabehandeling met bestraling) vaak in 
combinatie met perioperatieve medicamenteuze behandeling (chemotherapie, endocriene therapie 
en/of doelgerichte therapie). Deze medicamenteuze behandelingen kunnen gegeven worden 
vóór (neoadjuvant) of na (adjuvant) resectie van de tumor. Deze medicamenteuze behandelingen 
hebben ten doel om zowel het risico op een lokaal recidief als het risico op uitzaaiingen op afstand te 
verminderen. De beslissing om (neo)adjuvante behandeling te geven en vervolgens in welke vorm, 
wordt genomen op basis van kenmerken van de tumor en van de patiënten. Een groot deel van de 
patiënten die behandeld worden voor vroegstadium borstkanker ontvangt postoperatieve bestraling 
van de borst/thoraxwand en/of locoregionale lymfklierstations ter vermindering van het risico van 
lokaal recidief en verbetering van de overleving. 
Uitgezaaide borstkanker
Helaas ontwikkelt een deel van de patiënten die behandeld zijn voor vroegstadium borstkanker 
op enig moment een lokaal recidief, uitgezaaide borstkanker of een tweede primaire borstkanker. 
Daarnaast presenteert ongeveer 5% van de borstkankerpatiënten zich bij diagnose reeds met 
uitzaaiingen op afstand.
Wanneer patiënten uitzaaiingen op afstand hebben ontwikkeld is genezing in het algemeen niet 
meer mogelijk. Behandeling is dan gericht op levensverlenging en behoud of verbetering van 
kwaliteit van leven. De levensverwachting wisselt sterk tussen patiënten met uitgezaaide borstkanker 
en hangt sterk af van tumorkenmerken, de uitgebreidheid en de locaties van de uitzaaiingen en de 
mate waarin de uitzaaiingen reageren op behandelingen. De beslissing om medicamenteuze anti-
kanker behandeling te geven en vervolgens in welke vorm hangt ook bij uitgezaaide borstkanker 
sterk af van de kenmerken van de tumor, maar ook van kenmerken en wensen van de patiënt. Bij 
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patiënten met botuitzaaiingen kunnen osteoclastremmers (bisfosfonaten of denosumab) het risico 
op botcomplicaties verminderen. Helaas geldt ook bij de behandeling van uitgezaaide borstkanker 
dat alle middelen geassocieerd zijn met bijwerkingen, die een negatief effect kunnen hebben op de 
kwaliteit van leven.
Eén van de grote uitdagingen in het wetenschappelijk onderzoek naar de behandeling van borstkanker 
is om effectiviteit van behandelingen te verbeteren, zonder toename van ernstige bijwerkingen 
(toxiciteit) of het verminderen van toxiciteit zonder verlies van effectiviteit. Dit proefschrift beschrijft 
wetenschappelijk onderzoek verricht met als doel het optimaliseren van de behandeling van 
borstkanker. Toxiciteit kan hier op verschillende manier in gebruikt worden. De behandeling kan 
verbeterd worden door: (1) het verminderen van toxiciteit, met behoud van effectiviteit, (2) verbeteren 
van effectiviteit, zonder klinisch relevante toename van toxiciteit,  (3) verbeteren van effectiviteit door 
dosisescalatie op basis van toxiciteit en (4) voorkomen van (complicaties van) toxiciteit van anti-
kanker behandelingen. 
Inadequaat DnA reparatie-mechanisme en toename van bijwerkingen
Vrouwen (en mannen) met een mutatie in het BRCA1 of BRCA2 (BRCA1/2) gen hebben een verhoogd 
risico op het krijgen van borstkanker. In 5-10% van de vrouwen met borstkanker speelt een mutatie 
in één van deze genen een oorzakelijke rol. De BRCA1 en BRCA2 eiwitten hebben een belangrijke rol 
in het repareren van dubbelstrengs DNA breuken via het mechanisme van homologe recombinatie. 
Zowel ioniserende straling als chemotherapeutica leiden tot DNA schade door verschillende 
mechanismes zoals het induceren van dubbel strengs DNA breuken. Patiënten met BRCA1/2-
geassocieerde borstkanker zouden daardoor een verhoogd risico kunnen hebben op toxiciteit ten 
gevolge van deze behandelingen die noodzakelijk zijn voor de behandeling van de kanker.
Ioniserende straling
BRCA1/2 genmutatie draagsters hebben een verhoogd risico op het krijgen van borstkanker. Daarnaast 
hebben patiënten met BRCA1/2-geassocieerde borstkanker een verhoogd risico op het ontwikkelen 
van een tweede primaire ipsilaterale of contralaterale borstkanker. Ioniserende straling leidt tot het 
ontstaan van DNA schade en is op de langere termijn een risicofactor voor het ontstaan van borstkanker. 
Patiënten met een BRCA1/2 mutatie zouten gevoeliger kunnen zijn voor de negatieve effecten van 
ioniserende straling. In hoofdstuk 2 geven we een overzicht en interpretatie van de literatuur over 
het risico op het ontwikkelen van een eerste en tweede primaire borstkanker als late toxiciteit van 
diagnostische en/of therapeutische ioniserende straling (=radiotherapie) met speciale aandacht voor 
BRCA1/2 genmutatie draagsters. Er blijkt een duidelijke relatie te zijn tussen radiatie-dosis en risico 
op borstkanker. Jonge leeftijd ten tijde van blootstelling aan ioniserende straling is geassocieerd met 
een verhoogd risico op borstkanker. Gegevens over de negatieve effecten van ioniserende straling in 
de subgroep van BRCA1/2 genmutatie draagsters zijn zeldzaam. Terughoudendheid met ioniserende 
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straling lijkt gerechtvaardigd voor jonge patiënten met een BRCA1/2 genmutatie.
Met het in hoofdstuk 3 beschreven onderzoek hebben we nieuwe inzichten toegevoegd met 
betrekking tot het belangrijke vraagstuk over het mogelijke negatieve effect van adjuvante 
radiotherapie op het verhogen van het risico op ipsilaterale of contralaterale borstkanker bij 
BRCA1/2 genmutatie draagsters. In dit hoofdstuk beschrijven we de resultaten van een onderzoek 
vanuit de database van de polikliniek erfelijke tumoren van het Erasmus MC in Rotterdam. In dit 
onderzoek includeerden we alle bewezen of obligate (niet getest, maar zeker op basis van geteste 
familieleden) BRCA1/2 genmutatie draagsters die behandeld werden voor vroegstadium borstkanker, 
gediagnosticeerd tussen 1 januari 1980 en 1 januari 2013 (n = 790). Doel van dit onderzoek was om 
de invloed van adjuvante radiotherapie voor primaire borstkanker op het risico op contralaterale 
borstkanker bij BRCA1/2 genmutatie draagsters te bepalen. Er werd geen associatie gevonden tussen 
bestraling voor primaire borstkanker en het risico op contralaterale borstkanker in de totale groep, 
maar ook niet in de patiënten die bestraald werden voor de leeftijd van 40 jaar. De aantallen zijn echter 
te klein om definitieve conclusies te trekken. Aanvullend werd in kaart gebracht of er tendensen waren 
in het aandeel van contralaterale risico-reducerende mastectomie en keuzes voor de verschillende 
locoregionale behandelingen over de tijd. Het aantal patiënten dat een contralateraal borstkanker 
zou kunnen ontwikkelen, nam substantieel af over de tijd, omdat een groot deel van de patiënten 
gecensureerd  (censurering = uitval uit een studie als gevolg van redenen die ook samenhangen 
met de uitkomst) werden na contralaterale risico-reducerende mastectomie of terugkeer van de 
borstkanker. Over de jaren werd daarnaast een toenemende voorkeur gezien voor lokale behandeling 
middels mastectomie zonder bestraling, oplopend van minder dan 30% in 1995 tot bijna 50% na 
2010. Het percentage patiënten dat kiest voor contralaterale risico-reducerende mastectomie nam in 
de afgelopen decades toe van minder dan 40% in 1995 tot meer dan 60% na 2010. Verdere toename 
in het aantal patiënten dat kiest voor risico-reducerende mastectomie is te verwachten door de 
toenemende bewustwording van het risico op borstkanker en de risico-reducerende mogelijkheden 
in de BRCA1/2 populatie.
Desondanks is de vraag of adjuvante radiotherapie een negatieve invloed heeft op het risico op 
contralaterale borstkanker nog steeds relevant voor patiënten die hun (ipsilaterale en) contralaterale 
borst willen behouden. Op basis van de in hoofdstuk 2 beschreven literatuur en dit onderzoek kan 
geconcludeerd worden er geen hard bewijs is betreffende een mogelijk verhoogd carcinogeen 
effect van adjuvante radiotherapie op het ontwikkelen van een tweede primaire borstkanker 
voor BRCA1/2 genmutatie draagsters die borstkanker ontwikkelen boven de leeftijd van 30 jaar 
en kiezen voor borstsparende behandeling. Gezien het mogelijk verhoogd risico op een tweede 
primaire (contralaterale) tumor, lijkt terughoudendheid met betrekking tot borstsparende chirurgie 
en bestraling gerechtvaardigd voor BRCA1/2 genmutatie draagsters, die jonger dan 30 jaar zijn bij 
diagnose van borstkanker. Verder onderzoek in grotere studie populaties met een minimale follow-up 
duur van 10 jaar is nodig om een beter inzicht in de werkelijke negatieve effecten van bestraling op 
het risico van contralaterale borstkanker bij BRCA1/2-geassocieerde borstkanker patiënten te krijgen.
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Chemotherapie
Naast de mogelijk verhoogde toxiciteit van ioniserende straling bij BRCA1/2 genmutatie draagsters, 
kan men ook veronderstellen dat de toxiciteit van chemotherapie toegenomen zou zijn bij deze 
patiënten, omdat meerdere soorten chemotherapie werken via het induceren van dubbelstrengs 
DNA breuken. In hoofdstuk 4 bespreken we de resultaten van een retrospectieve cohort studie naar 
verschillen in toxiciteit van (neo)adjuvante chemotherapie tussen BRCA1/2 genmutatie draagsters en 
sporadische borstkankerpatiënten. Voor deze studie werden alle vrouwelijke patiënten geselecteerd 
die in het Erasmus MC werden behandeld met adjuvante of neoadjuvante chemotherapie (bestaande 
uit anthracyclines en/of taxanen) voor primaire borstkanker of lokaal/ locoregionaal recidief (PB/LR) 
zonder afstandsmetastasen tussen 01-01-2004 en 31-12-2014. Totaal konden de gegevens van 701 
patiënten gebruikt worden voor de analyses. Er waren 85 patiënten (12%) met een BRCA1/2 genmutatie 
(n = 67 BRCA1 en n = 18 BRCA2). Als primaire uitkomst werd relatieve totale dosis-intensiteit (RTDI) 
genomen, een maat voor toegediende (actuele) dosis-intensiteit (toegediende dosis over de hele 
tijdsperiode van de behandeling), gerelateerd aan de geplande dosis-intensiteit. Door het gebruik 
van RTDI worden de effecten van dosisreducties, uitstel en vroegtijdig staken van behandeling 
meegenomen. We vonden geen verschillen in RTDI (zowel voor anthracyclines als voor taxanes) 
tussen borstkanker patiënten met een BRCA1/2 genmutatie en sporadische borstkankerpatiënten. 
Ook vonden we geen verschillen tussen beide groepen in het optreden van aantal patiënten waar 
neutropene koorts optrad, uitstel van chemotherapie toediening of verandering van chemotherapie 
schema ten gevolge van toxiciteit nodig was. De afwezigheid van toegenomen acute toxiciteit ten 
gevolge van (neo)adjuvante chemotherapie onder BRCA1/2 genmutatie draagsters, vergeleken met 
sporadische borstkankerpatiënten, laat zien dat de reparatie mechanismes voor dubbelstrengs DNA 
schade van gezonde lichaamscellen met slechts één normale kopie van ofwel het BRCA1 gen ofwel het 
BRCA2 gen voldoende functioneel zijn zodat niet meer ernstige acute chemotherapie geassocieerde 
toxiciteit van de onderzochte chemotherapie schema’s gezien wordt in BRCA1/2 genmutatie 
draagsters vergeleken met sporadische borstkankerpatiënten. Echter platinum derivaten en in de 
toekomst mogelijk ook PARP remmers worden steeds vaker gebruikt bij BRCA1/2-geassocieerde 
borstkanker. Deze geneesmiddelen hebben een veel hogere capaciteit om dubbelstrengs DNA 
breuken te induceren vergeleken met antracyclines. Gegevens over de toxiciteit van deze middelen 
bij BRCA1/2 genmutatie draagsters zullen dan ook moeten volgen uit lopende en nieuwe studies.
Kan toxiciteit gebruikt worden om behandeling te optimaliseren? 
Het is een interessant gegeven dat het optreden van toxiciteit door anti-kankertherapie geassocieerd 
kan zijn met hogere effectiviteit. Meerdere studies hebben laten zien dat de mate van hematologische 
toxiciteit door behandeling met chemotherapie bij borstkankerpatiënten, gerelateerd lijkt aan de 
effectiviteit. Hierdoor kan toxiciteit gebruikt worden om effectiviteit van bijvoorbeeld medicamenteuze 
anti-kanker therapie te verhogen door de dosering te verhogen bij patiënten met geen of slechts 
beperkte toxiciteit. In hoofdstuk 5 beschrijven we de resultaten van een single-center prospectief 
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onderzoek naar de haalbaarheid van dosisverhoging van anthracycline-cyclofosfamide bevattende 
chemotherapie bij sporadische borstkankerpatiënten op geleide van het aantal neutrofielen. 
Tweeëndertig patiënten die startten met drie-wekelijkse anthracycline-cyclofosfamide bevattende 
chemotherapie zonder G-CSF, in adjuvante dan wel gemetastaseerde setting, werden geïncludeerd 
in deze studie. De eerste chemotherapie kuur werd gegeven in een standaard dosis, gebaseerd op 
lichaamsoppervlak. Bij patiënten met geen of milde verlaging van de neutrofielen (CTC graad 0–2) en 
geen andere dosis-limiterende toxiciteit werd de dosis van de tweede kuur met 10-25% geëscaleerd, 
met de mogelijkheid voor een eventuele verdere dosisescalatie van 10-25% bij de derde kuur. 
Twee van de 23 patiënten (9%) die behandeld werden met FEC (fluorouracil 500 mg/m2, epirubicine 
100 mg/m2 en cyclofosfamide 500 mg/m2) ontwikkelden, na de eerste FEC-kuur toediening slechts 
een milde verlaging van het aantal neutrofielen. Bij deze twee patiënten werd dosisescalatie toegepast 
(30% bij de ene en 15% bij de andere patiënte). Na dosisescalatie waren er geen complicaties, zoals 
neutropene koorts. Bij geen van de patiënten die behandeld werden met FAC (fluorouracil 500 
mg/m2, doxorubicine 50 mg/m2 en cyclofosfamide 500 mg/m2) of AC (doxorubicine 60 mg/m2 en 
cyclofosfamide 600 mg/m2) kon dosisescalatie worden toegepast omdat al deze patiënten reeds na 
de eerste kuur ernstige verlaging van het neutrofielen aantal (CTC graad 3-4) ontwikkelden. Escalatie 
van de huidige standaard dosis van anthracycline-cyclofosfamide bevattende chemotherapie zonder 
G-CSF is slechts mogelijk in een klein deel van de patiënten,  maar lijkt dan wel haalbaar. Onderzoek 
naar dosisverhoging op geleide van het aantal neutrofielen ten einde de effectiviteit te verhogen zou 
wellicht zinvol kunnen zijn voor andere chemotherapeutica. 
Bijwerkingen van behandeling, therapietrouw en spiegelbepalingen
Adjuvante endocriene therapie, die vaak jarenlang gebruikt moet worden, is een belangrijk onderdeel 
van de behandeling van hormoonreceptor positieve borstkanker met bewezen gunstig effect. 
Desondanks is aangetoond dat er vaak sprake is van verminderde therapietrouw, vaak ingegeven 
door hinderlijke bijwerkingen, die een belangrijke invloed kunnen hebben op de kwaliteit van leven.
Therapietrouw, verandering in leefstijlfactoren en mogelijk resistentiemechanismen kunnen de 
blootstelling van een geneesmiddel over de tijd veranderen. De beste manier om voortgang te boeken 
in individualiseren van behandeling lijkt ‘therapeutic drug monitoring’ (TDM) te zijn. De vaak gebruikte 
methode van TDM door het herhaaldelijk meten van plasmaconcentraties van geneesmiddelen of 
metabolieten over de tijd is moeilijk in te bouwen in de klinische praktijk gezien de belasting voor 
de patiënten. Een methode, die (achteraf ) informatie geeft over de gemiddelde concentratie van 
antikanker geneesmiddelen (en de metabolieten) over de tijd, zou gevonden kunnen worden in 
het meten van deze concentraties in hoofdhaar. Dit geeft de mogelijkheid om, afhankelijk van de 
lengte van het verzamelde haar, het gemiddelde van geneesmiddel concentraties over de tijd te 
bestuderen. Dit maakt herhaaldelijke bloedafnames onnodig. In hoofdstuk 6 beschrijven we de 
validatie van een eerder ontwikkelde UPLC-MS/MS (ultra performance liquid chromatography/
tandem mass spectrometry) methode voor het kwantificeren van tamoxifen en de drie belangrijkste 
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metabolieten (N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen, en 4-hydroxy-N-desmethyl-tamoxifen) 
in hoofdhaar. Met de gegevens uit dit onderzoek kunnen we concluderen dat het meten van de 
concentratie van tamoxifen en de belangrijkste metabolieten in haar mogelijk is met de UPLC-MS/MS 
methode. Het lijkt voor tamoxifen echter niet mogelijk om de blootstelling over de tijd vast te stellen 
met segmentele analyse van haar, meest waarschijnlijk grotendeels ten gevolge van het effect van 
UV straling, waardoor tamoxifen en de metabolieten afgebroken worden. Verder onderzoek naar de 
waarde van geneesmiddelconcentraties in hoofdhaar zou zich daarom dan ook moeten toespitsen 
op het kwantificeren van anti-kanker geneesmiddelen, die minder gevoelig zijn voor UV straling. 
Voor onderzoek naar TDM bij patiënten die behandeld worden met tamoxifen, blijft het meten van 
endoxifen concentraties in plasma de gouden standaard.
Preventie en behandeling van toxiciteit
Eén van de belangrijke bijwerkingen van de behandeling van borstkanker is het optreden van 
vroegtijdig verlies van botdichtheid. Dit kan ontstaan door verschillende mechanismes: vroegtijdige 
menopauze door chemotherapie en/of endocriene therapie, lagere spiegels van oestrogeen ten 
gevolge van aromatase-remmers en de directe invloeden van chemotherapie en ondersteunende 
medicatie, zoals steroïden. Daarnaast zijn botuitzaaiingen vaak de eerste uiting van uitgezaaide 
borstkanker. Het ontstaan van botcomplicaties, gedefinieerd als pathologische breuken, noodzaak 
voor bestraling of operatie ten gevolge van (dreigende) compressie van het ruggenmerg of 
hypercalciëmie ten gevolge van botmetastasen, heeft een negatieve invloed op de kwaliteit van 
leven. Lange tijd zijn bisfosfonaten de hoeksteen geweest van de preventie en behandeling van 
botcomplicaties zowel bij uitgezaaide borstkanker als bij botverlies ten gevolge van behandeling 
bij vroegstadium borstkanker. Denosumab, een volledig gehumaniseerd monoklonaal antilichaam, 
dat bindt aan de receptoractivator van het nucleaire factor kappa-B ligand (RANKL) is ontwikkeld als 
een nieuwe botgerichte therapie, die gebruikt kan worden in zowel vroegstadium als uitgezaaide 
borstkanker. In hoofdstuk 7 beschrijven we de huidige indicaties voor denosumab zowel bij 
vroegstadium als uitgezaaide borstkanker. We concluderen dat er nog steeds een aantal vragen 
om beantwoording vragen, zoals waar denosumab te plaatsen ten opzichte van bisfosfonaten, of 
individualisering van de dosering (bijvoorbeeld op basis van bot turnover marker) mogelijk is en of er 
een plaats is voor denosumab in de preventie van het ontstaan van botmetastasen of mogelijks zelfs 
in de preventie van het ontstaan van borstkanker. Desalniettemin is denosumab een zeer effectief 
middel om botcomplicaties door osteoporose of botuitzaaiingen van borstkanker te voorkomen, met 
beperkte bijwerkingen.
uitstellen van toxische chemotherapie bij her2-positieve uitgezaaide borstkanker?
De standaard eerstelijns behandeling voor de subgroep van HER2-positieve uitgezaaide borstkanker 
bestond tot recent uit een combinatie van trastuzumab met een taxaan (docetaxel of paclitaxel). 
Vooruitgang in de behandeling van deze subgroep van patiënten kan op meerdere manieren 
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gemaakt worden. Een manier zou kunnen zijn het verhogen van de effectiviteit van de behandeling 
door het toevoegen van een nieuw medicament met beperkte bijwerkingen. Een andere optie zou 
kunnen zijn om te proberen de toxiciteit te verlagen door het starten van chemotherapie uit te stellen 
door het toevoegen van een nieuw medicament met beperkte toxiciteit aan trastuzumab en alleen 
te starten met chemotherapie bij progressie onder dit schema. Bevacizumab, een monoklonaal 
antilichaam tegen vasculaire endotheliale groei factor (VEGF), zou een van de medicamenten kunnen 
zijn om in de genoemde strategieën te gebruiken. 
In hoofdstuk 8 beschrijven we de resultaten van een open-label, gerandomiseerde, niet-
vergelijkende fase 2 studie, waarbij 84 patiënten werden gerandomiseerd tussen HAT (de combinatie 
van bevacizumab, trastuzumab en wekelijks paclitaxel) en HA-HAT (starten met trastuzumab en 
bevacizumab met toevoegen van wekelijks paclitaxel bij progressie). Het percentage patiënten dat 
progressie-vrij was na een jaar was 74.4% (95% betrouwbaarheidsinterval, BI 61.8-89.4) en 62.2% (95% 
BI 49.6-89.4) in respectievelijk de HAT en HA-HAT arm. De mediane progressie-vrije overleving in de 
HAT arm was 19.8 maanden (95% BI 14.9-25.6), en de mediane totale progressie-vrije overleving in de 
HA-HAT arm was 19.6 maanden (95% BI 12.0-32.0). In de HA-HAT arm was de mediane progressie-vrije 
overleving voor behandeling met alleen bevacizumab en trastuzumab 10.4 maanden (95% BI 6.2-
15.0) en de mediane progressie-vrije overleving voor behandeling met trastuzumab, bevacizumab 
en paclitaxel na eerste progressie was 8.2 maanden (95% BI 7.0-12.6). Het aantal en de ernst van de 
bijwerkingen was vergelijkbaar tussen de twee armen en was in het voordeel van starten met alleen 
bevacizumab en trastuzumab.
Wanneer vergeleken wordt met historische controles, suggereren de uitkomsten dat bevacizumab 
de antitumor activiteit verhoogd van de trastuzumab-gebaseerde schema’s, zoals gebruikt in 
dit onderzoek. Met de publicatie van de resultaten van de CLEOPATRA trial, waarin een mediane 
totale overlevingsvoordeel van 15.7 maanden gezien werd voor de combinatie van trastuzumab, 
pertuzumab en docetaxel, vergeleken met de combinatie van trastuzumab en docetaxel, is dit schema 
de standaard eerstelijnsbehandeling geworden voor patiënten met HER2-geassocieerde uitgezaaide 
borstkanker. Deze gegevens en het gunstige bijwerkingenprofiel van pertuzumab vergeleken met 
bevacizumab in ogenschouw nemende, is het onwaarschijnlijk dat er nog fase 3 studies gedaan zullen 
worden naar de combinatie van trastuzumab, bevacizumab en chemotherapie. De resultaten van ons 
onderzoek laten wel zien dat het concept van starten met een minder toxische, chemotherapie-vrije 
behandeling met alleen monoklonale antilichamen een strategie is die verder onderzoek verdient. 
Vanuit het oogpunt van kwaliteit van leven gezien, is het van groot belang om behandelingsschema’s 
te ontwikkelen waarbij gestart wordt met minder toxische behandelingen. 
Conclusie
In de afgelopen jaren is duidelijke voortuitgang geboekt in de behandeling van zowel vroegstadium 
als uitgezaaide borstkanker. Deze vooruitgang gaat helaas (deels) ten koste van toxiciteit. Eén van 
de belangrijke doelen in het onderzoek naar de behandeling van borstkanker moet dan ook zijn het 
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verminderen van de met de behandeling samenhangende acute en lange-termijns toxiciteit. Daarom 
is het van groot belang om zowel preklinisch onderzoek, klinisch onderzoek en observationeel 
onderzoek (prospectief en retrospectief ) te blijven verrichten. 
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DAnKWOOrD
Dit hoofdstuk zal waarschijnlijk één van de meest gelezen hoofdstukken van dit boekje zijn. Dit terwijl 
de wetenschappelijke waarde van dit hoofdstuk zeer beperkt is. Desondanks is er veel reden om 
iedereen te bedanken die een bijdrage heeft geleverd aan de totstandkoming van dit proefschrift. 
Een aantal mensen wil ik hier in het bijzonder bedanken.
 
Als eerste wil ik mijn promotor noemen, prof.dr. S. Sleijfer. Beste Stefan. Heel veel dank voor het 
vertrouwen dat je me de afgelopen jaren hebt gegeven. Toen ik net gestart was met de deelspecialisatie 
interne oncologie, vroeg ik je een keer of er mogelijkheden waren voor wetenschappelijk onderzoek 
binnen de afdeling. Kort daarna kwam je al met opties voor onderzoek wat zou kunnen resulteren 
in een promotie-onderzoek. Zowel tijdens de periode dat ik in het Erasmus MC werkte, als na mijn 
vertrek voor een baan in een niet-academisch (perifeer klinkt zo afgelegen) ziekenhuis, ben je altijd 
zeer betrokken en laagdrempelig toegankelijk geweest. Genoemd moet ook worden de snelheid 
waarmee jij manuscripten beoordeelde, met altijd een paar zinvolle globale suggesties voor 
verbetering, maar ook oog voor details.
 
Als tweede (of gedeelde eerste, zoals dat met auteursplaatsen bij wetenschappelijke artikelen ook 
gaat) mijn promotor, dr. A. Jager. Beste Agnes, veel dank voor de begeleiding in de afgelopen jaren. 
Jouw reacties op manuscripten lieten soms wat langer op zich wachten, maar waren dan in het 
algemeen ook uitgebreid en op een manier, waarop het verbeteren van een manuscript voor mij ook 
een leertraject was. Dank ook voor het feit dat je bij herhaling meedacht over nieuw onderzoek, op de 
momenten dat een voorgenomen onderzoek niet door kon gaan vanwege financiering of vanwege 
onvoldoende resultaten in de pilot fase. Dank voor alle tijd die je in mijn begeleiding gestoken hebt.
 
Leden van de kleine commissie, prof.dr. J.P. Pignol, prof.dr. C. Verhoef en prof.dr. E. van der Wall, jullie 
wil ik hartelijk bedanken voor jullie bereidheid en tijd om mijn proefschrift te beoordelen. Fijn dat 
jullie alle drie ook bij de verdediging aanwezig hopen te zijn. Daarnaast wil ik ook de leden van de 
grote commissie, prof.dr. C.C.D. van der Rijt, dr. L.B. Koppert, dr. J.R. Kroep, hartelijk bedanken voor de 
tijd en moeite om het proefschrift te beoordelen en de bereidwilligheid om aanwezig te zijn bij de 
verdediging. De behandeling van borstkanker is nagenoeg altijd multidisciplinair. Een multidisciplinaire 
borstkankerpatiëntenbespreking kan, zonder tekort te doen aan de andere participerende disciplines, 
in de praktijk niet van start gaan zonder aanwezigheid van een oncologisch chirurg, een medisch 
oncoloog, en een radiotherapeut. Dit geldt mijns inziens ook voor de beoordeling, maar ook voor de 
verdediging van dit proefschrift. Dank dat jullie hier dan ook zorg voor dragen. 
 
Bij de multidisciplinaire behandeling van borstkanker zijn nog vele anderen medisch specialisten en 
zorgprofessionals betrokken, zoals: fysiotherapeut, klinisch geneticus, maatschappelijk werkende, 
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mammacare verpleegkundige, medisch psycholoog, oncologieverpleegkundige, palliatief 
verpleegkundige, patholoog, plastisch chirurg, radioloog, verpleegkundig specialist enzovoorts.
 
Dit geldt evenzeer voor dit proefschrift. Zonder de hulp, ondersteuning en bijdrage van velen  was dit 
proefschrift er nooit gekomen. Een aantal van hen wil ik met name noemen.
Beste Delal, dank voor het meedenken en meeschrijven aan het artikel over radiotherapie en risico op 
contralaterale borstkanker (Hoofdstuk 3). Dit artikel is voor jou ook het eerste manuscript voor jouw 
proefschrift. Heel veel succes met al het werk dat nog voor je ligt. Daniëlle, dank voor het opmaken 
van de figuren in dit hoofdstuk.
Beste Nyree en Nasrin. Dank voor jullie bijdrage aan het statusonderzoek wat ten grondslag ligt aan 
Hoofdstuk 4. Annette, veel dank voor het verrichten van de statistische analyses en het meedenken 
over deze studie.
Beste Tilly, dank voor je meedenken en inclusie van patiënten in de ‘Tamoxifen in haar’ studie 
(Hoofdstuk 6). Dankzij jou hadden we snel de benodigde patiënten bij elkaar. Peter, dank voor het 
verrichten van en de uitleg over de analyses, zoals die in jouw laboratorium verricht zijn. Ron, dank 
voor de begeleiding bij dit onderdeel van het proefschrift.
Beste Harm, Harriet, Steffen en Elise, dank voor jullie ondersteuning bij dataverzameling, interpretatie 
en logistiek van de HAT studie (Hoofdstuk 7). 
Beste Caroline, Maartje, Margreet en Inge-Marie, dank voor jullie kritisch meedenken en meeschrijven 
met één of meerdere studies in dit proefschrift.
 
Medewerkers van de afdeling hyperthermie en genetica, dank voor jullie bijdrage in het hyperthermie 
biopten project. Helaas heeft dit project tot nog toe geen beschrijvenswaardig wetenschappelijk 
resultaat opgeleverd.
Dit laatste geldt ook voor de AMH studie, met dit verschil dat de resultaten wel op niet al te lange 
termijn tegemoet gezien kunnen worden. Collega’s  uit Erasmus MC, Maasstad, SFG en Ikazia, dank voor 
de gestage inclusie in deze studie. Mandy, dank voor het overnemen van de logistiek van deze studie.
  
Alle co-auteurs wil ik bedanken voor hun kritisch meedenken, meeschrijven en doen van suggesties 
voor verbetering van de manuscripten. 
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De stafleden van de afdeling interne oncologie van het Erasmus MC wil ik bedanken voor hun 
betrokkenheid  en de inclusie van patiënten in een deel van de gedane studies.
Veel dank aan alle secretaresses (van beide locaties), datamanagers, (research)verpleegkundigen en 
verpleegkundig specialisten van de afdeling interne oncologie van het Erasmus MC, die op welke 
manier dan ook, een bijdrage hebben geleverd aan de totstandkoming van dit proefschrift. Silvia, 
mijn secretaresse in de periode als chef de clinique in het Erasmus MC, veel dank voor het puzzelen 
met alle afspraken die gemaakt moesten worden. Dank ook dat je in de periode dat ik formeel geen 
recht meer had op secretariële ondersteuning toch de dingen voor me deed die een secretaresse veel 
sneller en efficiënter kan doen dan een dokter. 
Van mijn mede-promovendi wil ik een aantal met name noemen. Evelien Kuip, Astrid Oosten 
en Annemieke van der Padt. Wij zaten min of meer in het zelfde schuitje: beginnen aan een 
promotieonderzoek aan het eind van of zelfs na de opleiding tot internist-oncoloog. Favoriet 
gespreksonderwerp was dan ook vaak de moeilijkheden, maar ook de voordelen en uitdagingen die 
het combineren van klinische taken, staftaken en promotieonderzoek met zicht meebrengt. Ik heb er 
alle vertrouwen in dat ik ook van jullie (binnenkort) een boekje te zien krijg. 
 
Mijn huidige collega’s, intussen maten, in het Ikazia Ziekenhuis: Ad, Adrienne, Claudia, Esther, Felix, 
Fransien, Geert, Ginette, Hestia, Marieke, Michel, Pieter en Rob. Dank voor de fijne samenwerking die 
we al weer twee jaar mogen hebben. Veel dank voor de mogelijkheid, die jullie gegeven hebben om 
de eerste periode dat ik in het Ikazia werkte, voldoende tijd vrij te maken om aan dit proefschrift te 
werken. Zonder die mogelijkheid, had dit proefschrift langer op zich laten wachten. Nu ik toegetreden 
ben tot de maatschap en dit boekje af is, hoop ik meer tijd vrij te kunnen maken voor andere niet-
patiënt gebonden taken. 
 
Bijzondere dank voor mijn oud-opleider Ad Dees, die mij voor start van de opleiding tot internist al 
naar het Erasmus MC wilde sturen voor promotieonderzoek binnen de vasculaire geneeskunde, maar 
mij uiteindelijk toch de opleiding tot internist in wist te helpen.
Daarnaast bijzondere dank voor Felix de Jongh, die tijdens mijn periode als arts-assistent in het Ikazia 
voor een eerste echte kennismaking met de interne oncologie zorgde. Mede dankzij jou, heb ik 
uiteindelijk besloten om me te specialiseren in de interne oncologie. Dank ook voor de mogelijkheid 
die je bood om de analyses en het manuscript van de ANCHOR studie uit te werken, zodat deze studie 
in dit proefschrift opgenomen kon worden (Hoofdstuk 5). Dit kwam erg gelegen op het moment dat 
twee andere veel belovende projecten strandden. Heel fijn dat je me op de dag van de verdediging 
ter zijde wil staan als paranimf.
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Mijn broer Peter, fijn dat je paranimf wilt zijn op deze dag. Dit ondanks je recente nieuwe neventaak, 
die ook de nodige tijd, aandacht en energie zal vragen. Gezien de ervaringen bij onze bruiloft, waarbij 
je ceremoniemeester was, heb ik alle vertrouwen in je organisatietalenten. 
Beste broers, zwagers, zussen, schoonzussen, dank voor jullie (welgemeende) interesse in dit 
proefschrift. Ik hoor graag terug wie van jullie het hele boekje gelezen heeft. Dank ook voor de 
afleiding die jullie mij bezorgden als we bij elkaar waren.
 
Beste pa en ma, dank voor jullie stimulans en steun tijdens dit promotie-traject, maar ook in de jaren 
daarvoor. Pa, het van u geërfde arbeidsethos, heeft me erg geholpen in dit hele project. Ma, dank voor 
uw interesse en praktische hulp op de momenten dat dat nodig was. 
Beste schoonvader, heel veel dank voor uw interesse in mij en mijn werkzaamheden. U heeft van 
heel dichtbij met borstkanker te maken gehad. Ook na het overlijden van uw vrouw aan de indirecte 
gevolgen van de ziekte waarover dit proefschrift gaat, heeft u altijd oprechte interesse getoond. 
Daarnaast stond u regelmatig klaar voor Arine en de jongens, als ik even geen tijd voor hen had. Dank 
ook voor de afleiding, onder andere door de familievakanties in Limburg. Hartelijk dank daarvoor.
Lieve Jacco, Bart en Sander. Ik weet dat jullie dat niet willen, maar toch noem ik jullie namen aan 
het eind van dit boekje. Jullie hebben er voor gezorgd dat ik geen kluizenaar geworden ben. Jullie 
‘dwongen’ me iedere keer weer om tijd voor jullie vrij te maken en de computer uit te zetten of zelfs 
uit te laten. Dank jullie wel daarvoor.
Lieve Arine, dank je wel voor alles wat je voor mij betekent. Je zal het me niet kwalijk nemen, dat ik 
dat ‘alles’ niet helemaal uitleg in dit dankwoord. Dank voor je onvoorwaardelijke liefde. Dank voor alle 
emotionele, psychische, maar ook praktische hulp. 
Ik zou mezelf, maar ook mijn gezinsleden, te kort doen als ik nu niet zou beloven de komende jaren 
meer tijd vrij te maken voor jullie. Eerlijkheidshalve moet ik er wel direct bij zeggen, dat ik verwacht 
dat een deel van de tijd die vrij komt, gevuld zal worden met andere taken.
Boven alles past dankbaarheid aan God. Hij gaf mij de talenten, maar ook de kracht en lust om dit 
werk te doen.
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Curriculum vitae
CurriCulum vitae 
Jan Cornelis Drooger werd geboren op 3 april 1982 te Rotterdam. In 2000 voltooide hij het gymnasium 
aan het Wartburg college, locatie Guido de Brès te Rotterdam. In hetzelfde jaar begon hij de studie 
Geneeskunde aan het Erasmus MC. In 2004 behaalde hij zijn doctoraal examen. In 2003 startte hij 
met een Master of Sciene programma bij het Netherlands Institute for Health Science, wat hij in 2004 
afrondde met behalen van de titel Master of Science in Public Health. In 2006 deed hij artsexamen in 
het Erasmus MC. Aansluitend werkt hij als arts niet in opleiding tot specialist in het Ikazia Ziekenhuis 
in Rotterdam, alwaar hij 1 januari 2008 aan de opleiding tot internist begon (opleiders prof.dr. 
J.L.C.M. van Saase en dr. A. Dees). In 2010 vervolgde hij zijn opleiding in het Erasmus MC. Vanaf 2011 
specialiseerde hij zich binnen de interne geneeskunde in de medische oncologie (opleider dr. A. van 
der Gaast). Tegelijkertijd werd gestart met wetenschappelijk onderzoek binnen de afdeling Interne 
Oncologie van het Erasmus MC Kanker Instituut, onder supervisie van dr. A. Jager en prof.dr. S. Sleijfer. 
Vanaf september 2013 werkte hij als internist-oncoloog in het Erasmus MC Kanker Instituut, locatie 
Daniel den Hoed. Vanaf 1 februari 2014 werkt hij als internist-oncoloog in het Ikazia Ziekenhuis. Tot 1 
februari 2015 had hij nog een gedeeltelijke aanstelling in het Erasmus MC voor het afronden van zijn 
wetenschappelijk onderzoek, wat uiteindelijk heeft geresulteerd in dit proefschrift.

Appendix
samenvatting
 Dankwoord
 Curriculum vitae
 list of publications
 PhD portfolio 
Appendix
176
lIsT Of PuBlICATIOns
Drooger JC, van Tinteren H,  de Groot SM, ten Tije AJ, de Graaf H, Portielje JEA, Jager A, Honkoop A, 
Linn SC, Kroep JR, Erdkamp FLG, Hamberg P, Imholz ALT, van Rossum-Schornagel QC, Heijns JB, van 
Leeuwen-Stok AE, Sleijfer S. 
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach 
in HER2-positive metastatic breast cancer: the HAT study (BOOG 2008-03), a Dutch Breast Cancer 
Research Group trial. 
Cancer 2016, e-pub ahead of print: doi:10.1002/cncr.30141.
Drooger JC, de Jongh FE. 
Dubbele winst met een genexpressieprofiel; borstkankerbehandeling op maat spaart bijwerkingen 
en kosten. 
Medisch Contact 2016;16:36-38.
Drooger JC, Heemskerk-Gerritsen BAM, Smallenbroek N, Epskamp C, Jager A. 
Toxicity of (neo) adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer. 
Breast Cancer Res Treat 2016;156:557-566.
Drooger JC, Akdeniz D, Pignol JP, Koppert LB, Seynaeve CM, Hooning MJ, Jager A. 
Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of 
contralateral breast cancer with special attention for patient irradiated at younger age. 
Breast Cancer Res Treat 2015;154:171-180.
Drooger JC, Jager A, Lam MH, den Boer MD, Sleijfer S, Mathijssen RHJ, de Bruijn P. 
Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its 
main metabolites in human scalp hair. 
J Pharm Biomed Anal 2015;114:416-425.
Drooger JC, van Pelt-Sprangers J, Leunis C, Jager A, de Jongh FE. 
Neutrophil-guided dosing of anthracycline-cyclophophamide-containing chemotherapy in patients 
with breast cancer: a feasibility study. 
Med Oncol 2015;32:113
177
List of publications
Drooger JC, Hooning MJ, Seynaeve CM, Baaijens MH, Obdeijn IM, Sleijfer S, Jager A.
Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, 
with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature. 
Cancer Treat Rev 2015;41:187-196.
Drooger JC, van der Padt A, Sleijfer S, Jager A. 
Denosumab in breast cancer treatment. 
Eur J Pharmacol 2013;717:12-19
Drooger JC, van de Luijtgaarden KM, Weidema WF, de Jongh FE. 
Perioperatieve chemotherapy bij het resectabel maagcarcinoom. 
Ned Tijdschr Oncol 2010;7:161-167
Drooger JC, Dees A, Swaak AJ. 
ANCA-positive patients: the influence of PR3 and MPO antibodies on survival rate and the association 
with clinical and laboratory characteristics. 
Open Rheumatol J 2009 Mar 4;3:14-17
Drooger JC, Troe JW, Borsboom GJ, Hofman A, Mackenbach JP, Moll HA, Snijders RJ, Verhulst FC, 
Witteman JC, Steegers EA, Joung IM. 
Ethnic differences in prenatal growth and the association with maternal and fetal characteristics. 
Ultrasound Obstet Gynecol 2005;26:115-122

Appendix
samenvatting
 Dankwoord
 Curriculum vitae
 list of publications
 PhD portfolio 
Appendix
180
PhD POrTfOlIO (2011-2016)
Year Workload
eCTs
1. PhD training
General courses
     - Good clinical practice
     - Integrity in research, Erasmus MC
     - BROK (basiscursus Regelgeving Klinisch Onderzoek) course 
2011-2014
2014
2015
1
1
1
specific courses (e.g. research school, Medical Training)
Seminars and workshops
     - opleidingsdagen/avonden jNVMO
     - Course ‘communicatie in de oncologie’
     - Course ‘Desiderius cursus ziekenhuismanagement’
     - Roche4young, ‘nascholing voor jonge oncologen’
2011-2013
2012
2013
2014-2015
1
1
1
1
Presentations
     - Klinische research bespreking, oral presentations
     - IKNL netwerkdagen, Middelburg, oral presentation
     - OVUM overleg, oral presentation,
     - Mamma beleidsgroep, oral presentation
     - Radiotherapie researchbespreking, oral presentation
     - San Antonio Breast Cancer Symposium, poster presentation
     - Oncology TV, oral presentation
     - Scientific meeting Medical Oncology, oral presentation
     - NABON/BOOG meeting, oral presentation
     - European Breast Cancer Conference, poster presentation
2011-2014
2012
2012
2013
2013
2014
2014
2015
2015
2016
1
1
0.5
0.5
0.5
1
0.5
1
1
1
(Inter) national conferences
     - Oncologiedagen
     - Internistendagen
     - ESMO Annual meeting, Vienna, Austria
     - Jaarsymposium Continuüm oncologie
     - San Antonio Breast Cancer Symposium, San Antonio, USA
     - Symposium borstkanker behandeling beter
     - European Breast Cancer Conference, Amsterdam
2011-2016
2012, 2016
2012
2013
2014
2011-2016
2016
1
1
1
1
1
1
1
Other
     - Monodisciplinair onderwijs Medical Oncology, Erasmus MC      
     - OMBO training, Erasmus MC
     - Referereerbijeenkomst Medical Oncology, Erasmus MC
     - Polikliniekbespreking Medical Oncology, Erasmus MC
     - Complicatiebespreking Medical Oncology, Erasmus MC
     - Scientific meeting Medical Oncology, Erasmus MC
     - Borstkanker research bespreking, Erasmus MC
     - Regiobijeenkomst fertiliteitsbehoud
2011-2013
2011-2014
2011-2014
2011-2014
2011-2014
2012-2015 
2014
2015
1
1
1
1.5
0.5
1
0.5
0.5
181
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Year Workload
eCTs
2. Teaching
lecturing
     - biennially education radiation therapy operators
     - education oncology nurses, Ikazia
     - education AIOS/ANIOS, Ikazia
     - NPV Barendrecht: lecture ‘Borstkanker, en dan…’
2012-2015
2015
2015
2016
1
0.5
0.5
0.5
Supervision
     - supervision review article minor students 
     - supervision medical students clinical research
2014
2014-2015
0.5
1
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